生物醫藥 - BTBA Mentor/Mentee 招募開跑

BTBA-Boston Taiwanese Biotechnology Association

Mentorship 火熱開跑~~ 你還在猶豫什麼!加入BTBA認識更多來自各方的生技人教學相長吧!
小編偷偷分享個BTBA的好康:前幾日碰上研究瓶頸的小編無意中發現有該專業的人才在BTBA裡面，馬上大腿抱起來獲得許多建議與啟發(雖然data沒有因此就生出來QQ)，這樣難得的經驗通過mentorship program會更有機會擁有唷!

  BTBA 2022-2023 Mentor/Mentee 招募 開跑
同在波士頓生醫領域的你/妳，是否想要了解自己未來職涯的可能性？或者是否在同一個位置許久，希望轉換跑道，尋求成長呢？
BTBA 將在今年秋天成立mentorship program，讓在特定生醫領域的導師們提供來自該領域的專業意見，帶領mentee 一起成長！
我們目標招募來自生醫學術界與業界的mentors，以包含生醫領域的各個面向。我們將以group meeting 的形式來配對mentor and mentee，以提高彼此之間的互動機會。期待各位舊識與新知加入我們的行列！
報名從速，收件只到12/4為止：
https://reurl.cc/gQm3yz
Are you in Boston area and want to explore more possibilities of your career in biotech? Are you looking for a career change or career development opportunities?
BTBA is starting a mentorship program this fall. Mentors from different biomedical fields will share their experiences in their fields to help mentees' growth.
We are recruiting mentors from both academia and industry, to include different aspects of biotechnology. To match mentors and mentees, there will be a group meeting to facilitate the interactions between them. We are excited to see all old friends and new friends to join us in the mentorship program!
Fill up the form before Dec. 4th to participate in the program:
https://reurl.cc/gQm3yz

May be an image of one or more people and text that says 'Together, ve can ၅၀ further 2022 BTBA Mentorship Program Deadline to register: Dec. 4th SCAN SCANME ME'

Yu-Tien Hsu, Jerry Lin and 17 others

The Sino-American Pharmaceutical Professionals Association–New England/Boston (SAPA-NE) is glad to announce that SAPA-NE 2022 Bimonthly Workshop - November Efficient on-target delivery of oligonucleotides (and beyond): in vitro and in vivo performance of Sapreme’s endosomal escape enhancers for various tissues and targets, will be held in 7 days. The workshop will be presented by Dr. Miriam Bujny, Chief Development Officer at Sapreme Technologies BV. This event will be held virtually on Wednesday, Nov 2, 2022, 12:00 PM - 1:00 PM EDT (美东时间).
 
Please contact us at info@sapa-neweb.org if you have any membership or registration-related questions. 
 

Keypoints
Sapreme’s endosomal escape enhancers optimize cytoplasmic release to reveal full efficacy
Delivery of oligonucleotides and protein therapeutics with broad applicability
Targeting through ligand-conjugation to increase cell/tissue-specificity
 
Abstract
For most current therapeutic oligonucleotide formats, attaining sufficiently high levels of cytoplasmic or nuclear target engagement while keeping off-target toxicities at bay remains problematic, as most compound remains trapped in the endosomes. Sapreme’s technologies allow for highly relevant improvements in potency by enabling efficient endosomal escape. Moreover, it allows for exquisite tissue- or cell selective targeting through the use of targeting ligands, including GalNAc for hepatic targeting, and antibodies or other ligands for non-hepatic tissues.
Here, we will present select in vitro and in vivo data to illustrate the versatility and general applicability of Sapreme’s endosomal escape technologies for different tissues and targets. Specifically, we will show data to support that in vivo gene expression knock-down achieved with Sapreme’s endosomal escape technology occurs at substantially reduced oligonucleotide doses, for example in the liver. Furthermore, we will share data showing longer term persistence of relevant downstream biomarkers, demonstrating improved cytoplasmic delivery does not preclude convenient dosing schedules. Combined with a benign tox profile, this supports an attractive developability profile. Lastly, we will highlight how such concepts translate to extrahepatic tissue targeting for diverse payloads, including oligonucleotides and protein payloads, to illustrate the general applicability of Sapreme’s platform.
 
Speaker
Miriam Bujny, PhD, Chief Dev. Officer, SapremeTechnologies BV
Dr Miriam Bujny joined Sapreme as CDO in 2020. She is an experienced translational science lead with background in RNA and antibody therapeutics, and uses this background at Sapreme to drive the development of next-generation macromolecules that circumvent endosomal entrapment.
Over the last twelve years, Miriam has held leadership positions in various drug discovery and early clinical development roles. At ProQR Therapeutics, she headed the Translational Science department with early development activities for several RNA therapy programs. Most recently, as Senior Director R&D at ProQR, she served as project leader responsible to lead an oligonucleotide candidate for a front-of-eye indication from research into the clinic. From 2012 to 2016, she worked in various roles for The Janssen Pharmaceutical companies of Johnson&Johnson, including anti-viral antibody therapy development and as Principal Scientist Predictive Biomarkers. From 2010 to 2012, Miriam worked as Scientist at Crucell, before its acquisition by Johnson & Johnson, in the Innovation & Discovery Labs on therapeutic antibody discovery. Miriam holds a Ph.D. in biochemistry from the University of Bristol with a specialization in endosomal transport. She completed postdoctoral training in the lab of Dr. Xiaowei Zhuang at Harvard University.

Wednesday, Nov 2, 2022, 12:00 PM - 1:00 PM EDT (美东时间)
FREE ZOOM WEBINAR

Registration Now

XXXX

SAPA-NE 24th Annual Conference

Saturday, Sep 24, 2022, 9 AM – 4 PM EDT (美东时间)
FREE ZOOM WEBINAR

Dear SAPA-NE Members and Friends,
 
Welcome to the SAPA-NE 24th Annual Conference, New Era and Unprecedented Opportunities for Developing Novel Therapies. This year’s conference comprises a full-day scientific program that focuses on RNAi Based Therapeutics and Novel RNA Bioengineering. The event features a series of lectures and presentations as well as panel discussions to be delivered by distinguished experts and leaders from both academic and industry. This annual conference will be held virtually on Saturday, Sep 24, 2022, 9 AM – 4 PM EDT (美东时间).
 
Topics include:
•            Future of Drug Discovery and Development
•            New Modality Platforms and Frontiers 
•            Enabling Technology Advancement and Applications 
•            Targeted Drug Delivery and Regulatory Issues
 
During the lunch session, we are delighted to hold career development panel discussion to help you build a successful career in the bio-pharmaceutical industry. Panelists from Moderna, BMS and Beam Therapeutics are looking forward to seeing many of you and are excited to share their diverse career experiences in developing gene, cell, mRNA and biologics therapies.
 
SAPA-NE Annual Conference is a great platform for participants to share their knowledge, wisdom, and viewpoints on science, technology, and business in the biomedical/pharmaceutical field. We sincerely thank all the keynote speakers and conference sponsors who have made this exciting program possible. Regardless of your interest in the subject matter, you would find their talks in the program stimulating and insightful, which may help to generate new ideas, innovations, and collaborations in your drug discovery and development efforts.
 
Please plan to register for the event early to ensure a visual seat is available for you!! Also, contact us at info@sapa-neweb.org if you have any membership or registration-related questions.
 
Thank you,
 
SAPA-NE 24th Annual Conference Organizing Committee

Saturday, Sep 24, 2022, 9 AM – 4 PM EDT (美东时间)
FREE ZOOM WEBINAR

Registration Now

How to become a SAPA-NE Member?

Join/Renew SAPE-NE Membership

Paid Membership Rate
Student & Postdoc (Annual): $15
Professionals (Annual): $30
Life-time: $300
Note: Paid membership will be effective immediately after purchase

Get Our Latest Updates

Add your email...

SAPA Annual Election of President-Elect and Executive Council (EC) Members

Dear SAPA member and friends,

SAPA is a not-for-profit and non-political organization registered in the State of New Jersey in the United States. The primary purpose of SAPA is to serve its membership, the pharmaceutical sciences as a whole, the biomedical and biotechnological communities, the health professions, and public interests.

The election of SAPA President and EC is an important annual step to ensure the success and continuity of SAPA operation. The election process has already started until 5 pm ET, Sunday, September 25, 2022. The election results will be announced during the SAPA 2022 Annual Conference at the Plenary Session on Saturday Oct 1^st.

Only the active SAPA members are eligible to vote. The voting links have already been distributed to the official SAPA members based on the emails we have on file (including members from the SAPA chapters). If you are a SAPA member and have not received the link after checking Spam Folder, or have any questions related to the voting please email election2022@sapaweb.org.

Together we can make SAPA stronger and better.

SAPA Election Committee

Jian Liu, PhD

Chair, Board of Director

John Sun, PhD

Immediate-Past-President

Xiaodong Chen, PhD

President

Yongmei Li, PhD

President-Elect

Greetings from BTBA!

Time is running out to secure the best rate for the 2022 BTBA Annual Symposium, which will be held in Cambridge, MA at the Harvard University Northwest Building, from July 23-24. We are now accepting abstract submission, this is a great opportunity for you to build connections, establish potential collaborations, and discuss your research with experts and journal editors in the relevant fields.

By submitting the abstract, you will have a chance to be selected as “selected speakers” and awarded a $30 gift card and a waiver of registration fee. In addition to 3 selected speakers, we will also select a few “best poster awards” from other poster presenters. (Number of awardees depends on the total number of presenters). Whether selected or not, these presentation experiences could help in building up the resume/CVs.

The deadline for both abstract submission and early bird registration is June 1.

By registering today, you'll get access to great sessions and workshops on:

Keynote speeches by Dr. Robert Langer and Dr. Jo Viney
Special talk in the advancement in individualized therapies by Dr. Timothy Yu
Leadership & management skills
Academia career development
Getting internship & Co-Op opportunities
Starting up a biotech company
Data-driven innovation in healthcare industry
Poster & oral presentations
Networking and more!

Also, don't miss our Gala celebrating BABA's 10th anniversary in the evening on July 23. See the full schedule.

Registration: https://btbatw.org/2022/

Abstract Submission Site (Ends 6/1/2022)

Please read carefully the following instructions before proceeding with the online submission.

Abstract should be 500 words or less in a single page.
2. A complete abstract should include background, methods, results, and conclusions.
Please prepare your abstract submission using the template. Download MS-Word Template.
If this is your first time using the EasyChair system, please create a new account.
The person who submits the abstract should mark him/herself as the corresponding author. (Due to the constraints of the EasyChair system settings, only the corresponding author is allowed to submit the abstract.)

Click HERE to learn more and register today!

We are looking forward to seeing you in Boston this summer!

Sincerely,

2022 BTBA Annual Symposium Organizing Committee

General Co-Chairs: Yu-Tien Hsu & Chih-Hung Chou

BTBA Committee

https://btbatw.org/

*If you don't wish to receive emails from us, please reply to unsubscribe.

**Please use AmazonSmile to buy your Amazon products. Amazon donates 0.5% of the price of your eligible AmazonSmile purchases to the charitable organization of your choice.

2022 波士頓臺灣人生物科技協會十週年年會將於7月23-24哈佛大學舉辦

麻州波士頓 – 2022年7月11日波士頓臺灣人生物科技協會 (Boston Taiwanese Biotechnology Association, BTBA) 將於7月23及24日於麻州劍橋哈佛大學 Northwest Building 舉行 BTBA2022 十週年年會，並於7月23日晚間舉辦十週年慶祝晚宴。年會採實體型式，搭配線上直播部份講座，讓世界各地生醫人能共襄盛舉。

十週年會邀請到兩位重量級學者、創業家擔任重點演講嘉賓，包含麻省理工學院學院教授，有「生醫界愛迪生」之稱的 Robert Langer 博士，其為莫德納 (Moderna) 等多家公司的聯合創始人，本次演講將講述從奈米科技至mRNA疫苗的發展及其影響力；以及在波士頓創下連續創業佳績的企業-科學家 Jo Viney 博士，其新創公司致力於應用AI技術於免疫藥物開發。此外，哈佛醫學院個人化基因治療專家Timothy Yu (游維文) 醫師將擔任特別演講講者，其為罹患罕見疾病貝登症(Batten disease) 的病童提供量身打造的治療藥物，開創了將個人化精準醫療應用於極罕見疾病的治療典範，游醫師將於年會分享為孤兒疾病的個體化治療的心得。

除了三位知名講者外，年會安排五大橫跨學業界的座談，邀請在美國生技醫藥界成功人士擔任座談者，包含Broad Institue核心成員、前基因科技生化研究公司 (Genentech Inc.) 副總沈華智教授(Morgan Sheng)、安博生物 (Ambrx Inc.) 法規事務副總裁洪筱玲博士、醫乘智慧有限公司

(AIXMED Inc.) 創辦人陳聖雄博士等。主題包括學業界職涯規劃與軟實力、創業經驗談、研究生的業界實習經驗分享等，涵括不同階段、學業界的需求。座談講者們更將與參與者一同參與午餐圓桌對談，與參與者們深入交流。

7月24日將舉辦早餐會，邀請三十位在美國不同地區的生醫人士與參與者交流互動，分享其職場心得還有工作機會。年會活動將帶給參與者在職涯發展的啟發，裝備其職場軟實力，並提供各國生技醫藥人士交流合作平臺。

今年度是波士頓臺灣人生物科技協會創會十週年，協會將於7月23日晚間於 Boston Marriott Cambridge 飯店舉辦十週年紀念晚宴。晚宴邀請到於新英格蘭音樂學院 (New England Conservatory) 任教的小提琴家黃竹君博士 (Jean Huang) 以及黃崇校先生帶領的 Boston You & Me 樂團擔任演出嘉賓，慶祝協會十年的積累、展望協會的成長與發展。

波士頓臺灣人生物科技協會創立於2012年，由在美的生醫領域留學生、博士後研究員、科學家、學業界專業人員組成的非營利組織。其創會理念為創造一個能讓生醫領域人士交流、互助、合作的平台，並作為台美兩地生技交流的橋樑。協會每月固定舉辦講座等活動，主題包括小型學術研討會分享、職涯發展講座，並於每年夏季舉辦年會。本次年會與哈佛臺灣學生會共同主辦，由駐波士頓科技組、駐波士頓教育組共同指導，感謝駐波士頓經濟文化辦事處、波士頓華僑文教中心、iHisto、AST Products、波克萊臺灣商會、新英格蘭玉山科技協會、BioLegend、Vizuro、Lantheus Medical Imaging支持贊助。了解更多波士頓台灣人生物科技協會活動資訊及會議註冊，請洽年會官網：https://btbatw.org/2022/。

New England Healthcare
Executive Network

12th Annual Summer Social with Lightning Pitches

August 1st, 2022

8:00am - 10:00am

Foley Hoag LLP
155 Seaport Boulevard, Boston
For Driving and Parking Information, CLICK HERE

Program Description
We are thrilled to return to an in-person event.
We are pleased to announce the 12^th Annual Summer Social Networking Event, Including Lightning Pitches and Keynote Speaker Kendalle Burlin O’Connell, Esq., President & Chief Operating Officer, MassBio, to be held on August 1^st.

This is the event of the year that you don't want to miss!
This program features several snapshot presentations, or lightning pitches, from local pre-venture and early-stage Life Science and Medical Device companies. Each pitching company will have 1 minute to impress us with their value proposition, and there will also be plenty of opportunities to network with the companies and fellow members.

Keynote Speaker

Kendalle Burlin O’Connell, Esq., President & Chief Operating Officer, MassBio
The Boston area is the number one life science cluster in the U.S. As President and COO, Kendalle leads the strategic direction, global expansion, and business operations of the organization, ensuring that Massachusetts life sciences companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world.

Pitching Companies
Abionic USA, Inc. - The fastest, laboratory-quality point of care sepsis test based on cutting-edge nanotechnology
Breathe BioMedical - Developing an accessible, non-invasive, and accurate breath test for early disease screening in Oncology and Neurology.
Cellens Inc - A next-generation diagnostic company developing non-invasive cancer diagnostics test for bladder cancer
Curadel Surgical Innovations - Injectable contrast agents that target tumors and anatomic structures during surgery using NIR light
Embrace Prevention Care - A value-based suite of preventive telehealth and pharmacy services designed to reduce hospitalizations and improve health for older adults
Enchanted Pursuit - We are invested in developing clothing and accessories for our customers who are restricted due to their medical devices
Genomic Expression - RNA Platform for detecting disease, monitoring health, and designing the next generation cures
HydroSpire Medical Inc - Hydrogen gas therapy to ameliorate ischemia/reperfusion injury from cardiac arrest and stroke
Imagine Scientific, Inc. - Monochromatic X-ray source for high quality, low dose imaging for radiology.
IMMAD LLC - Impairment Measurement of Marijuana
KevaHealth - SaaS platform for remote monitoring of patients with respiratory illness
Navigation Sciences, Inc. - Real-Time Margin Measurement for Precision Cancer Surgery
Neuronasal, Inc - Clinical phase biotech company with novel short-term drug treatment for Parkinson's and concussions with approved IND, phase 1 protocol
Novaurum Biosciences - Cell-based Coatings for Medical Devices
Predictive Healthcare - Connected Postoperative Wound Care Management
StetPulse LLC - Automatic UVC lightbox for use in hospital settings to disinfect medical equipment within 60 seconds
Svyet - Developing the first handheld, high-intensity, laser light therapy device to alleviate musculoskeletal pain and reduce recovery time
Synthera Health - We provide a virtual care and at home diagnostic solution for iron deficiency and iron deficiency anemia
VF24 - an innovative, science-based, on-the-go juice with demonstrated ability to promote well-being and healthy aging

Please register now for the event. This has been one of the most well-attended events of the year, with health innovation professionals from all backgrounds coming to see what's new and exciting in the local biotech, med-tech, pharma, and health IT economy.

We are looking forward to seeing you on August 1st. Please share this with your network!

Foley Hoag requires anyone that visits their office to be fully vaccinated, including the booster, if eligible (per CDC guidelines) that is, 14 days past the second Moderna or Pfizer shot or 14 days past the single J&J. They also require confirmation on you registration ticket of such vaccination status. In addition, no one will be permitted to come into their offices who have within the last ten days either tested positive for Covid or been in close contact with someone who tested positive for Covid. Masks are optional at this time, but guests should have one with them in case they are asked to wear one.
* Visitors cannot claim a religious or medical exemption to this policy.
* Walk-ins are not permitted at this time.

If you have any questions, please let me know.

Best,
NE Healthcare Executive Network

SAPA Members and Friends

Greetings from the Sino-American Pharmaceutical Professionals Association (SAPA). Over two years into the COVID-19 pandemic, life science and pharmaceutical innovations have brought hopes and miracles to humans. This year, we witnessed special hardship in the financial condition of start-up ventures due to economical fluctuations. As a global pharmaceutical professional organization, SAPA has always been committed to promoting the advancement of pharmaceutical science and biotechnology. To this end, the SAPA Healthcare Investment Forum and Roadshow is intended to bridge break-through science and capital investment, helping companies to grow, prosper, and succeed.

On June 18^th, we are pleased to have conducted a successful Roadshow showcasing 15 promising start-up ventures. We are now looking forward to building on that event with Roadshow II, taking place this coming Friday, June 24^th and further support the healthcare industry entrepreneurs and investors through our 2022 SAPA 5th Healthcare Investment Forum on Saturday, Jun 25^th.

A reminder that registration is still open for this year’s Healthcare Investment Forum and Roadshow.

For Roadshow II, we will be highlighting start-ups from biopharma and medtech to showcase their portfolio of innovations and business plans for further development. Seasoned investors have also been invited to provide professional feedback for each of our highlighted ventures.

In addition to Roadshow II, Friday, June 24^th, we will host a variety of events featuring renowned speakers and investment experts in the 2022 SAPA 5th Healthcare Investment Forum on Jun 25^th both in person and online. This year’s forum highlights entrepreneur crash courses, a round table clinic, and discussions between key experts around cross-border collaboration between the US and China across healthcare. Whether you are an entrepreneur, an investor, or an industry professional, we welcome you to join and learn the latest trends in healthcare and pharmaceutical industry!

Seats are limited, so make sure you claim your spot if you have not yet registered!

Event Schedule

Sat, Jun 18	Roadshow I (Virtual, completed)
8 – 11 pm EDT	Healthcare Investment Roadshow Nights
Fri, Jun 24	Roadshow II (Virtual)
8 – 11 pm EDT	Healthcare Investment Roadshow Nights
Sat, Jun 25	Investment Forum (Hybrid)
9 am – 11:55 am EDT	Morning Session Plenary session Fireside Chats
1 – 4:25 pm EDT	Afternoon Session Entrepreneurship Crash Course Round Table Clinics
4:45-5:45pm EDT	Networking Session Reception & networking at Hilton East Brunswick, sponsored by Medicilon
Fri, Jun 24 – Tue, Jun 28	Private 1:1 Meetings with Investors

Registration for Investment Forum and Roadshow

Online access to the Investment Forum on June 25^th is complimentary to SAPA members.

Registered Projects and Investors have complimentary access to the Forum, all Roadshows, and Private 1:1 Meetings. Details will be sent shortly to emails registered in applications.

https://sapaweb.org/2022-roadshow-registration/

Join SAPA*

https://sapaweb.org/become-member/

* We encourage you to join SAPA as a member to enjoy the member benefits for a whole year, including discounts to attend other SAPA events.

Investor Registration by Jun 24th

US investors: https://docs.google.com/forms/d/e/1FAIpQLSdPwCe5ktFaXzIivG5D2s4XiuIcBb3_27lIivjhpXnZGwMerg/viewform?usp=pp_url

Investors based in China: https://sapaweb.org/investor-contact-form

More details including the event brochure can be found on SAPA website.

Sneak Peek at Participating Companies in Roadshow II (Jun 24^th)

Partial List of Investors and Corporate BDs

Sponsors and collaborators

We look forward to meeting you onsite and virtual soon!

Sincerely,

2022 SAPA Healthcare Investment Forum & Roadshow Organizing Committee

Share This Email

ABOUT SAPA

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA. Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with seven chapters and more than 6,000 members.

SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization’s large membership base and superb scientific and technical abilities have allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.

As a non-profit organization registered in the US, SAPA receives generous sponsorship and support from numerous multinational companies in the US and overseas. SAPA will continue to provide a broad platform for scientific and technical discussion, talent exchange, and training for colleagues in the pharmaceutical industry from the US and China.

To ensure continued delivery of this e-mail, please add announcement@sapaweb.org to your e-mail address book.

How to add announcement@sapaweb.org to your safe sender list in Gmail:

1. Go to settings.

2. Click on the “Filters and Blocked Addresses” tab.

3. Click on “Create a new filter”.

4. Enter announcement@sapaweb.org in the “Filter from” area.

5. Click on “Create filter”.

6. Check the box before “Never send it to Spam”.

7. Click on “Create filter”.

You are in for a treat! Yes, instead of a “fireside chat”, we will have a “piano-side chat” — with the same concept and relaxed atmosphere but with a tune-twist in it, to warm up your heart and soul, and to light your paths forward.

We are delighted to invite back the keynote speaker Margaret Wacyk from last year’s SAPA Career Development Workshop Mater Class, and this time joined by one of her students who is also a truly seasoned executive and an exemplary leader in the pharma industry — Dr. Andreas Jessel to join this engaged conversation. We will learn from both of them the joy and essence of integrating art and leadership to enhance our capabilities and communication styles, and we invite you to be part of this unforgettable conversation.

Time: Tuesday, February 8, 2022, 8 – 9:30 pm.

Andreas Jessel, MD

VP, Global Project Head
Sanofi

Dr. Jessel is the Global Project Head at Sanofi. A physician-scientist with broad experience across the full pharmaceutical R&D value chain with focus on project leadership in multiple therapeutic areas, including immunology, cardio-vascular, and oncology.

Dr. Jessel has advanced analytical skills, strategic thinking capabilities and strong team leadership competencies. He is independent, engaged, with a positive and goal-directed work style.

Margaret Wacyk

Classical Pianist, Author, Educator,
and Founder of TheGrandManner.com

Hailed by the American Music Guide for her “versatility in many styles that emphasize chameleon-like transformations” Margaret is a trailblazer who is breathing new life into the art of piano playing.

Margaret is a concert pianist trained in the 19th century tradition of Golden Tone. Additionally, she is the author of two books, a composer and recording artist. Her second recording, Piano Works was chosen as Gramophone Magazine’s Best New Releases from North America.

Sincerely,

SAPA Executive Council

You are currently subscribed to receive email news and promotions from SAPAweb.org.

To ensure continued delivery of this e-mail, please add sapa-announce@sapaweb.org to your e-mail address book.

How to add sapa-announce@sapaweb.org to your safe sender list in Gmail:
1. Go to settings.
2. Click on the “Filters and Blocked Addresses” tab.
3. Click on “Create a new filter”.
4. Enter sapa-announce@sapaweb.org in the “Filter from” area.
5. Click on “Create filter”.
6. Check the box before “Never send it to Spam”.
7. Click on “Create filter”.

If you would like to unsubscribe from SAPA, please send an email to sapa-announce@sapaweb.org with the subject “UNSUBSCRIBE”

Sino-American Pharmaceutical Professionals Association
P.O. Box 3228, 213 Carnegie Center, Princeton, NJ 08540

Event by BTBA-Boston Taiwanese Biotechnology Association

Public Anyone on or off Facebook

【Career Development Series】How to Interview Like a Pro?

How to make your application stand out?

What are the top interview mistakes?

“You are hired!” learn from the perspective of a hiring manager

Welcome to the first workshop of the Career Development Series! This workshop will focus on practical tips to help you stand out in your interviews. Join the workshop to learn key skills and career strategies to improve future possibilities!

𝗧𝗶𝗺𝗲: January 23 (Sun), 2 pm to 4:00 pm EST

𝗣𝗹𝗮𝗰𝗲: Virtual event

𝗥𝗦𝗩𝗣: https://forms.gle/35PWZniogrjaMLbX6

＊＊＊本活動將會以英文進行＊＊＊

想知道如何才能從眾多履歷中脫穎而出嗎?

想知道面試中大家經常犯哪些錯誤呢?

「你被錄取了！」想知道主管在面試時，都會看哪些眉眉角角呢？

想得到理想中的工作嗎？絕不要錯過 Career Development Series 的第一場講座 – How to Interview Like a Pro? 我們邀請到曾任職於以Co-op著稱的東北大學職涯顧問及三位藥廠主管，他們將分享如何在面試中脫穎而出的技巧，以及面試中的常見誤區，讓你求職過程更加如虎添翼！

時間: 1/23 (日), 東岸時間下午 2-4點

地點: 線上活動

報名: https://forms.gle/35PWZniogrjaMLbX6

SPEAKERS

✽ Nancy Waggner. Former Graduate Coop & Internship Coordinator, Department of Pharmaceutical Sciences, Northeastern University

✽ Yvonne Meng, PhD. Principal Scientist, Biologics Discovery, Janssen Biotherapeutics (JBIO) at Johnson & Johnson

✽ Ho-Chou Tu, PhD. Associate Director, Alnylam Pharmaceuticals

✽ Shian-Huey Chiang, PhD. Director, Head of Emerging Science Biology, Target Sciences, ES&I, Pfizer Inc.

MODERATOR
✽ Yvonne Meng, PhD. Principal Scientist, Biologics Discovery, Janssen Biotherapeutics (JBIO) at Johnson & Johnson (https://www.linkedin.com/in/hwyvonnemeng/)

Event agenda:
2:05 pm - 2:30 pm Speech by Ms. Nancy Waggner
2:30 pm - 3:10 pm Panel discussion
3:10 pm - 3:25 pm Q & A
3:25 pm - 3:45 pm Networking

Next Career Development Series Event:
1/25 (Tue) 8:30 pm - 10:00 pm Professional Career – Where Do We Go From Here? (Hosted by NEACP)

Co-Host Organizations:
Education Division, TECO in Boston
Harvard GSAS Taiwan Student Association (HTSA)
New England Association of Chinese Professionals (NEACP)
The Federation of Taiwanese Students Association of New England (FTSANE)

Guest Bio

NANCY WAGGNER
Nancy has over 25 years of experience helping students and alumni prepare for success in their chosen fields or discovering new fields of interest if the need arises. Nancy is recently retired, after working at Northeastern University for nearly twenty years, as well as Brandeis University and Roger Williams School of Law. In her most recent position at Northeastern’s Department of Pharmaceutical Sciences, she developed and taught a course to prepare students, most of whom were international, for looking for and finding jobs. She enjoys helping people find their talents and learning how to help potential employers know what those talents are.
Linkedin: https://www.linkedin.com/in/nancy-waggner-125922a/

HO-CHOU TU
Dr. Ho-Chou Tu is an Associate Director at Alnylam Pharmaceuticals, where she is a research lead in multiple early-stage pre-clinical programs using RNAi-based therapies. These include interdisciplinary approaches combining clinical, in vitro & in vivo models, bioinformatics & data analysis to address important topics in the drug discovery process, including exploratory biomarker identification & validation.
Ho-Chou holds a B.S. in Zoology from National Taiwan University and a Ph.D. in Cell and Molecular Biology from Washington University. Previously, Ho-Chou worked as a Research Fellow at the Memorial Sloan-Kettering Cancer Center (2010-2011) and Boston Children’s Hospital (2011-2015).
Linkedin: https://www.linkedin.com/in/ho-chou-tu/

SHIAN-HUEY CHIANG
Dr. Shian-Huey Chiang, is currently Director and Head of Emerging Science Biology, Target Sciences, in Emerging Science & Innovation (ES&I) organization in Pfizer, Boston. Her research focuses on target validation in inflammatory diseases, rare diseases, cancers, metabolic syndrome, and fibrosis.
Shian-Huey received her bachelor’s degree from the Department of Agriculture Chemistry, National Taiwan University in 1991 and a master’s degree in Biochemistry from National Yang-Ming University in 1994. Shian-Huey received her PhD in the Cellular and Molecular Biology Program at the University of Michigan, Ann Arbor in 2001, where she studied the insulin signaling pathway. During her tenure at the University of Michigan, she published numerous first-author papers in Nature, Cell, and Nature Medicine. After that, she joined GlaxoSmithKline as an investigator in North Carolina (2011-2015) and joined Pfizer as a Principal Scientist and Senior Principal Scientist at Centers for Therapeutic Innovation (CTI) in Boston (2015~2019).
Linkedin: https://www.linkedin.com/in/shianhueychiang/

YVONNE MENG
Dr. Yvonne Meng is currently a Principal Scientist of Janssen Biotherapeutics (JBIO) at Johnson & Johnson in Boston. Her research interests focus on therapeutic biologics discovery and protein engineering.
Prior to Johnson & Johnson, Yvonne received her BSc in Life Sciences from the National University of Kaohsiung in 2006, and her PhD in Biomedical and Biological Sciences from Cornell University in 2013. After graduation, she joined the industry as a Postdoctoral Research Fellow at Pfizer (2014-2015), Staff Scientist at Takeda (2015-2016), Senior Scientist at Merck (2016-2020), and a Senior Scientist Group Lead at Entrada Therapeutics (2020).
Linkedin: https://www.linkedin.com/in/hwyvonnemeng/

Co-Host Organizations:

◆ Education Division, TECO in Boston
◆ Harvard GSAS Taiwan Student Association (HTSA)
◆ New England Association of Chinese Professionals (NEACP)
◆ The Federation of Taiwanese Students Association of New England (FTSANE)

See less

Thank you very much for attending the first 2022 BTBA Academic Seminar! We want to thank the speakers -- Drs. Ya-Yun Cheng and Meng-Ju Wu -- for sharing their research with us! Special thanks to the moderator, Dr. Fan-Yun Lan, for hosting and facilitating the panel discussion.

If you miss the workshop, check out
������ https://youtu.be/LInxDLriykc

Save the dates!!
Career Development Series
PART I: How to Interview Like a Pro?
 Time January 23 (Sun), 2:00 pm to 4:00 pm EST
 Host Organization: BTBA; HTSA
 RSVP: https://forms.gle/DutEGitzx6xXst5H9

PART II: Professional Career: Where Do We Go From Here?
 Time January 25 (Tue), 8:30 pm to 10:00 pm EST
 Host Organization: NEACP
 RSVP: https://forms.gle/Dr8ARV9GGagZwwWT6

BTBA January Monthly Meeting
Link:  https://harvard.zoom.us/j/95162985672?pwd=SmpHRS9VSHNRVzNha2hBanVieWdzUT09

Happy Innovative Holidays!

Have a safe and happy holiday season! The World Medical Innovation Forum is coming in the New Year. Gene and cell therapy – medicine’s game changer, is the focus.

MAY 2–4, 2022

Join us for three unrivaled days in May.

Early bird rates expire January 15.

Register Today

The Forum team will continue to monitor COVID-19 and event safety protocols. Updates regarding the format of our event will be shared later this winter.

Confirmed Speakers

Global leaders will share their insights on GCT, biotech and the future of care.

Albert Bourla, PhD

CEO, Pfizer

Robert Bradway

CEO, Amgen

Marc Casper

CEO, Thermo Fisher Scientific

Sekar Kathiresan, MD

CEO, Verve Therapeutics

Anne Klibanski, MD

CEO, Mass General Brigham

Stephen Knight, MD

President & Managing Partner, F-Prime Capital

Peter Marks, MD, PhD

Director, Center for Biologics Evaluation and Research, FDA

Andrew Plump, MD, PhD

President, R&D, Takeda

John Reed, MD, PhD

EVP, Global Head of R&D, Sanofi

Ned Sharpless, MD

Director, National Cancer Institute

Selected Topics

1st
Open Box Science
x
BTBA-Boston Taiwanese Biotechnology Association
Joint Seminar!
==SEMINAR MODERATOR HIGHLIGHT==
Jerry Lin | Massachusetts General Hospital
2:15 pm-3:15pm EST Jan 24th (Sunday), 2021
Google Meet: http://meet.google.com/tbh-zkdu-yti
Join Open Box Science email list:
https://forms.gle/x5u4Tsx55Eh9RQrx5
The 22nd SAPA-NE Annual Conference
A New Era in Biotech and Life Science

Sat, Jan 23 | Free Zoom Webinar
9:00 AM – 6:00 PM EST
Seats are limited
Please register ASAP
Register Now (Free)
Time: Sat, Jan 23rd, 9:00 AM – 6:00 PM EST
Language: English
Venue: Zoom Webinar, Spatial Chat (Virtual Networking, Job Hunting, Vendor Show)
Speakers & Presentation Topics
Register Now (Free)
Agenda
Morning Sessions: 9:00AM-12:30PM
Noon Sessions: 12:30PM-2:00PM
Afternoon Sessions: 2:00PM-6:00PM
Register Now (Free)
Speaker Bio
Dan Barouch, M.D., Ph.D.
Member, National Academy of Medicine; William Bosworth Castle Professor of Medicine, Harvard Medical School; Director, Center for Virology and Vaccine Research, BIDMC; Member, Ragon Institute of MGH, MIT, and Harvard
Eric Fischer, Ph.D.
Eric Fischeris an Independent Investigator at Dana-Farber Cancer Institute, Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Co-Director of the DFCI Center for Protein Degradation. He and his lab have significantly contributed to our understanding of small molecule mediated protein degradation, and its widespread application in academia and industry. Dr. Fischer has co-founded Civetta Therapeutics, Jengu Therapeutics, and Neomorph and serves on the scientific advisory board for the Institute for Protein Innovation.
John Evans, MBA
John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners.
Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune.
Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
Jamie Stokes, Ph.D.
Jamie received his PhD from University of Cambridge in 2014. Between 2014 and 2017 Jamie was a Roche Postdoctoral Research Fellow at Cambridge where he worked on a number of projects at the chemistry-biology interface including the design and synthesis of de-novo antibiotic-quorum sensing small molecule conjugates and the development of methodology to allow access to diverse collections of small molecule screening collections. Jamie has worked at Concept Life Sciences since 2017 on a number of different medicinal chemistry programs and has a special interest in new approaches to synthesis and antibody drug conjugates.
Zonghai Li, M.D., Ph.D.
Zonghai Li is the Chairman, Chief Executive Officer, Chief Scientific Officer and Founder of CARsgen Therapeutics. He is dedicated himself to develop curable treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become one of the most widely used peptides in antitumor study now. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper and advancing the first clinical trial of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. He earned a M.D. and M.S. from Xiangya Medical School of Central South University and a Ph.D. from Fudan University.
Liang Schweizer, Ph.D.
Liang Schweizer is the co-founder, President and CEO of HiFiBiO Therapeutics, an emerging multinational biotherapeutics company. Previously, she was a co-founder and CSO for Harbour Biomed. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi and Director of Leads Evaluation at Bristol-Myers Squibb Company. Under her leadership, her various teams made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple immunomodulation drug candidates.
Dian Su, Ph.D.
Dian is a Senior Scientist in Drug Metabolism and Pharmacokinetics (DMPK) at Genentech. Her research focus has been on ADC/small molecule/peptide DMPK areas mainly in the pre-clinical stage. At DMPK, her primary focus lies in small molecule and peptide drug metabolism in discovery stage. In this role, her responsibilities include: 1) developing new generation assays for metabolite identification (Met ID) to improve the throughput and tackle challenges associated with drug metabolite ID; 2) exploring deep understanding of metabolite formation and biological impact, and establish structure−metabolism relationship (SMR) for drug metabolites.
Yan Chen, Ph.D. Founder, President and CEO of Elpis Biopharmaceuticals
Yan brings more than 20 years of expertise in both mRNA display technology and biologic drug discovery in the oncology disease area. She was Biotherapeutics Discovery Head at Juno Therapeutics in Boston and Senior Vice President of Research at X-Body Biosciences which was acquired by Juno in 2015. Previously, she was an investigator and project leader in Oncology Biotherapeutics at Novartis Institutes for Biomedical Research. Earlier in her career, she was a scientist at Phylos and Adnexus playing instrumental roles in establishing the mRNA antibody and protein display technology platforms. Yan was a postdoctoral trainee in Immunology at Tufts Medical School and received her PhD in Tumor Immunology from National University of Singapore. She is the co-inventor of more than 20 antibody technologies and biologic therapeutics patents.
Sanchayita Ghose, Ph.D.
Sanchayita Ghose is currently the Executive Director of Global Downstream Bioprocess Development at Bristol Myers Squibb. She leads a multi-site team responsible for downstream process development of BMS’ entire clinical biologics portfolio. Sanchayita has > 20 years of experience in bioprocess development with increasing roles of responsibility in a variety of biopharmaceutical companies: BMS (9), Amgen (6), Biogen (5). Over her career, she has made numerous technical contributions in this field and is the author of > 100 conference presentations, publications, book chapters and patents. She has a PhD in Chemical & Biological Engineering from Prof. Steve Cramer’s lab at Rensselaer (Troy, NY) and a BS in Chemical Engineering from Jadavpur University, India. Sanchayita is the mom of two-school aged kids and has lived if four US states across both coasts. In her free time, she enjoys travel, reading and hiking.
Brad Warsen
Brad Warsen is the Executive Director of Quality for the Devens Cell Therapy Facility at Bristol Myers Squibb. Brad joined Bristol Myers Squibb in 2013 and previously served as the Head of Quality for US Biologics overseeing quality operations at the Devens and Syracuse sites. Previous to this, he served as the Director of Quality at Devens, interim Director of Quality at Syracuse and as head of Quality Control Operations and Quality Assurance Operations both at Devens. Brad has over 20 years of quality experience and previously served in quality leadership roles overseeing external manufacturing of biologics drug product at Shire and internal manufacturing of drug substance at Pfizer (including raw materials, compliance and QA Operations roles). Brad began his career in manufacturing and process development at Pharm-Eco Laboratories and has a BS in Chemistry from Wheaton (IL) College.
Ji Li, Ph.D.
Ji Li is a Principal Scientist at BMS Kendall square site, Mechanism of Cancer Resistance TRC. He currently services as the Biology Lead for two drug discovery projects. He also leads a DepMap data analysis effort and leverages a genome-wide CRISPR screening platform to discover novel cancer targets. Prior to BMS, he worked at the Broad Institute and Dana-Farber Cancer Institute, where he led efforts in functional cancer genomics and the identification of synthetic lethality in breast cancer. Ji received his Ph.D in Cell Biology from NYU School of Medicine and a Bachelors’ degree in Biomedical Sciences from Peking University.
Chun Shao, Ph.D.
Chun Shao is a Principal Scientist at BMS Devens site, who joined Bristol-Myers Squibb in 2018. Chun interfaces closely with biologics process development upstream/downstream team and provides mass spec analytical support for bioprocess optimization. Chun is also co-leading Devens PAN chapter to drive Diversity & Inclusion initiatives. Prior to BMS, Chun worked at GlaxoSmithKline between 2016 and 2018 as characterization lead to support biologics process development. Chun received her PhD degree in Biochemistry from Boston University in 2016. Chun is a big fan of Boston Celtics and Bruins and looking forward to shouting out loudly in TD garden soon with crowds!
Robert Flaumenhaft, M.D., Ph.D.
Dr. Flaumenhaft is a Professor of Medicine at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis. His laboratory focuses on endothelial & platelet biology and mechanisms of thrombus formation. Dr. Flaumenhaft is director of the T32 training program, “Blood Coagulation and Vascular Biology” and has editorial positions at Blood, JCI Insight, Thrombosis and Haemostasis, Thrombosis Research, and Seminars in Thrombosis and Hemostasis. He is Chairperson of the Hemostasis, Thrombosis, Blood Cells, and Transfusion NIH Study. He was the scientific co-chair of the ASH 2019 meeting and was the Chairman of the FASEB meeting on Functional Disulfide Bonds in Health and Disease. He has received awards from the Burroughs Wellcome Fund, the American Society of Hematology, and the American Heart Association. He was elected to the American Society for Clinical Investigation and subsequently to the American Association of Physicians. He is the recipient of an Outstanding Investigator Award from NIH.
Ai-Min Hui, MD, Ph.D. President of Global R&D, CMO, and Chair of the Scientific Committee of Fosun Pharma；Director of Shanghai Key Laboratory of Stem Cell Therapy; Former global Vice-President of Clinical Development Oncology at Sanofi
Dr. Hui has 30 years of experiences in cancer treatment and innovative drug development in world's top medical centers and pharmaceutical companies. He has led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. He has recently led the deal of the joint development of an mRNA vaccine against COVID-19 BNT162 between BioNTech and Fosun Pharma and the execution of the program.
Julia Ding, Ph.D.
Julia Ding is leading process analytical development at Bristol Myers Squibb biologic development sites in US. She is leading diverse and cross-functional teams responsible for: Establishing strategic vision and implementation of global biologic PAT and rapid analysis technology development; Establishing and advancing new technologies in PAT and real-time release of biologic process; Developing and implementing analytical methodologies to enable and support bioprocess development and characterization; Advancing analytical CMC control strategies throughout biologic clinical development phases.
Prior to joining Bristol Myers Squibb, Julia Ding led a multifunctional analytical development team responsible for analytical assay development/validation/life cycle management, characterization and cGMP quality control testing of biologic products at PPD. Julia obtained her Ph.D. in physical organic chemistry from Emory University and postdoc from University of California at Berkeley.
Qingcong Lin, Ph.D.
Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation, focusing on providing services on gene-targeting and humanized mouse models, using cutting-edge ESC and CRISPR-Cas9 technology for immuno-oncology antibody candidate in vivo efficacy and toxicity assessment. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.
Ambar Boodhoo
Ambar is Americas Life Sciences Strategy and Transactions Leader at EY. He advises life sciences and health care clients on their capital and transaction agendas from strategy through execution, primarily focusing on large, complex investments. Over the last 20 years, he has supported private equity funds and corporate clients in transformational transactions to realize their strategic objectives and improve growth. His experience includes financial and operational diligence in taking companies private, leveraged recapitalizations, carve-outs, rollups, divestitures, PIPE and public financing. He has worked extensively in the UK and the US, and has led global engagements with clients and transaction teams in Europe, India, the Middle East and Asia.
Alex Li, Ph.D. Managing Director of TF Capital
Board Director of SAPA, previous president of SAPA-NE
Dr. Alex Li is a venture capital investor with investing experience in both United States and China. He specialized in the life science industry with focus on cutting edge technology and first-in-class therapeutic medicine. He currently serves on the boards of five innovated companies. TF Capital, one of the premium venture capital fund in China, have invested in near 100 companies, with successful exits like Zai Lab, Hua Medicine, Henlix, and Frontage, etc. Alex is one of the three investment decision committee members in TF Capital. Before Joining TF Capital, Alex was Managing Director of Fosun Pharma for three years. Alex worked as a research scientist in Biogen for seventeen years. Alex obtained his Ph.D. degree in Biochemistry, Cellular and Molecular Biology (BCMB) from the University of Tennessee.
Register Now (Free)
How to become a SAPA-NE Member?
Join/Renew SAPA-NE Membership
Paid Membership Rate
Student & Postdoc (Annual): $15
Professionals (Annual): $30
Life-time: $300
Note: Paid membership will be effective immediately after purchase.
2021摩根会议周期间 SAPA与BioNJ联合推出网络研讨会（链接更新）

SAPA-HQ 美中药协SAPA

2021年J. P. Morgan会议周期间，美中药协SAPA与BioNJ将联合推出网络研讨会，关注医药领域美中企业间的合作。

2020年十月初在第28届SAPA年会上，SAPA与BioNJ签订了长期合作的协议。此次网络研讨会将是两个组织联手举办的第一个活动。

本次研讨会主题包括

01
美中生物制药行业现状
02
新泽西相关的美中合作机会
03
两国的监管环境与流程
04
投资者对在美中开展业务的见解

时间
1月14日, 2021
8:30-10:30 AM EST
网页介绍：
http://campaign.r20.constantcontact.com/render?preview=true&m=1102061150585&ca=e0e04c4c-ecb1-46d4-a3f8-ff81b39e0968&id=preview

本活动免注册费。注册链接更新，已注册的仍然有效。
注册链接:
扫描下方二维码注册或点击阅读原文注册

https://myemail.constantcontact.com/Webinar---China-and-U-S--Collaboration--Innovation-on-the-Horizon.html?soid=1102061150585&aid=56d6P4bovQA

Modified on 2021-01-10
2020 SAPA-NE Career Development Webinar

Original SAPA-NE 美中药协SAPA

S
M
T
W
T
F
S

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

2020
DECEMBER
2

活动时间：
2020年12月2日 8:00 PM - 9:00 PM
(EDT, 美国东部时间）

请点击以下链接或扫描右侧二维码进行注册
https://www.sapa-neweb.org/2020stock_tax

美中医药开发协会新英格兰（SAPA-NE）将于2020年12月2日携手安永（EY），邀请行业专家为你详细讲述美国员工股权激励计划以及相关税务影响。

不管你是初入职场，创业达人，或者企业高管，员工股权激励计划都与你息息相关。当下，股权激励已经成为薪酬架构中非常重要的一部分。一方面，公司通过股权激励来吸引和保留人才，另一方面，员工有机会借助税务递延的优势实现财富的积累。然而越来越复杂的股权激励计划是否常常让你困惑？各种形式的股权激励计划到底是什么意思？在注定不平凡的2020年以及后疫情时代，如何更好的在员工股权计划中受益？我们邀请到安永的资深专家为大家剖析不同形式的股权激励计划，以及相关的公司或个人层面的美国税务影响。

演讲嘉宾
Jason S French
Managing Director, People Advisory Services

Jason is a Managing Director in the People Advisory Services practice of EY, with 15 years of experience related to the analysis, design and implementation of compensation and benefit matters for both US domestic and internationally mobile employees. Jason’s areas of expertise are specifically within the compensation and benefits space for both US and multinational companies around the globe, equity compensation, global equity, golden parachutes, annual & long-term incentive plan and design, payroll and tax withholding, and US tax technical matters. Jason also advises companies on SEC Executive Compensation Proxy Disclosure rules and director compensation matters.

Claudia Timmermans
Senior Manager, People Advisory Services

Claudia has over 8 years of experience advising clients regarding (global) compensation and benefits arrangements. Claudia has significant experience on assisting clients with maximizing the benefits of equity compensation plans for mobile employee workforces, which includes advising clients on equity plan design and implementation, tax feasibility and due diligence, risk mitigation, global payroll transformation and employee education. She also advises clients on the implications of Internal Revenue Code Sections 162(m), 280G (golden parachutes), 409A, and 457A.

点击阅读原文(Read More) 进入注册链接
Read more
Reads 272

2020 CABA Boston BioForum Online

Original Jo Lee CABA
收录于话题
#Biotech Forum 2

#Investment 2

#Covid-19 2

#Clinical Study 2
Boston
BioForum
On

在疯狂的2020年压抑了太久，CABA Boston BioForum Online将于12月19日举行，为这不平凡的一年做个强势收官，总结COVID-19带来的危与机，预测生物医药投资趋势，并展望美中两个大经济体生物医药业的未来。会议邀请了数位行业大咖与大家齐聚线上，与您分享探讨2020年生物医药大事件！

Topics
热点话题
1
Chuan He, PhD, Professor, HHMI, University of Chicago
RNA Methylation in Human Diseases

Speaker Bio:
Dr. He is the John T. Wilson Distinguished Service Professor in the Department of Chemistry and Department of Biochemistry and Molecular Biology at the University of Chicago. He received his bachelor of science degree in 1994 from the University of Science and Technology of China and his Ph.D. in chemistry from the Massachusetts Institute of Technology in 2000, studying under professor Stephen J. Lippard. After training as a Damon-Runyon postdoctoral fellow with professor Gregory L. Verdine at Harvard University, he joined the University of Chicago as an assistant professor, rising to associate professor in 2008 and full professor in 2010. He was selected as an investigator of the Howard Hughes Medical Institute in 2013. Dr. He’s research spans a broad range of fields including chemical biology, RNA biology, epigenetics, biochemistry, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. In 2011, his group discovered reversible RNA methylation as a new mechanism of gene expression regulation. His laboratory has spearheaded the development of enabling technologies to study the biology of RNA and DNA modifications.
2
Robert DeLuccia,
Managing Partner and Founder, Acurx Pharmaceuticals
Acurx Developing a New Class of Antibiotics: Preparedness for the Next Infectious Disease Pandemic, Antimicrobial Resistance

Speaker Bio:
Bob DeLuccia has 50 years’ executive and hands-on experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Mr. DeLuccia has held senior executive positions in both companies and has also been Chief Executive Officer of two publicly (NASDAQ) traded biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP). He was most recently Executive Chairman of publicly-traded (NASDAQ) Dipexium Pharmaceuticals, Inc., a development-stage biopharmaceutical company based in New York City which he co-founded and subsequently took public. In April, 2017, Dipexium closed a merger with PLx Pharma Inc. (PLXP-NASDAQ), a late-stage specialty pharmaceutical company focused on developing Aspertec^TM, its aspirin product in its proprietary PLxGuard^TM drug delivery system to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy and better tolerated treatment. He is currently Co-Founder and Managing Partner of Acurx Pharmaceuticals, a New York-based, development-stage biopharmaceutical company focused on developing a new class of antibiotics to treat common infections caused by certain Gram- positive bacteria and to combat the global crisis of antimicrobial resistance (AMR) to currently available antibiotics. He is also a member of the Board of Directors of IBEX Pharmaceuticals, a publicly- traded (IBT.V/TSXV.IBT), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use and arthritis assays widely used in osteoarthritis research.
His therapeutic areas of marketing experience include new product introductions and drug development in the following areas: Antibiotics and antidiabetic agents: (doxycycline, bacampicillin, cefaperazone, chlorpropamide and glypizide); Cardiovasculars: amrinone, iohexol contrast media, clopidogrel. New drug development areas included: topical creams/gels for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection.
Mr. DeLuccia received his undergraduate degree and MBA from Iona College, New York. Military Service, Officer, U.S. Army Corps of Engineers.
3
Ricky Sun, PhD, Partner, Bain Capital Life Sciences
Life Science Investing, a Global Perspective

Speaker Bio:

Experience
Dr. Sun joined Bain Capital Life Sciences in 2016 and is a partner. He is currently a member of the Board of Directors of Arcutis (NASDAQ: ARQT), Annexon (NASDAQ: ANNX), and Savara (NASDAQ: SVRA). He is also a board observer of Pharvaris. Previously he also served as a board observer for Replimune (NASDAQ: REPL).
Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.

Education
Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a BA in chemistry.
4
Chris Garbedian, CEO, Xontogeny
Venture Investment in Rare Diseases

Speaker Bio:

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.
Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.
5
Angus Grant, PhD, Chief Business Executive, BeiGene
Building Portfolio with Business Development Support for China

Speaker Bio:

Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant will oversee business development and alliance management, and help drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.

日期：2020年12月19日
时间：美东时间早上9点/中国时间晚上10点
Join Zoom Meeting

Meeting ID: 879 9988 3589
Passcode: 498231
长

按二维码参加会议

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Chinese-American BioMedical Association

【预告】数字科技下的精准精神健康治疗｜医路领航第四期

Original 哈佛中国健康协会 Harvard Healthcare Club

本文共1841字，阅读约需6分钟

数字科技下的精准精神健康治疗

医路领航研讨会第四期

在世界范围内，大约有七分之一的人曾患有精神健康疾病，而且这个比例还在持续增长。除了未满足的医疗需求外，精神健康疾病还会导致社会生产力下降约35％，人均预期寿命缩短10-25年，从而导致巨大的社会和经济负担。一方面，早期筛查和诊断以及进行早期干预治疗可以有效地延迟甚至预防疾病的发作，并最大程度地减少对患者和家庭造成的情感和经济损失。另一方面，从长远角度来看，持续的随访和治疗进展监测对于预防复发和提高患者的生活质量至关重要。但是，与当前护理模式中的疗法相比，预防和随访在很大程度上被忽略了。

通过先进的人工智能算法和多模式大数据，数字化精神健康产品现在能够捕获个人的数字化生物标记物，从而在整个连续治疗过程中提供个性化护理，包括提供早期诊断、治疗建议以及进行持续的患者监测。

我们很荣幸地邀请到了两位来自数字化精神健康治疗领域的发展先驱公司的演讲嘉宾，与我们分享他们的公司愿景，以及他们对数字化精神健康治疗未来的看法：Paul Dagum博士（Mindstrong的创始人和前首席执行官），Sharief Taraman博士（Cognoa首席医务官）。Cognoa专注于儿童神经发育障碍的治疗，例如自闭症和注意缺陷与多动障碍；Mindstrong关注对严重的精神障碍的治疗。

Dr. Paul Dagum

Mindstrong是一家医疗创新公司，以Mindstrong的创始人，副董事长兼首席科学官Paul Dagum博士的前瞻性研究作为基础。Mindstrong致力于通过数字化测量，利用数据科学和线上护理模型的创新来改变精神健康状态。

Mindstrong提供的解决方案和健康服务有助于在护理过程中抢得先机以改善治疗效果。他们得到了ARCH Venture Partners，General Catalyst，Foresite Capital，Optum Ventures，8VC等投资公司的支持。

Paul Dagum博士是Mindstrong的创始人，并在2019年11月前一直担任其首席执行官。他是一位企业家，也是医师和计算机科学家，他曾作为创始人、首席科学官、首席技术官和首席执行官，将产品、技术和商业模式的创新引入医疗健康、网络安全和供应链领域，并受到了多家知名风险投资公司的支持。Dagum博士对动态贝叶斯网络的早期研究已在许多现代应用中使用。他还开发了用于数据科学的大规模可扩展算法，应用于大量世界领先的数据公司，以及通过从移动设备被动捕获的人机交互中，创建了首个脑功能数字化量度技术，两者均获得了专利。同时，Dagum博士也在持续测量技术和人工智能赋能的远程医疗基础上，设计了用于精神健康的数字化护理模式。

Dagum博士在斯坦福大学期间领导了由美国国家科学基金会（NSF）和美国国立卫生研究院（NIH）资助的研究，发表了超过85篇在计算机科学和医学领域的同行评审文章和书籍章节，并获得了超过25项专利。Dagum博士获得了多伦多大学的理论物理学硕士学位和理论计算机科学博士学位，以及斯坦福大学的医学博士学位和外科住院医师培训。

Dr. Sharief Taraman

Cognoa是一家市场领先的专注于儿科行为健康的公司。Cognoa正在开发处方数字疗法，以更早地识别和治疗行为健康问题，从而改变护理标准，并改善会影响儿童终身的治疗效果。Cognoa的主要处方产品，包括首个针对自闭症的数字诊断技术和首个针对自闭症儿童的处方数字化疗法，均已获得FDA的突破性设备称号。

该公司的AI技术平台还同时支持Cognoa的其他产品线，包括解决来自ADHD和焦虑症等其他未满足的临床需求。

医学博士Sharief Taraman获得了神经病学领域的双重认证，包括美国精神病学委员会的儿童神经病学和美国预防医学委员会的神经病学及临床信息学的专业资格认证。他是CHOC儿童专科学院的儿科神经病学系主任，也是加州大学欧文分校医学院的临床副教授。

Taraman博士是儿科行为健康公司Cognoa的首席医务官，该公司的前两个处方数字化设备均获得了FDA突破性设备的称号，这两种设备旨在提高行为健康问题的早期治疗的护理标准。

活动安排

研讨会主题

数字科技下的精准精神健康治疗

主讲嘉宾

Mindstrong - Paul Dagum, MD, PhD

Cognoa - Sharief Taraman, MD

活动方式

Zoom 直播

活动时间

美东时间: 11月21日 8:00-9:00 pm

美西时间: 11月21日 5:00-6:00 pm

北京时间: 11月22日 9:00-10:00 am

报名链接

扫描下方二维码或点击“阅读原文”报名

审核通过后，将由邮件确认参会方式

活动鸣谢

统筹：茅傲岳朱子溪闫姿秀王目阔

王硕王紫戴钰

文字：闫姿秀

美编：王紫朱霁清

特别感谢：盛开

医路领航研讨会

医路领航研讨会（Frontier Healthcare Cross Talk）以激励创新技术转化为目的，以研讨会为载体，邀请中美的顶级投资人、头部企业、优秀创业公司、及来自哈佛、MIT等的专家学者，帮助哈佛及友校的学生学者群体跟踪最实用的前沿医疗产业动态，协同中美医疗业界掌握最干货的前沿科学研究成果。通过定期跨学科、跨领域的不断探讨，共同助力技术创新上、中、下游的对接与耦合。

往期回顾

医路领航第三期丨数字疗法重新定义精神健康治疗

医路领航第二期丨人工智能赋能药物研发

医路领航第一期丨AI如何助力数字化战疫

哈佛中国健康协会是哈佛大学首个专注于中国医疗系统系统和健康产业的学生组织，致力于通过对话顶尖世界学者及行业领袖、中国产业参访行和专题研讨会等活动，帮助哈佛学生学者打破学术和产业界的信息壁垒、深入探讨中国医疗健康发展趋势，凝聚专业化的人才网络，启迪未来医疗健康领域的引领者。

有興趣在美國長期發展的朋友看過來囉！

波士頓台灣人生物科技協會 (BTBA) 與哈佛台灣學生會 (HTSA) 將合作舉辦「綠卡&H1B申請線上講座與經驗分享」，邀請綠楓法律集團創所律師陳啟耕律師 (Danny Chen) 主講綠卡及H1B申請的過程，並邀請三位不同身份轉換取得綠卡的學長姊分享自身經驗。本講座將包含以下主題：

- 各種身份 (F, J, OPT)如何銜接轉換綠卡或H1B？
- 何種條件、時機可以開始申請綠卡？要累積什麼經驗、資歷對申請綠卡有幫助？
- EB1、EB2申請難度及條件？
- 學長姊過來人經驗分享，若時光倒流他們會/不會做的事是什麼？
- 近期移民政策對申請綠卡、H1B的影響

歡迎同學們和BTBA的各位，請先填寫與會報名表，也讓我們知道你有什麼問題，我們會先行告知律師和學長姐準備回答你的問題喔！
https://forms.gle/yDByicWFSp73MdUk6

[活動分享] BTBA monthly Seminar!

=========================================

BTBA Monthly seminar is back! We are happy to have two outstanding scientists from the Harvard community to present their recent work.

Kai-Ting Shade (Instructor, Massachusetts General Hospital)

"Sialylation of immunoglobulin E is a determinant of allergic pathogenicity"

Annie Cheng (Postdoc, Brigham and Women's Hospital)

"Nanoparticles: A multifunctional vehicle for theranostics"

Moderator: Jerry Lin (Postdoc, Massachusetts General Hospital)

Meeting link coming soon!

https://www.facebook.com/events/318160246139364/

SAPANE獎學金9/18報名截止

在这个Covid-19给大家带来很多困难的特殊时刻，新英格兰美中医药开发协会（SAPA-NE）一如既往的支持社区、鼓励有志于医药研究领域的下一代。请符合条件的2020应届高中毕业生尽快申请今年度的奖学金。

申请条件：

1.美国国籍或绿卡，居住在新英格兰地区。

2. GPA3.3以上，SAT1450以上（或其他考试的同等成绩）。

3. 今年考入4年制大学并学习与生命科学相关专业。

4. 奖学金金额$1000。

截止日期9/18, 要准备Essay等。详细申请信息见链接： https://www.sapa-neweb.org/scholarship

最近開始有點秋天的氣息，就表示新的年度又要來了！！感謝過去一路以來大家的支持和鼓勵，就是下週日9/13，
BTBA-Boston Taiwanese Biotechnology Association
要來舉辦2020-2021 Welcoming party!!

走過路過不要錯過～派對上我們要一起來討論接下來新活動內容，另外也想聽取大家的意見跟未來活動喜好。相較於過往的學業界活動，新的一年我們還有新面向的互動方式喔～希望在這個疫情期間，BTBA的大家可以透過迎新趴認識一下新來到波士頓的朋友，還有一路陪伴的老朋友們！

滑鼠往下按連結就可以報名參加這次的迎新派對了！希望下週日可以線上見囉！如果有任何問題歡迎聯絡今年負責人

22021 BTBA VIy

We are excited to invite everyone to come and join 2020-2021 Boston Taiwanese Biotech Association (BTBA) Virtual Welcome Party on September 13, 2020!

Hope everyone is well, healthy, and safe during the pandemic. As the new school year arrived, BTBA welcomes everyone who calls Beantown a new home to join our virtual welcome party on September 13, 2020! No matter you are an academic professional, a biotech professional, a postdoctoral researcher or a student, we sincerely invite you to come and connect with us. At BTBA, you will find a group of passionate scientists and enthusiasts to network and discuss career opportunities & possibilities, healthcare related topics, life science research, pharmaceuticals, drug discovery start-ups as well as the innovation and technology that powers it all.
We thrive because of you!
We are thrilled to get to know you, so come and join us!

各位親愛的朋友，大家好！希望大家在COVID期間都健康平安！新的學年又要開始囉！波士頓台灣人生物科技協會 (BTBA) 今年的第一場活動將在 9月13日登場~! 歡迎新朋友&老朋友一起來互相認識，不管是來念書，來工作，來當Postdoc，都不要錯過BTBA的活動。不是生物領域，也沒有問題！來聽聽看新的一年可以有甚麼精彩可期的活動!

時間 / Time:
2020-09-13 (Sun) 1 pm - 3 pm

地點 / Place:
Microsoft Team Meeting
Meeting link will be sent separately, please make sure leave your e-mail below!

聯絡人 / Contact:
Yvonne Meng 孟憲薇; hsienweimeng@gmail.com
Erica Cai 蔡佩珊; ericapscai@gmail.com

Please complete this form to RSVP (Registration is free!).

Follow & Like us on Facebook: https://www.facebook.com/btbatw/

會議流程 / Event:
1:00 am – 1:30 pm Meet and Greet
1:30 pm – 2:00 pm BTBA Introduction
2:00 pm – 3:00 pm Networking

美中藥協年度科學盛會【2020 SAPA科學論壇】將於8月15日（星期六）以網絡會議形式舉行。

今年主題是“生物醫學創新轉型的驅動力”，將重點關註生物醫學創新在🩺診斷與精準醫學，🧬細胞與基因療法，以及藥物研發的新技術等領域的最新趨勢與突破。世界知名的科學家，包括哈佛大學的George Church教授和斯坦福大學的Richard N. Zare教授，以及諸多製藥行業領導者、科學家和企業家，將分享他們對生物醫學創新的思考與見解。 🔛論壇還設有互動交流小組會議，提供了同主講人和資深業內人士在線面對面交流的機會。
SAPA會員福利免費註冊，學生註冊享優惠！
⏰時間：2020年8月15日週六 9:00 AM-5:00 PM EDT
🔗註冊鏈接：https://sapaweb.org/event/2020-scientific-symposium/

2020 BTBA Virtual Symposium in two weeks!!!

https://btbatw.org/2020/

This year, we are honored to have Dr. Taiyin Yang, the Executive Vice President of Gilead Sciences, who supervised the development of Remdesivir, to deliver the keynote address.

Please also check out the rest of meeting agenda!

Register NOW:
https://www.eventbrite.com/e/2020-btba-virtual-symposium-re…

*Flyer designed: Amy Kao

7月11日 OCEAN-BIO SEMINAR：中美投资并购中的国家安全审查和出口管制问题

Original OCEAN BIO 海华会生物分会 2 days ago

2020年02月13日，美国财政部于今年年初颁布的全面实施《2018年外国投资风险审查现代化法案》（Foreign Investment Risk Review Modernization Act of 2018）（“FIRRMA”）的两项最终实施条例（“实施条例”）正式生效实施。

FIRRMA及其实施条例正式施行后，有可能给未来的中美投资及并购带来“寒蝉效应”。中美投资并购活动将面临更为复杂的监管环境，必须及时从国家安全审查角度进行有效的评估，并据此提前进行合适的筹划安排。

00100

2020年07月11日，海外华人企业家联合会生物分会（OCEAN-BIO）将邀请著名国际律师事务所Dorsey & Whitney（德汇律师事务所）合伙人、德汇全美及中国联合业务主席——潘惜唇律师，为大家做“中美投资并购中的国家安全审查和出口管制问题”的主题演讲。

直播时间

美东时间 2020年7月11日，周六，晚八点

July 11, 2020, Saturday, 8PM, US Eastern Time
Zoom Link: https://us02web.zoom.us/j/8151859178

Zoom ID: 815 185 9178

Mobile: +13126266799, 8151859178# US (Chicago)

+19292056099, 8151859178# US (New York)

----------------------------------------------------------

本次网络直播会议

对全球华人企业家免费开放

SAPA 健康投资论坛暨路演六月线上举行项目资本双向征集

Original SAPA-HQ 美中药协SAPA 3 days ago

2020 SAPA Roadshow

新冠肺炎疫情给全球社会经济带来深刻影响，整个创业生态和风险投资领域面临着极大的冲击。然而“危”中有“机”，医药健康行业逆行而上获得高度关注，疫情同时也激发产业变革，催生新的发展机遇。

2018年以来在大纽约地区名声鹊起，广受投资人和企业家们喜爱的美中药协（SAPA）旗舰活动 – 2020 SAPA健康产业投资峰会暨项目路演，将因时而变，重新设计为线上和线下两个部分：第一部分为线上部分，包括投资论坛有关投资和创业的主题演讲和讨论，一系列的线上路演，1对1会议。

首轮路演将于2020年6月20日举行。第二部分线下会议将在10月初的SAPA 2020年会上举行。

在这里，您将通过SAPA创投平台：

• 了解最新生物医药的投资和研发最新动态

• 与顶尖的投资人交流互动

• 与天使轮到Pre-IPO的各类投资人和各大药厂的BD高层交流互动，了解投资全周期细节

• 企业家和投资人1对1会面，充分展示/了解项目和交流融资兴趣

• 除了获得投资，还可能有对外授权技术和产品的机会

• 获得SAPA药界资深专家和投资界人士的专业评审和建议

• 与同行交流分享经验心得

• 广结善缘，获得更多潜在的人才与合作伙伴资源

• 全线上活动，无地域限制，低成本参与，会后可观看活动录像

壹

征集路演1对1项目

项目报名要求：

生命科学行业，包括但不限于：制药生物技术公司医疗器材诊断与数字化健康公司。

每一份申请都会由SAPA投资论坛组委会认真严格审阅，最为优秀的部分项目会邀请在投资论坛进行线上路演，或与投资人进行线上1对1会面。

请填写下方的Google form或者QQ survey报名：

• Google form:

https://forms.gle/ks8DLZLj5X7BnXUF9

• QQ survey, （如无法使用Google form）:

https://wj.qq.com/s2/5912374/a9d1

贰

征集投资者

我们将邀请知名生命科学领域投资机构投资人担当路演评委。同时也欢迎对活动感兴趣的投资人以及公司BD联系我们，商务拓展负责人及其他相关人员联系我们参加1：1会议。

请填写下方的Google form或者QQ survey

• Google form:

https://forms.gle/hU2xYhNQ2N32m5A36

• QQ survey, （如无法使用Google form）:

https://wj.qq.com/s2/6153302/f8f3

首轮线上创投路演报名截止时间:

2020年5月29日，星期五，11:59 pm (EDT)

若有疑问或了解更多详情请联系

roadshow@sapaweb.org

叁

欢迎合作伙伴与赞助商

同时，SAPA也邀请您成为我们的合作伙伴与赞助商！具体方式详见下方宣传手册，有意向者请联系：fundraising@sapaweb.org

本次活动稍后将开放观众注册，敬请关注SAPA微信公众号和SAPA LinkedIn主页！

第8屆BTBA Annual Symposium]🔥🔥🔥

第8屆的台灣人生物科技協會(BTBA)年會將在7月11日於隆重登場！學生會是活動的Co-Host喔~

因應疫情，今年將改為半天的線上活動，雖然時間縮短，但一樣內容精彩可期，邀請了吉利德藥廠的講者來擔任Keynote speaker。更多資訊將在6月陸續公布，期待跟大家線上見！

BTBA是由在波士頓從事生物、醫學、科技相關的台灣學者、博士、學生組成的社團，希望能互相給予彼此在專業、研究上發展的支持
👉更多資訊，請發落粉專：https://www.facebook.com/btbatw/
👉BTBA Monthly seminar：https://www.facebook.com/events/842317972853712/

注册链接 https://zoom.com.cn/webinar/register/2915864885850/WN_AlNghXDqQlO36-IP508RPg

2020 World Medical Innovation Forum | Virtual, Interactive, State of the Art | Monday, May 11

Our Mass General Brigham Harvard faculty including front line clinicians, CEOs and top journalists will examine the coronavirus response, the future of medicine, and AI. Reporters from the New York Times, TIME and CNBC will moderate. Added highlights are digital adoption, new infectious disease technology, investment prospects and national security leadership perceptions on health care challenges and opportunities.

Join Us and Get Answers from a doctor / epidemiologist- What You Need to Know About COVID-19
JOIN at https://harvard.zoom.us/j/861442364

This is a rapidly evolving situation. Many information is confusing and not relevant to yourself. I thought it would be best to have a communication with a physician who experienced SARS outbreak, and then now COVID outbreak. Dr. Lin is an infectious expert, received his medical training from National Taiwan University and doctorate degree from Harvard.

Speaker: , Dr. Hsien-ho Lin, MD, ScD.林先和
About
http://www.daai.tv/news/life/241795

Agenda:
8pm -8:15pm sharing (Hsien-ho)
8:15-8:30pm Q&A (general public)

Event Page:
https://www.facebook.com/events/145654656856593/

#重量級講者 #Baxter台灣總經理 #數位醫療趨勢 #腹膜透析
隨著破壞性科技如AI、物聯網的應用在醫療照護領域逐一落地，醫療數位化與智慧化已成為未來醫療的趨勢。比翼加速器很榮幸能邀請到國際前十大醫材廠Baxter 臺灣&香港區總經理Gary Wang 來分享 “ Embrace the Digital Healthcare Future”。
Baxter (NYSE:BAX) 為全球前十大醫材廠，主要專注於腎臟與腹膜透析領域。總經理 Gary 將分享當前數位醫療的趨勢，並進一步介紹Baxter 如何在數位醫療領域創新及結合數據打造更好的醫療服務。
Gary Wang 在醫療領域有長達25年的豐富經驗，除了Baxter 外曾任職於GSK、楊森藥廠、SANOFI。同時Gary也是香港科研製藥協會 (The Hong Kong Association of the Pharmaceutical Industry) 的成員。更多資訊詳見Gary的LinkedIn: https://www.linkedin.com/in/gary-wong-a1768534/

活動報名網址：https://www.accupass.com/event/2002180841306745931680

附註：本次活動將以英文進行

2019-2020 BTBA Seminar series

Sunday, December 8, 2019 at 2 PM – 3:30 PM EST

Tomorrow

MIT Building E25: Room 119/121

[11/17/2019]
Ming-Ru Wu 吳明儒: Synthetic Genetic Circuits for Cancer Immunotherapy: Turning Cancer Cells Against Themselves
Yu-Ru Lee 李育儒: Targeting PTEN Dimerization and Selective Ubiquitination for Cancer Therapy

[12/8/2019]
Jim Chou 周駿:
Plotting against cancer: which killers to hire?
Zhongyou Li 李忠佑:
The immune regulatory effect of a 5' tRNA half in outer membrane vesicles induced by tobramycin

[01/26/2020]
Vicky Chen-ching Yuan 袁禎璟
Zoe Liu 劉紀秀

[02/23/2020]
Po-Cheng Lin 林柏成
Szu-Ta Chen 陳思達

[03/22/2020]
Fan-Yun Lan 藍凡耘
Ying-Chih Lo 羅盈智

[4/19/2020]
I-Cheng Ho 何宜虔
Chi-Hua Yu 游濟華

[5/17/2020]
Pin Kuang Lai 賴品光
Jason Lu 盧彥君

[6/14/2020]
Chia-En Lien 連加恩
Chi-An (Annie) Cheng 程吉安

The 11th CABA MDDI SYMPOSIUM

MDDI CABA

11th MDDI

Precision Medicine

The 11th CABA Medical Device and Diagnostics Innovation Symposium (MDDI), co-sponsored by NECINA and HMS CSSA, is scheduled for Saturday, December 14th, 2019 at the Conference Center at Waltham Woods, 860 Winter St, Waltham, MA 02451.

The annual MDDI Symposium is a major CABA event that attracts prominent entrepreneurs, investors, biotech and pharmaceutical executives, academic and industry scientists, as well as professionals in the legal, financial, and healthcare industries, both locally and internationally. Past symposiums were extremely well attended. More than 200 professional attendees will be expected.

The theme of this symposium is “Precision Medicine”. Tailoring medical treatment to the individual characteristics of each patient not only has the potential for better therapeutic outcomes, but also provides crucial information for healthcare decision-making. A holistic assessment of patients' data, including genomic, epigenetic, and clinical information, will offer great insights on and better approaches to effective treatment. Topics of the symposium will include classification of human cells into subpopulations for CAR-T therapy, application of AI in kidney pathologic diagnosis, and novel biomarkers on clinical mass spectrometry for better maternity diseases management.

Speakers

John Hallinan, MassBio Chief Business Officer
Wilson Zhang, CEO/ Milu Labs
Regina Au, Principal, New Product Planning/Strategic Planning, BioMarketing Insight
Mingru Wu, Cancer Immunology & Virology; Dana-Farber Cancer Institute, Member of Faculty Department of Immunology; Harvard Medical School
Shen Luan, Senior Director, Thermofisher Science
Allena J. Ji, Director of Clinical Mass Spectrometry Laboratory, Sanofi

Symposium December 4th, 2019, Boston, USA “Gene Regulation in Differentiation and Cancer” Agenda

8:45-9:15 Registration and Continental breakfast

9:15-9:30 Opening Remarks Alan Rosmarin, M.D.

9.30-11:15 Session I: Chair: Dr. Alan Rosmarin 9.30-10:00 Keynote Speaker Jonathan Licht M.D. Director- The University of Florida Health Cancer Center, The Marshall E. Rinker, Sr. Foundation and David B. and Leighan R. Rinker Chair Disorders of histones and histone methylation in cancer

10:00 to 10:15 Ulrich Steidl, M.D. Ph.D. Lineage Commitment and Differentiation – 15 years later

10:15-1:30 Shannon Elf, Ph.D. Identifying novel molecular dependencies in CALR-mutated myeloproliferative neoplasms

10:30-10:45 Huimin Chen, M.D. Ph.D. 3D Bioprinting Application in Cartilage Repair

10:45-11:00 Annalisa DiRuscio, M.D. Ph.D. RNAs: the real writers of the epigenetic code

11:00-11:15 Sophia Adamia, Ph.D. AML epigenetics for the 21st century: novel biomarkers and drug targets

11:15-12:30 Session II Chair: Dr. Ulrich Steidl

11:15-11:30 Dong-Er Zhang, Ph.D. Dynamics of RASSF2 in leukemogenesis

11:30-11:45 Justin Wheat, Ph.D. Single Molecule Analysis of Spi1 Transcription Dynamics During Differentiation

11:45-12:00 Meritxell Alberich-Jorda, Ph.D. Chronic inflammation, stem cells and leukemia

12:00-12:15 Britta Will, Ph.D. Novel safeguards of hematopoietic stem cell identity

12:15-12:30 Barbara Wegiel, Ph.D. Scavenging of free heme by hemopexin is a key check-point in cancer growth and metastases

12:30-1:30 Lunch break

1:30-3:30 Session III Chair: Dr. Dong-Er Zhang

1:30-2:00 Keynote Speaker David Livingston, M.D., Deputy Director, Dana-Farber/Harvard Cancer Center Chief, Charles A. Dana Division of Human Cancer Genetics Emil Frei Professor of Genetics and Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts En route in a normal mammary epithelial cell to BRCA1 breast cancer

2:00-2:15 Dan Costa, M.D., Ph.D. Dan Tenen and lung cancer: an accidental encounter that helped revolutionize precision oncology

2:15-2:30 Gang Huang, Ph.D. Pseudohypoxia - An Underlying Mechanism and therapeutic Target of Myelodysplastic Syndromes

2:30-2:45 Hideyo Hirai, MD. Ph.D. C/EBPbeta isoforms regulate hematopoietic stem cells under stress condition

2:45-3:00 Philipp Staber, MD. Ph.D. Identifying functional switches in hematologic malignancies

3:00-3:15 Rob Welner, Ph.D. Targeting Leukemia through the Marrow Microenvironment

3:15-3:30 Anne Satterthwaite, Ph.D. Signals controlling plasma cell accumulation and autoantibody production in lupus

3:30-3:45 Coffee Break

3:45-5:30 Session IV Chair: Dr. Dan Costa

3:45-4:00 Alan Rosmarin, MD. A tribute to Dan Tenen

4:00-4:15 Elena Levantini, Ph.D. Identification of a targetable KRAS-mutant epithelial population in NSCLC

4:15-4:30 Li Chai, M.D. Targeting SALL4 in Cancer

4:30-4:45 Omid Harandi, Ph.D. MRNA-based Engineering of Red Cell Therapeutics (RCTs) to Generate Potent, Allogeneic Cellular Therapies

4:45-5:00 Bon Trinh, Ph.D. RNA Regulation of Promoter-Enhancer Communication

5:00-5:15 Balazs Halmos, MD. Ph.D. Precision lung cancer medicine- a "personal" journey

5:15-5:45 Closing ceremony Daniel G. Tenen, M.D.

5:45-6:00 Group Picture

6:00-8:30 Dinner party (Invited only)

Honoring Daniel G. Tenen, M.D.

For his many contributions to the scientific community

Date: Wednesday December 4th, 2019

Time: 8:45am – 6:00pm

Location: DFCI Jimmy Fund Auditorium Binney Street, Boston, MA, 02115

Symposium Committee Co-Chairs Alan G. Rosmarin, M.D. Deputy Editor of Hematology at UpToDate Chief Mission Officer, the Samuel Waxman Cancer Research Foundation. Dong-Er Zhang, Ph.D. Professor of Pathology and Biological Sciences University of California San Diego Moores UCSD Cancer Center La Jolla, CA Ulrich Steidl, M.D., Ph.D. Professor of Cell Biology and Medicine, Albert Einstein College of Medicine - Montefiore Medical Center New York, NY Daniel Costa, M.D., Ph.D. Associate Professor of Medicine, Harvard Medical School Co-director Lung cancer research program within Cancer Research Institute at BIDMC Co-leader of the lung cancer program at Dana-Farber/Harvard Cancer Center

Symposium Organizing Committee Contacts: gang.huang@cchmc.org lchai@bwh.harvard.edu pu.zhang@Novartis.com

Gene

Special Talk//台灣大學農學院盧虎生院長：台灣農業的現況: 生物經濟及智慧農業

Friday, November 15, 2019 at 5:30 PM – 7:30 PM EST

TMEC 250 mini amphitheater, 260 Longwood Ave, Boston, MA 02115

*講者: 臺灣大學生物資源暨農農學院長盧虎生教授
*講題: 台灣農業的現況: 生物經濟及智慧農業
*時間: 11/15/19 (Fri) 5:30 pm
*地點: Harvard Medical School TMEC 250 Mini amphitheater
(260 Longwood Ave, Boston, MA 02115)
http://www.bioagri.ntu.edu.tw/cbaintro03.php
*提供簡單茶水點心
(感謝TECO贊助協辦)

哈佛医学院华人专家学者联合会

Chinese Scientists and Scholars Association at Harvard Medical School

HMS-CSSA

Website: http://www.hms-cssa.org

微信公众号: hmscssa

HMS-CSSA助手微信号：hmscssa2007

（添加好友后可由助手号邀请加入 HMS-CSSA 学术群、HMS-CSSA 生活群）

2019美中生物医药协会投资创业论坛

From: Jo Lee CABA

2019美中生物医药协会投资创业论坛

2019 Chinese-American BioMedical Association (CABA) Investment and Entrepreneurship (IE) Symposium

2019年9月28日（周六）美东时间早上8点

Boston Marriott Newton

2345 Commonwealth Avenue

Newton, Massachusetts 02466 USA

活动介绍

2019美中生物医药协会投资创业论坛又将如期登陆波城，现论坛诚邀各位怀揣热情的投资人及创业者共同参与。自2008年起，IE论坛已经连续多年于波城举办并且取得圆满成功。我们持续与生物制药创业公司和投资者携手合作，发掘并推动制药领域的投资创业。此次IE论坛，我们再次邀请到多位来自工业界和学术界的专家，以及资深的投资人和律师，就生物制药领域的一系列前沿话题进行交流探讨，并提供针对行业现状及未来趋势的重要见解。
Nandita Shangari, Ph.D. Principle, Novartis Venture Fund
Brian Gallagher, Ph.D. Partner, Abingworth
Hong Cheng, Ph.D. Head of Research Strategy, Sanofi
Lixin Shen, Ph.D. Founder and Chief Executive Officer, Guangzhou Alagen PharmTech
Yihan Wang, Ph.D. Founder and Chief Executive Officer, Shenzhen TargetRx, Inc.
Yongzhong Wang, Ph.D.   Chief Executive Officer, CMAB Biopharma
Linda Ji, J.D. Partner, McDermott Will & Emery
Hugh Davis, Ph.D. Chief Business Officer, Frontage Laboratories, Inc
Jens Stephan, Ph.D.   Professor, East Michigan University
Dapeng Sun, Ph.D. Chief Technology Officer, ABclonal Technology
John Giszczak Vice President, Business Development MORE Health
Shaoyu Chang, M.D.   Vice President, FC Capital
Pengpeng Li, Ph.D.  Analyst, 5AM Ventures
Joe Zhou, MBA  Fouding Partner, BAC Investment
Hongkai He Venture Partner, Skylight Investment
Jianying Shi, Ph.D.  Vice President, HD Biopharmaceuticals
Michael Zhao   Founder, QTang Ventures
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Chinese-American BioMedical Association

The 2019 BTBA symposium will be held on August 3-4th at Harvard University Northwest Science Building, Cambridge, MA. This event will feature more than 20 speakers, including experts who lead clinical development activities in human diseases, and professionals in the field of gene regulation and molecular immunology. We have crafted an agenda that includes inspiring presentations and interactive forums focused on the novel technologies in synthetic biology, penetrating insights into biotech environments around the US and practical experiences about how to survive in academia/industry. No matter you are biotech entrepreneurs, professionals or students, you can find what you need to advance your future career in here. Please join our annual symposium by registering here>>>

👉👉👉👉👉Ticket: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

👍👍For more information, please visit our website: http://btbatw.org/2019/website

一年一度的BTBA symposium開放售票囉!!
來自各個領域的專家數十載企業實戰經驗透徹犀利的職場分析全部無私分享給你
還在等甚麼，還不趕快來報名!!!!!!!
時間: 2019 Aug 3-4th
地點: Harvard University Northwest Science Building
🎈🎈🎈報名連結: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

2019 SAPA-NE 21st Annual Conference

Deliver Optimal Medicines to All Patients

(Boston Cambridge Marriott, June 8th, 2019)

秉承20年发展壮大的辉煌，胸怀治愈人类疾患的梦想，新英格兰美中医药开发协会SAPA-NE将于2019年06月08日在Boston Marriott Cambridge 宾馆 (50 Broadway, Cambridge, MA) 隆重举行第21届年会。届时，学术精英、企业领袖、投资英才、药界同仁等将云集全球医药创新的圣地—波士顿剑桥，围绕Developing and Delivering the Advanced Medicines to All Patients 的会议主题展开学术交流、共同探讨人类医药事业发展之未来。欢迎光临，敬请注册。

更多详情：https://www.sapa-neweb.org/ac2019

注册链接（早鸟截至日期：5/17/2019）：https://www.sapa-neweb.org/ac2019event

Upcoming Event: 2019-06-08 SAPA-NE 21st Annual Conference: Deliver Optimal Medicines to All Patients

Selected keynote speakers:

* Edward Hu, Co-CEO, WUXI AppTec

* Sridaran Natesan, PhD, Vice President, Sanofi

* X. Shirley Liu, PhD, Professor at Dana–Farber Cancer Institute and Harvard T.H. Chan School of Public Health

* Brad Loncar, CEO, Loncar Investments

* Shi Wenzhao, President of Digital China Health Technologies Corporation Limited

* Shaun R. Coughlin, MD, PhD, VP, Global Head of Cardiovascular and Metabolism at Novartis

SAPA-NE 2019 年会将集中探讨医药行业前沿，热门人工智能，大数据分析，先进肿瘤免疫疗法，多重治疗模式，等等话题。会议还将组织CEO论坛，与大家面对面分享经验。精彩不容错过，欢迎光临，敬请注册：https://www.sapa-neweb.org/ac2019 （早鸟截至日期：5/17/2019：https://www.sapa-neweb.org/ac2019event ）

Speaker介绍：Gregory Verdine博士
FogPharma由生物技术领域知名连续创业家、哈佛大学终身教授Gregory Verdine博士创立。这家新锐公司致力于突破现有的常规手段，找到全新的新药分子。其核心技术是Verdine教授在哈佛大学研发的新型技术- 可穿透细胞的迷你蛋白（CPMP）。它有望靶向“不可成药”的靶点，为新药发现与研发带来变革。
除了FogPharma之外，Greg Verdine博士还创办并领导了LifeMine Therapeutics，该公司创建了首个基于真菌基因组的药物开发平台，可以高效快速开发新药。LifeMine Therapeutics和FogPharma总部都设在马萨诸塞州剑桥，并于2016年成立。Verdine博士因其在生涯中担任生命科学家，企业家，投资人和首席执行官的成功角色而得到高度评价。他是哈佛大学和哈佛医学院的Erving教授，先后创建了多家纳斯达克上市的生物技术公司，包括Wave LifeSciences，Enanta，Eleven Bio，Variagenics，Tokai，Aileron和一家私有公司Gloucester制药公司，由Celgene于2010年收购。

Sino-American Pharmaceutical Professionals Association
New England (SAPA-NE)
High School Excellence Scholarship Program

Eligibility
The applicant must meet the following criteria:

The applicant must be a United States citizen or legal resident alien residing in the New England area (MA, NH, RI, VT, CT, ME).

The applicant must be a graduating high school senior with a GPA of 3.3 (out of 4.0) or greater and an SAT score above 1450 (out of 1600) or equivalent.

The applicant must be enrolling for the first time in a full-time undergraduate course of study at an accredited 4-year college or university in the upcoming academic year. The applicant should pursue or intend to pursue a major related to life sciences.

Members of SAPA-NE Board of Directors, the SAPA-NE Advisory Committee, or the SAPA-NE Scholarship Selection Committee cannot participate on the selection process. Any member of the SAPA-NE Executive Committee must disclose should his or her relative become an applicant. Failure to disclose a position of conflict of interest will not only disqualify the candidate, but also lead to disciplinary action towards the executive member.

Application procedures
Application materials

The applicant must submit:

A brief resume illustrating major accomplishments during the applicant’s K-12 education

An essay (~600 words) to illustrate what the applicant will be pursuing at college and what inspired him or her to make such a decision

A recommendation letter from the school counselor and two letters of recommendation from teachers who can attest and comment on the applicant's achievements and development potentials

A copy of high school transcript and a copy of standard test results.

A copy of acceptance letter from the college the applicant intends to enroll

An application fee ($30) needs to be submitted along with the application. Please make any checks payable to SAPA-NE. The application fee can be waived if the applicant’s parent or legal guardian is a member of SAPA.

Online application form is available: http://www.sapa-neweb.org/scholarship-application/. You may fill in the online application form, print the application, and send the application along with recommendation letters, a copy of acceptance letter from the college, and application fee to the following address.

Application Deadline
May 17, 2019 (Postmarked)

Application Mail Address:
Please enclose ALL the materials, including sealed recommendation letters, in ONE package and send to SAPA-NE:

SAPA-NE High School Excellence Scholarship
12 Arbor Lane, Winchester MA 01890

Email Addresses:
Please notify Drs. Huo Li and Guiqing Liang after you send out the application
Huo Li: huoli2@gmail.com; Guiqing Liang: lianggq1@gmail.com

Selection Procedures
An independent Scholarship Selection Committee appointed by the SAPA-NE Executive Committee will evaluate all valid applications and nominate several strongest candidates. SAPA-NE Executive Committee will make the final selection of up to three award recipients.
Applicants will be evaluated on:

Academic performance, leadership quality, and community/school service.

Demonstrated potential and commitment to a career aspiration that has a broad impact in the society.

Award Acceptance
Recipients of 2019 SAPA-NE High School Excellence Scholarship will be notified by Scholarship Selection Committee by email and will also be posted at SAPA-NE homepage http://www.sapa-neweb.org/scholarship.

Upon contact by Scholarship Selection Committee, a SAPA-NE Scholar must submit an acknowledgment letter stating the acceptance of the scholarship award. The recipients (required) and their parents/legal guardians (optional) will attend the 2019 SAPA-NE High School Excellence Scholarship Award Ceremony at 21st SAPA-NE Annual Conference on June 8, 2019 at Boston Marriott Cambridge, Cambridge MA. A short speech (5 minutes) made by each award recipient will be expected at the ceremony. Each recipient will be awarded up to $1000 one-time scholarship.

2019 Boston BioForum (CABA) Driving Transformation in Life Sciences Industry

2019波士顿生物医药论坛｜ CABA

Date and time: Saturday, May 4, 2019 @ 8AM EST
The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451

Register Now

The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and healthcare fields to talk about hot topics in the Life Science industry.

Future of Immuno-Oncology

Outlook of Cell & Gene Therapy

AI & Big Data in Health

Evolving Landscape for Life Science Investment

Next Big Thing in Biotech & Pharma

Speakers

Will Brownsberger
MA State Senator

Jos Melenhorst
Director, CAR-T Product Development
University of Pennsylvania

Jonathan Terrett
Head of Immuno-Oncology
CRISPR Therapeutics

Sadik Kassim
Executive Director
Kite Pharma

Nenard Grmusa
SVP, Head of External Innovation
Takeda

Lei Xiao
CEO
Innovative Cellular Therapeutics

Derrick Li
Head of Strategy and Investor Relations
Cellular Biomedicine Group

Nick Valiante
Founder and CEO
Glyde Bio

F. Stephen Hodi
Directot, Center for IO
Dana Farber Cancer Institute, Harvard Medical School

William Cao
CEO
GraCell Bio

Weichang Zhou
Chief Technology Officer
Wuxi Biologics

Scott Brown
Director
Computational Chemistry
Sunovian

Catherine Sabatos-Peyton
Direcctor
Novartis Institutes for BioMedical Research

2019年哈佛华人生物医学年会

From HMS-CSSA HMSCSSA 3/23

欢迎大家参加哈佛大学2019年华人生物医学年会！本次学术年会将于4月28日（周日）在波士顿儿童医院召开。参会报名请见文末注册链接（.edu 邮箱注册免费）。

哈佛华人生物医学年会学术论坛自2009年举办以来，每次都吸引了数百名来自中国和美国学者参加，已成为中美生命科学和医学领域重要的学术会议之一。今年的学术论坛恰逢此学术盛会十周年，将覆盖从基础研究到肿瘤治疗，从技术创新到临床应用的最新进展，涵盖肿瘤免疫学、表观遗传学、神经学、转化医学等多个热门和前沿课题。

邀请的十位演讲嘉宾包括：

（图片可轻按放大）

姓名

单位、职务

研究方向

施扬

哈佛医学院，波士顿儿童医院

可控的表观遗传机制和转录调节因子

Harvey Lodish

麻省理工学院生物工程系、Whitehead研究所创始成员；美国科学院院士，《分子细胞》作者

红血细胞，脂肪细胞功能及生物疗法应用；长链非编码RNA功能

何志刚

哈佛医学院、波士顿儿童医院

中枢神经系统损伤和其他神经系统功能的恢复

Ed Boyden

麻省理工学院、神经技术学

复杂生物(大脑)系统和功能的修复

任兵

加州大学圣地亚哥分校基因组医学研究所

人类胚胎干细胞分化和哺乳动物发育的基因组、表观基因组的分析

袁国丞

哈佛陈曾熙公共卫生学院、丹娜-法伯癌症研究所

计算生物学与生物信息学基因组分析以理解基因调控机制

蔡理慧

麻省理工学院Picower学习与记忆研究所所长

神经修复与阿尔兹海默症

冯国平

麻省理工学院大脑与认知科学系

神经突触和环路功能及精神疾病发生机理

刘勇军

赛诺飞研发高级副总裁兼全球研究负责人

肿瘤免疫转化医学

陈建柱

麻省理工学院生物学系

免疫记忆，抗肿瘤T细胞反应；人源小鼠模型的建立和应用

除了演讲之外，我们还会和CAHON（www.cahon.org; 美国华裔血液和肿瘤专家学会）一起组织一个 Immuno-oncology Panel Discussion，和大家就最新的热点领域进行交流：

（图片可轻按放大）

年会上我们还会颁发2019年度哈佛杰出华人生命科学研究奖（Harvard Chinese Life Science Annual Distinguished Research Award），欢迎大家自行报名或提名朋友同事，具体信息请参见下一篇公众号文章内容。

The Harvard Chinese Life Science Annual Symposium (HCLS) is the signature event organized by HMS-CSSA. The symposium covers basic life science research, translational medicine, and biopharmaceutical industries. It draws hundreds of attendees working in life science-related areas in the U.S. and China.

Time:
Sunday, April 28th, 8:30 AM - 5:00 PM

Location:
Folkman Auditorium, Ender's Building

Boston Children's Hospital

320 Longwood Ave, Boston, MA 02115

年度盛会，精彩内容，诚邀您的参与。

长按识别以下二维码进行注册（或点击文末“阅读原文/Read more”）

Refreshment and lunch will be provided with RSVP!

HMS-CSSA is a non-profit organization operated by volunteers who are full-time postdocs, students or visiting scholars at Harvard Medical School and its affiliated hospitals. We aim to create a platform for networking, cooperation, and career development among our members, hence serving as a bridge for intercultural communication between China and US.

This year’s event is the 10th annual meeting organized by HMS-CSSA, and HCLS Annual Symposium has become more influential and more recognized and appreciated by the HMS Chinese community during the years. Every year, more than 500 people register and attend the one-day-long symposium in person or watch the live broadcast online. Last year, Dr. George Daley, Dean of Harvard Medical School, gave the opening remarks. Last few years’ speakers include Lieping Chen, Gordon Freeman, Xiaoliang Sunney Xie, Chuan He, Shirley Liu, Matthew Meyerson, Yang Shi, Hao Wu, Kai Wucherpfennig,Tian Xu, Junying Yuan, Feng Zhang, etc.

The 2019 symposium will be equally exciting that Dr. Harvey Lodish, Dr. Yang Shi and Dr. Yongjun Liu etc. have accepted our invitation. We sincerely invite you join us! Your presence will make this year's program more exciting with more impact!

文案：唐爽梁丹祁亚楠萧安岳宏
编辑排版：萧安李江

【YSA x Z-Park】构建精准医疗未来版图（Frontiers in Precision Medicine）

YSA 青年学者联盟YSA 2 days ago

点击青年学者联盟YSA关注公众号

本期的Frontiers系列的话题是精准医疗（Precision Medicine），YSA和Z-Park有幸邀请到精准医疗领域优秀的企业家来给大家分享构建精准医疗未来版图。

With dramatic decreases in cost andturn-around time, next-generation sequencing (NGS) has become a powerful tool for basic research and various clinical applications. From the study of disease mechanisms to the search for predictive biomarkers to the design of personalized cancer vaccines, NGS is increasingly employed in applications of precision medicine.

Speakers:

Jeff Cheng, Ph.D.

Chief Scientific Officer at Novogene

Talk title: Leading Edge Next-Generation Sequencing and Bioinformatics Services

Jeff Cheng, PhD, is currently the Chief Scientific Officer and Global Head of Biopharmaceutical Services at Novogene Corporation, a global next-generation sequencing and bioinformatics provider.

Prior to joining Novogene, Jeff was the Biomarker Science Leader and China Site Head in the Department of Oncology Biomarker Development at Genentech and Roche Product Development in Asia Pacific. Before that, he was the Head of Scientific Liaison for Biomarker Research at Roche Pharmaceuticals in Shanghai and a Principal Investigator of In Vivo Oncology at BeiGene among other positions.

Jeff obtained his Bachelor’s degree in Chemical Engineering from Tsinghua University in Beijing, China. He then went to Rice University for his PhD in Chemical and Biomolecular Engineering which was followed by a post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School. His research there was focused on vascular biology and tumor micro-environment.

Mark Driscoll, Ph.D.

Co-founder and CSO at Shoreline Biome

Mark’s talk will present data that the combination of lysis, PCR design, long readamplicon, and database are key to identifying microbial strains that influence human health.

Dr. Mark Driscoll has led and supported teams launching transformative new sequencing innovations globally since 2000, including teams at 454 Life Sciences that launched the GS20, GS FLX, and the GS Junior Next Generation Sequencing systems. Mark has experience leading the development of hardware, software, informatics and reagents supporting transformative NGS technology advancements. As a co-founder and CSO of Shoreline Biome, Mark has been instrumental in the development of their high throughput DNA preparation and rRNA amplicon NGS kits, including the first all-in-one 16S-23S long read Amplicon kit and 16S-23S database, that, in combination with the PacBio sequencing system, enables differentiation of closely related bacterial strains using high-throughput, long read rRNA gene sequencing. Dr. Driscoll received his Ph.D. in Biochemistry from the University of Rochester.

About Novogene:

As the world’s largest NGS service provider, Novogene offers research, pre-clinical and clinical scientists abroad array of sequencing and bioinformatics services, including whole genome and exome sequencing, targeted panel sequencing, RNA sequencing, single cell sequencing and microbiome sequencing, for a wide spectrum of sample types. To date, we have:

The largest sequencing capacity in the world with: 27-Illumina NovaSeq, 30-Illumina HiSeq X, 20-PacBio Sequels, 5 Thermo Fisher Ion S5XL, and more!
Completed nearly 20,000 projects
Sequenced 3,700,000 samples for more than 10,000 global customers
Analyzed more than 500,000 biological samples (in 2017 alone!)
Published over 1,850 customer research papers in top publications, like Nature and Science
Accumulated approximately 50 NGS-related patents

In addition, Novogene has developed and validated several clinical-grade oncology assays for precision medicine following strict quality control standards to ensure the highest data quality. These include:

NovoFocus™ NSCLC CDx – A CFDA-approved 26-gene companion diagnostic assay for patients with non-small cell lung cancer
NovoFocus™ PARPi CDx – An analytically validated 45-gene companion diagnostic assay for patients who may benefit from PARP inhibitor treatment
NovoPM™ - A ~500-gene comprehensive genomic profiling panel for solid tumors
NovoNeoantigen™ - A robust bioinformatics pipeline for cancer neo-antigens identification using whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples

Novogene is fully committed to helping you meet your drug R&D goals with our state-of-the-art sequencing facilities, unparalleled scale, efficiency, quality, and price.

About Shoreline Biome:

Shoreline Biome is a start-up company witha passion for developing innovative discovery technologies for the microbiomeand bringing these products to market.

Shoreline Biome has created discovery tools that are advancing the leading edge of understanding how the human microbiome functions across the entire landscape of human health and disease. The initial products from Shoreline Biome, are the first DNA sequencing assays to comprehensively, rapidly, and inexpensively identify all members of the microbiome down to the subspecies or strain level. These results are achieved through our superior cell breaking technology and rational product design. Our companion analysis software enables straight forward identification and quantitation of all of the bacteria in microbiome samples.

Event location: 1000 Massachusetts Ave,Cambridge, MA 02138

Event time: Time: 5:30pm-7:30pm,Thursday, April-18-2019

(Pizza will be served)

Please scan the QR code to register:

Thank you for the full sponsorship from Novogene!

关于Z-Park中关村创新中心

Z-Park中关村创新中心 致力于搭建中美科技创新交流的桥梁, 中关村海外创新平台汇聚北美高精尖创新创业资源, 合作于众多知名投资基金、创业导师及学术专家,提供孵化加速、跨境培训、分析咨询为一体的专业服务。中关村帮助美国企业家和创业者在中国开拓市场,同时协助中国企业及投资者拓展海外业务,进行科学、合理合规的国际化战略规划。

旗下中关村硅谷、波士顿创新中心,位于美国创新创业资源两处核心地带,设有孵化器、共享办公空间、私人办公室、活动中心等多种功能空间,每年主办 200 余场技术分析会、学术讲座及创投活动,即吸引当地前沿技术和团队入驻孵化,又作为中国企业对外交流及拓展市场的软着陆点 ,是推动当地中美科技创新交流及产业化发展的重要交流中心。

关于青年学者联盟YSA

青年学者联盟YSA（Young Scholars Association）致力于打造青年学者的学术/工业交流平台，为广大青年学生学者服务。YSA希望聚集有志之士，上下求索，探未来之路。欢迎扫描二维码关注YSA公众号！

如果读者有加入YSA青年学者交流群，欢迎扫码添加 YSA小助手为微信好友，有问题继续交流。请注明：加入YSA交流群

綠葉製藥Rykindo^®有望成為我國首個在美獲批上市的創新藥

作為國家“重大新藥創制”科技重大專項之一，備受關注的自主研發新藥——注射用利培酮緩釋微球Rykindo^®（LY03004）已於美國東部時間3月28日，正式向美國食品藥品監督管理局（“FDA”）提交NDA新藥上市申請，有望成為我國首個在美獲批上市的創新藥。

綠葉製藥此次申報Rykindo^®被業界視為一大里程碑，意味著公司投入多年的長效緩釋製劑研發平臺成功突破產業化瓶頸。這不僅是綠葉製藥全球化戰略中的關鍵一步，也是中國在全球製劑創新舞臺上邁出的一大步，受到各界廣泛關注。通過製劑開發、CMC及工藝優化、產能放大，註冊審評、商業化籌備等層層考驗，綠葉製藥已為Rykindo^®及後續多個創新製劑的全球上市做好充分準備。

Rykindo^®是綠葉製藥自主研發的緩釋微球製劑，以肌肉注射的方式每兩周給藥一次，治療精神分裂症和雙向情感障礙。此次提交的NDA新藥申請包含了一項關鍵性及兩項支持性臨床試驗的結果，共涉及172名美國病患。該項關鍵研究顯示：與利培酮長效注射劑的市場參照產品相比，首次注射Rykindo^®後並無滯後期，且具有相等穩態藥代動力學。在所有三項研究中，Rykindo^®與參照產品的安全性基本相似；在療效上，Rykindo^®首次注射後三周毋須再服用口服製劑，且能更快達到穩態血藥濃度。Rykindo^®上市後，可改善口服抗精神病藥物在精神分裂症患者中普遍存在的用藥依從性，每兩周給藥一次，將簡化精神分裂症的療程。

綠葉製藥預計，Rykindo^®有望於2019年至2020年在美國和中國先後上市。與此同時，該新藥在歐盟和其他新興國家或地區的註冊也在同步順利推進中。

Rykindo^®所處的中樞神經用藥領域，全球患者人群異常龐大且不斷增加。綠葉製藥在該治療領域進行的一系列佈局，將成為其下一階段業務增長的關鍵發力點。目前，公司已上市的中樞神經藥物包括：思瑞康及其緩釋片、卡巴拉汀單日貼片、芬太尼貼片、丁丙諾啡貼片等，這些產品覆蓋全球80多個國家和地區，包括中國、美國、歐盟、日本等主要醫藥市場，以及快速增長的國際新興市場。後續在研產品線中，另有注射用羅替戈汀緩釋微球（LY03003）、鹽酸安舒法辛緩釋片（LY03005）、帕利呱酮緩釋混懸注射劑（LY03010）、卡巴拉汀多日貼片（LY30410）等中樞神經新藥已在中國和海外同步進行開發。公司期待將更多優質創新的原研藥品帶給全球患者。

綠葉製藥集團管理層表示：我們將全力推進Rykindo^®在美國和中國的上市，並加速多個已處於NDA準備階段、III期及關鍵臨床階段的新藥的註冊進度。我們期待綠葉製藥能把更多優質創新的原研藥品帶給有需要的全球患者！”

Dr. Mien-Chie Hung, the president of CMU, will be in Boston to recruit overseas talent. It is a great opportunity to learn about upcoming faculty job opportunities in Taiwan!

In addition to clicking "going", please fill out the registration form if you are interested in attending: https://goo.gl/forms/bUXKEx9tdXMTduK33

Friday at 6 PM – 8:30 PM

3 days from now39–48°F Cloudy

Room D1620, Dana-Farber Cancer Institute, 44 Binney Street, Boston

中國醫藥大學招聘說明會
Time: 6pm-8:30pm, April 5th, 2019
Location: Room D1620, Dana-Farber Cancer Institute, 44 Binney Street, Boston
Agenda:
6:00pm-7:00pm Registration and Reception dinner 報到 & 晚餐
7:00pm-8:00pm Recruitment talk by Dr. Mien-Chie Hung 中國醫藥大學洪明奇校長攬才演講
8:00pm-8:15pm Q&A
8:15pm-8:30pm Introductino of MOST programs for overseas talents 波士頓科技組謝水龍組長介紹海外人才歸國橋接方案

2019 Boston BioForum

CABA

Boston BioForum

May 4, 2019

波士顿生物医药论坛｜ CABA

Driving Transformation in Life Sciences Industry

ABOUT

The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and health- care fields to talk about hot topics in the Life Science industry.

- Future of Immuno-Oncology

- Outlook of Cell & Gene Therapy

- AI & Big Data in Health

- Evolving Landscape for Life Science Investment

- Next Big Thing in Biotech & Pharma

Time & Location

Saturday, May 4, 2019 @ 9AM EST

The Westin Waltham Boston

70 3rd Ave, Waltham, MA 02451

Confirmed Speakers

Will Brownsberger

MA State Senator

Jos Melenhorst

Director, CAR-T Product Development

UPenn

Jonathan Terrett

Head of Immuno-Oncology

CRISPR Therapeutics

Sadik Kassim

Executive Director

Kite Pharma

Nenard Grmusa

SVP, Head of External Innovation

Takeda

Lei Xiao

CEO

Innovative Cellular Therapeutics

Derrick Li

Head of Strategy and Investor Relations

Cellular Biomedicine Group

Nick Valiante

CEO

Glyde Bio

F. Stephen Hodi

Directot, Center for IO

Dana Farber Cancer Institute, Harvard Medical School

William Cao

CEO

GraCel

Rob Brainin

CEO

NextCODE

Catherine Sabatos-Peyton

Head of IO

Novartis

Partial List of Sponsors from Past CABA Events

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Chinese-American BioMedical Association

2019 SAPA-NE职业发展研讨会: Jump-Start Your Career!

SAPA-NE 美中药协SAPA
你想知道如何在职业生涯的不同阶段做出选择吗

你想了解求职中签证移民的准备策略吗？
你知道如何从导师那里受益吗？

你想成为一个更好的沟通者吗？
你想知道如何管理你的老板吗？
你想提升自己的领导能力吗？
你想拓展建立自己的社交网络吗？

你想拥有一张职场头像照片吗？

欢迎加入我们2019 SAPA-NE职业发展研讨会:

Jump-Start Your Career!

3月30日上午10:00 - 下午6:00

Tufts University, Robinson Hall Room 252, 212 College Ave, Medford, MA, 02155

寻求指导, 分享智慧, 建立职业生涯。

Speakers

K.C. Donovan

Executive Director, DonoVision

Yaran Pan, LLM

Attorney at Law Office of Yaran Pan

Huijuan Li, Ph.D.

Head of Analytical Development, Moderna Therapeutics

Chen Cui, Ph.D.

Associate, McKinsey & Company

Peng Meng Kou, Ph.D.

Commercial Development Manager, MicroMedicine

Sumiao Chen, M.D., M.S.

Pharmacologist, Novartis Institute for Biomedical Research

CEO of SUMIAO XIANG restaurant

Dominic Yee, J.D., Ph.D.

Corporate Counsel, Sunovion Pharmaceuticals

Michael H Zhao, Ph.D.

CEO, Longwood Biology Inc.

★ Program ★

文字编辑：李科杰，梁雪，郭佳微信编辑：李源涛

Registration Is Now Open for Biotech's Can't Miss Event: BIO 2019

In just 4 months, 16,000+ biotechnology and global pharma leaders will come together for an exciting week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

Join the global biotech community to discover the next generation of cutting-edge products, innovation, therapies, and cures at events all week long.

View all Registration Packages | Why Attend BIO 2019?

BTBA Special Talk: National Taiwan University AI Center

Saturday, December 1, 2018 at 10:00 AM – 12:00 PM EST

MIT Building E25; Room 119/121

BTBA Special Talk: We are the honor to invite Dr. George Tseng to give us an introduction of National Taiwan University (NTU) - Artifical Intelligence (AI) Innovation Research Center. This NTU-AI center was founded in 2018 and under Taiwan's Ministry of Science and Technology (MOST; 科技部). The Center is composed of two sub-centers: 1). Artificial Intelligence Technology sub-center and 2). All Vista Healthcare sub-center. Please come to join us for enjoying this BTBA special talk to know the Technology development in Taiwan!

BTBA 特別演講：這次我們邀請到台大人工智慧中心 (NTU-AI Center) 的曾柏元副執行長，來跟大家介紹科技部在2018成立的台大人工智慧中心！此中心的全名為人工智慧技術暨全幅健康照護聯合研究中心，簡稱台大人工智慧中心或台大AI中心，包括智慧技術和生技醫療兩個主題、人工智慧技術及全幅健康照護兩個子中心。歡迎大家一起來聆聽並了解一下台灣目前的科技發展！

著名的中医专家张季教授、中医科研专家李秀敏教授、中药颗粒剂专家天江药业总裁俞敏及Eric Brand博士将于11/11/2018莅临2018 哈佛中医药论坛暨天江中药配方颗粒学术论坛讲课。此次论坛将授予九个学分，收费（包括午餐）会员仅$60、非会员$90，哈佛Faculty, Fellow, Students 免费（需出示哈佛ID),

ISCT publishes annual report on cell and gene therapy market authorisations

Report to enable patients and entire cell therapy community to identify treatments approved by government regulatory authorities

Vancouver, Canada, November 20, 2018 – ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces the first publication of its new annual report detailing global cell and gene therapies (CGT) with market authorization.

The CGT market authorization report is intended to provide a centralized resource and increased clarity for all of those involved in the CGT industry. This involves the scientific community, healthcare stakeholders and patient associations. The report will be a regularly updated document that will be republished yearly, and accessible through the ISCT website, www.celltherapysociety.org, and www.isct-unprovencellulartherapies.org.

The report has been designed to react to the increase in momentum around a widening number of CGT authorizations, as well as a parallel increase of unproven approaches where cells are delivered as treatments without rigorous scientific and regulatory assessment and authorization.

The report has been prepared by select members of the ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell & Gene Therapies (UCGT) with lead authors Natividad Cuende (Executive Director, Andalusian Initiative for Advanced Therapies, Seville, Spain) and Laertis Ikonomou (Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA). The ISCT Presidential Task Force was formed in 2014 to support ISCT’s ongoing commitment to address the rise of commercially available unproven or insufficiently proven CGT treatments. These approaches are targeted at hopeful individuals seeking cures or health improvement for a variety of conditions. The PTF-UCGT characterizes unproven cellular interventions and promotes safe and effective practices worldwide.

The reliable, up-to-date resource will help patients to make informed decisions before receiving a CGT treatment so that they can avoid being exposed to unproven and unlicensed cell interventions not approved by a regulatory or medicine agency.

The report also provides an annual breakdown of CGTs that have received, as well in some cases, have withdrawn, market approval. This includes analysis on types of product and therapy as well as disease targeted. 44 unique products were identified. 84% were cell and tissue therapies, and 55% were autologous. More than one third target oncological or hematologic conditions.

In the US, there are over 16 cell, tissue and gene products with marketing authorization, 14 in Korea, eight in Europe, four in India and Japan, two in Canada, and one each in China and Australia. This contrasts with Russia, Middle East, Africa, Central and South America, which have no CGT market authorizations or data available.

“The number of market approved cell and gene therapy treatments continues to grow, with a high number of other therapies seeking approval. It is critical for all those involved in the sector, and most importantly those patients that may benefit from newly approved treatments, to have an annually updated resource detailing all approved cell and gene therapies,” said Massimo Dominici, Chair of the ISCT Presidential Task Force on Unproven and Unethical Cell & Gene Therapies. “This resource will give patients visibility on what cell and gene therapies have gone through proper approval processes, and help them alongside physicians to make more informed decisions about their treatment.”

In tandem with the efforts of professional societies like ISCT, it is imperative that the regulatory environment and guidance keep pace with the rapid advancements in cell and gene therapy. As such, this report also supports ISCT the FDA’s continued publication of numerous draft CGT guidance documents in 2018.

2018 Harvard TCM & Tianjiang Granule Extracts Forum
Time: 8:45am-6:00pm Sunday November 11, 2018
Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,
MA 02478
Parking: Free
CEUs (Continue Education Credit): 9 credits
Fee (lunch included): Members $60, none members $90
Free for Dr. Lee’s group, Harvard Faculty/Fellow (NO CEU, reservation
needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS
Supported: Tianjiang Pharmaceuticals. CO.
Program
8:45-9:15am Registration
9:15-11:30am 七方理論臨床運用心得张季
Experience in Clinical Application of Seven Formulas Theory dr.
Ji Zhang PhD, L.Ac
11:30-12:10pm Traditional Chinese Medicine, Western Science, and the Search
for a Cure for Allergies
Prof. Xiumin Li, MD New York Medical College
12:10-12:50pm 天江中药配方颗粒研究进展俞敏天江药业总经理
Progress on Tianiiang Granule Extracts Research Min Yu, CEO of Tiangjiang
Pharmaceuticals. Co.
12:50-2:10pm Lunch & discussion

2018 哈佛醫學院中醫藥論壇
暨天江中药配方颗粒学术论坛
2:10pm-2:40pm 配方颗粒的国际趋势：标准与临床特点 Eric Bran PhD
Global Trends in Granule Extracts: Standards and Clinical Styles Eric Bran
2:40-5:40pm 升陽益氣諸方劑在脾胃病的應用體會
Application Experience of Yang-raising and Qi-augmenting Formulas in
Spleen-Stomach Diseases Dr. Ji Zhang, PhD, L.Ac
5:40-6:00pm Discussion
Contact
Call Dr. Li 617 323 7809 or
Email:Johnzhang999@gmail.com
张季哈佛中医论坛講座簡介
1. 七方理論臨床運用心得
“七方“學說始見於《內經》。七方，即指大方、小方、緩方、急方、奇方，偶方、複方。歷代
醫家如金代張元素《醫學啟源》、張子和《儒門事親》、成無己《傷寒明理論》、明代李時珍《
本草綱目》均有闡發補充。國內各版高等中醫院校教材《方劑學》均認為“七方”為最早的方劑
分類法，臨床醫師多因其簡約古老而棄之不用；查閱中醫藥文獻，亦鮮見有關七方的理論與臨床
研究論文。而張季中醫師在臨床中體會到“七方“是指導臨床組方的利器，是提高臨床療效的法
寶，多年來鍥而不捨地研究“七方“理論的臨床應用，頗有心得。此次講座將結合臨床多個成功
案例分別加以詳細闡述。
2. 升陽益氣諸方劑在脾胃病的應用體會
胃腸道疾病在美國社會常見，與飲食不調和過重的精神壓力有密切關係，也有因長期使用西藥的
副作用而引發或加重。脾胃病為中醫之擅長。其治則不外疏肝解鬱，理氣止痛，益氣健脾，化濕
助運，活血化瘀，溫腎暖脾等等。但是對於一些疑難病症的治療，療效亦不甚滿意，張季中醫師
在脾胃病治療方面，宗金元易水學派張元素、李東垣等醫家的學說，在臨床中以臟腑標本虛實用
藥和升陽益氣、升陽除濕、升陽散火、升陽瀉濁法相結合，有一些體會，這次講座並將提供一些
治療成功的案例。
講員履历
張季，1978 年入學南京中醫藥大學中醫系，1983 年畢業後旋即留校任教，曾師從各家學說大家丁
光迪先生研究《諸病源候論》，碩士研究生期間又師從蜚聲海內外的《中醫學概論》、《中藥大
辭典》的主編吳貽谷導師，專攻中藥方劑的臨床應用，曾參加編寫《中華本草》《現代中藥學大
辭典》等10 餘部學術著作，其中多部獲獎。1992 年來美，又在美國獲DAOM 博士學位。張季中
醫師至今已在中美兩地臨床35 年，應用中藥方劑辨證施治，經驗豐富，對脾胃病、肝膽病、婦科
病、皮膚病的治療，特別是對過敏性疾病、感染性疾病和自身免疫性疾病的治療，頗有心得。自
1995 年起，先後執教於洛杉磯多家中醫院校碩士班和博士班。近年來，多次在美國各地中醫公會
講授再教育學分課程，並返回母校作多次學術演講，廣受好評。張季中醫師目前为世中聯內科專
業委員會理事、世中聯中醫藥推廣海外專家委員會委員、世中聯中藥上市後安全性再評估美國專
家委員會委員；并任南京中醫藥大學客座教授，南京中醫藥大學美洲校友會副會長，江蘇省中醫
院洛杉磯惠僑中心顧問。
俞敏，男，1973 年6 月出生，长江商学院EMBA 硕士，高级经济师，江苏省中药饮片研究专委会
常委副主委，现任江阴天江药业有限公司总经理。江阴天江药业有限公司成立于1992 年，隶属于
中国医药集团旗下中国中药控股有限公司。背靠中国医药集团这家中国规模最大、产业链最全、
综合实力最强的超千亿医药健康产业集团，天江药业及其中药配方颗粒产品致力于传承创新，以
优质中药产品和服务提升人民健康水平。天江药业是国内首家“全国中药饮片改革试点单位”，
首批“中药配方颗粒试点单位”，是中药配方颗粒行业的先驱者和领跑者。
俞总将详细介绍天江中药配方颗粒质量控制措施与机制，以及天江中药业配方颗粒生产工艺流程
Xiu-Min Li, M.D., M.S.. Dr. Li obtained her MD degree in Henan University
of Chinese Medicine (Zhengzhou) in 1983 and a Master’s degree in Clinical
Pediatric Immunology from The Graduate School of China Academy of
Chinese Medical Sciences (Beijing). She was a Visiting Scientist at Stanford,
and postdoctoral fellow in Clinical Immunology at Johns Hopkins (Baltimore)
where she was appointed instructor in 1997. She Joined the Division of
Pediatric Allergy and Immunology, Pediatric Department and was promoted
to Professor of Pediatrics with tenure at the Icahn School of Medicine at
Mount Sinai in 2009. She has combined expertise in immunology and
Chinese medicine. Her research has yield over 100 publications. She has trained over fifty
residents, clinical fellows, post-doctoral fellows, graduate students, medical students, and
visiting scientists. She has chaired prominent committees about the use of alternative medicines
for allergic diseases in the US and internationally. She recently joined Department of
Microbiology and Immunology as Professor and in the process to establish a Center of
Excellence for Clinical Immunology and Integrative Medicine. She was awarded the Future of
Health Technology Award for 2016. She is co-author of Traditional Chinese Medicine, Western
Science, and the Search for a Cure for food allergy with Henry Ehrlich.
Eric Brand is a licensed Chinese medicine practitioner with a passion for materia medica and
herbal quality discernment. After graduating from the Pacific College of Oriental Medicine in
2003, Eric spent over a decade pursuing academic and clinical opportunities in Taiwan, Hong
Kong, and mainland China. He earned his PhD at the School of Chinese Medicine at Hong
Kong Baptist University with a focus on Chinese herbal pharmacy, and he serves as a TCM
advisor to the American Herbal Pharmacopoeia. Eric has written or translated a variety of
modern and classical texts and peer-reviewed articles, and he served as Chair of the U.S.
delegation on the ISO Technical Committee for international TCM standards (ISO TC 249) from
2014 to 2017.

Welcome to the “1st International Conference on the Forefront of Complementary and Integrative Medicine,” which takes place at the Joseph B. Martin Conference Center of Harvard Medical School in Boston October 29-30, 2018. Please visit the website for more details: https://www.icfcim.com

2018年10月29-30日，哈佛大学医学院Josheph B Martin Conference Center 首届中西医替代及整合医学大会最后一周注册机会！大会由哈佛医学院和北京中医药大学主办 Journal of Phytomedicine ，麻州中医学会协办，届时世界顶级专家教授云集，包括哈佛医学院、NIH、斯坦福大学等十位著名教授李豫伟Thomas Efferth、北中医徐安龙校长，哈佛医学院结合医学系主任，NIH补充结合医学中心主任Helene Langevin，香港浸会大学中医学院院长吕爱平，香港中文大学中医药研究所所长梁秉中，北中医东方医院副院长林谦等。聆听中西医学发展前沿，领略名家风采，机会难得！对哈佛和MIT学生、Speaker 团队成员免注册费，提供会议午餐，但免费名额有限（签到时需提供学生或工作ID），请参会人员尽快注册https://www.icfcim.com/registration.html。

U.S.-China Health Summit Innovation Competition U.S. (Boston) Preliminary

Take a swing at networking with high-profile healthcare scholars, dedicated healthcare investorsand meeting corporate innovators!

Saturday, September 8th
1:00 - 5:00 p.m. (EST)
Harvard School of Public Health
Kresge G1

On-Site Judging Teams

Jessica Alderman Zeaske, Ph.D., MBA
Director, Healthcare Investments, GE Ventures

SU Lingyun
Director, Alibaba Health Research Institute

SHAO Qing
Senior VP at Porton;
Founder and Director, Beijing Bodun Chongde Charity Investments; Founder and Director of Network Think Tank;
Vice President, Moganshan Research Institute Expert Advisory Committee;
Vice Chairman, China Digital Assets Research Institute;
Director, United States Hope Investment Fund

Jing Ma, MD, PhD
Co-founder and Board Member, President, U.S.-China Health Summit; Director of China Center,
Associate Professor, Department of Population Medicine, Harvard Medical School

Kate (Xiaokui) Zhang
Senior Director, Global Bio-Therapeutic, Sanofi

Shaan Gandhi, MD, MBA
Principal , Longwood Fund

Olivia Ho. Cheng
Board Member, U.S.-China Health Summit; CEO, Aurora Healthcare Corp.

Grannum R Sant, MD, FRCS, FACS
Professor and Former Chair of Urology and Urology Residency Program Director, Tufts University School of Medicine

ZHANG Rui
Partner, Lodestone Capital Partners

YANG Hailing
Senior Analyst, Decision Resources Group

Register to connect with judge panel right now!

More information? please visit: https://www.uschinahealthsummit.org/innovation
Any questions? Reach us at info@uschinahealthsummit.org

各位会员：好消息。著名医学气功专家北京中医药大学博导刘天君教授将于9/30/2018周日莅临哈佛中医药论坛授课！本次讲课包括现场带领大家练习。名额有限，先来先得。欢迎大家参加！请提前报名！谢谢！John Zhang
药明生物宣布投资6000万美元在美国新建生产基地

–药明生物国际化战略再下一城
–首次在美国布局生物制药生产基地

美国马萨诸塞州伍斯特市，中国上海，2018年6月11日——全球领先的开放式生物技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布，公司计划投资6,000万美元（约合3.8亿人民币）在美国马萨诸塞州伍斯特市（隶属波士顿大都会区）新建现代化生物制药临床样品和商业化生产基地，并创造约150个工作岗位。

这是药明生物在全球范围布局的第十一个生产基地（药明生物十一厂），也是药明生物首次在美国新建生产基地，同时也是公司继爱尔兰、新加坡后投资建设的第三个海外生产基地。

药明生物为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，其使命是加快和转变生物制药发现、开发及生产，造福全球患者。

即将开建的药明生物美国基地将继续采用全球领先的一次性生物反应器，并率先应用“新一代生物制药生产技术”（连续生产工艺）开展商业化生产，致力于成为全球领先的生物制药“未来工厂”。该基地总产能将达到4,500升，包括2个2,000升流加细胞培养反应器与1个500升灌流工艺生物反应器，基地建成后将拥有生物工艺开发实验室，并同时具备临床样品生产和小规模商业化生产的能力。此项目的推进得到了马萨诸塞州政府、伍斯特商业发展局（WBDC）和麻省生命科学中心（MLSC）的大力支持。

“马萨诸塞州拥有技术领先的公司、顶尖的学术机构和充满竞争力的人才，已经形成全球最具活力的生命科学创新生态系统之一。”马萨诸塞州州长查理·贝克（Charlie Baker）先生说，“我们很高兴药明生物选择在马萨诸塞州进行战略布局，更多企业的投资和快速发展将共同构建更加完整的创新生态系统。”

“这几天在伍斯特市与药明生物管理层的会见交流，让我深信他们将对这里的生命科学产业做出巨大贡献。”马萨诸塞州副州长卡琳·波利托（Karyn Polito）女士表示，“我们很高兴为伍斯特市生物医药产业园的发展而努力，我们将继续为各个领域的合作伙伴提供支持。”

“伍斯特市正在打造全新的生物医药产业园区，我们热烈欢迎药明生物成为首家选择入驻于此的企业。”伍斯特市政执政官Edward M. Augustus, Jr.先生表示，“作为全球生物医药市场中地位日益攀升的投资目的地，伍斯特市十分期待新园区的正式开幕，同时帮助药明生物的首个美国生产基地顺利落成。”

“我们很高兴药明生物选择了美国马萨诸塞州，更重要的是选择了伍斯特市。在马萨诸塞州贝克-波利托政府和伍斯特市政府的支持下，我们通过巨大努力最终促成了此项目成功落地。对伍斯特市而言，今天又是一个重要的日子。”伍斯特商业发展局总裁兼首席执行官Craig L. Blais先生表示。

麻省生命科学中心（MLSC）总裁兼首席执行官特拉维斯·麦克瑞迪（Travis McCready）先生表示，“我们很高兴见证药明生物在美国伍斯特市布局生产基地这一重大里程碑。药明生物全球领先的生物制药专业技术和能力将进一步巩固这里的生命科学创新生态系统，帮助马萨诸塞州的生物制药公司更迅速高效地开发创新疗法。我们将继续为此项目的顺利完成而努力。”

“波士顿大都会区是公认的世界生命科学领域的创新聚集地，药明生物的美国新基地在公司国际化战略中具有至关重要的作用，有助于确保公司生产的符合最高质量标准生物药，通过健全强大的供应链网络，造福全球患者。非常感谢美国马萨诸塞州各界人士对我们的大力支持，相信在大家共同的努力下，这个振奋人心的项目将迅速得到推进。”药明生物董事长李革博士表示。

药明生物首席执行官陈智胜博士表示：“我们非常高兴能在美国伍斯特市投建公司在美国的第一个生产基地，公司众多重要合作伙伴距离此基地车程仅2小时。新基地将有助于满足药明生物日益增长的生物制药开发及生产需求，从而更好地帮助当地合作伙伴加速生物药开发进程。药明生物致力于打造全球生物制药领域更宽、更广、更深的生物制药能力和技术平台，赋能当地及全球合作伙伴。”

关于药明生物

药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。

WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States

– WuXi Biologics’ first overseas site in the United States

2018/06/11

WORCESTER, MA and SHANGHAI, June 11, 2018 – WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).

WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.

This state-of-the-art “facility of the future” will be built upon the novel approach that WuXi Biologics has pioneered in deploying single-use bioreactors. It is also designed to run continuous bioprocessing, a next-generation manufacturing technology to be implemented in America for the first time. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.

The new manufacturing facility supported by the Government of Massachusetts, the Worcester Business Development Corporation (WBDC) and the Massachusetts Life Sciences Center (MLSC), is the Company’s first overseas site in the United States, as well as the third outside China subsequent to Ireland and Singapore new sites.

“Massachusetts is home to one of the world’s most dynamic life sciences ecosystems, with leading companies, top-tier academic institutions, and a globally-competitive workforce,” said Massachusetts Governor Charlie Baker. “We are enriched when companies grow and invest here and are pleased to welcome WuXi Biologics’ expansion.”

“Having met WuXi Biologics’ leaders during their recent trip to Worcester, I am confident that they will contribute greatly to the city’s life sciences industry,” said Ms. Karyn Polito, Lieutenant Governor of Massachusetts. “I have been pleased to work on the development of Worcester Biomanufacturing Park and our Administration remains committed to supporting our public private partnership.”

“The City of Worcester is thrilled to welcome WuXi Biologics as its first tenant to the new Biomanufacturing Park,” said Worcester City Manager, Edward M. Augustus Jr.. “As a growing destination in the global biomedical market, the city looks forward to officially opening this impressive campus and is eager to host WuXi Biologics in their first US manufacturing facility.”

“We are delighted that WuXi Biologics has chosen the United States, Massachusetts, but most importantly Worcester. We competed very hard for this one and we prevailed. The Baker / Polito Administration and the City of Worcester stepped up to make this possible. Another great day for Worcester,” said Mr. Craig L. Blais, President and CEO of WBDC.

“We are excited to reach this important milestone on developing WuXi Biologics’ first US bio-manufacturing facility and to announce their intention to move to Worcester,” said Mr. Travis McCready, President and CEO of MLSC. “WuXi Biologics brings a global biologics manufacturing expertise that will enhance our life sciences ecosystem and help Massachusetts biopharma companies develop novel therapies quickly and efficiently. We look forward to continuing to work to finalize this project.”

“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. We believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.

Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. Many partners of WuXi Biologics are located within two hours of this new site. We are all very excited to initiate our first US site to enable local companies and expedite biologics development in the United States. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

20th SAPA-NE Annual Conference, Cambridge, MA,

Jun 2-3

Please Join Us to Discuss

How Can We Save the Lives of

Patients, Our Family Members,

Our Neighbors, and Ourselves.

Overview

June 2nd

8AM – 6PM

Annual Conference

Tang Center, MIT

June 2nd

6PM – 9:30PM

20th-Anniversary Banquet

Boston Marriott Cambridge

June 3rd

9AM - 3 PM

Investment Forum

Boston Marriott Cambridge

Agenda

Helping Patients with Unmet Needs Through Innovation and Collaboration

June 2nd, 2018

8:00 AM – 6:00 PM

MIT, E51, Tang Center, Wong Auditorium

2 Amherst St, Cambridge, MA

8:00–9:00

Registration and Breakfast

9:00–11:55

Session 1:

Patients with Unmet Needs Require New Treatment and Healthcare Innovation

11:55–13:00

Lunch and Exhibition

13:00–14:20

Session 2:

Transformative Innovation Demands Novel Platforms

14:20–15:00

Coffee Break and Exhibition

15:00–16:40

Panel Forum:

Collaborations and Opportunities Across the Ocean

16:40–17:40

Session 3:

Global Collaboration Drives Biomedical Innovation and Productivity

17:40–18:00

Closing Remark and Networking

SAPA-NE 20th Anniversary Celebration Banquet

(Biocytogen Night)

6:30 PM – 9:30 PM

Boston Marriott Cambridge

50 Broadway, Cambridge, MA

18:00–18:30

Networking

18:30–18:35

Welcome Remarks

18:35–19:10

Keynote Speech and Award

19:10–21:30

Dinner / Celebration

Biotech/HealthCare

Investment Forum

June 3rd, 2018

9:00 AM – 3:00 PM

Boston Marriott Cambridge

50 Broadway, Cambridge, MA

9:30–9:40

Opening Remark

9:40–11:20

Keynote Talks

11:20–12:00

Panel Discussion

12:00–13:00

Lunch

13:00–14:30

Roadshow Presentation

14:30–15:00

Conclusion

Invited Speakers

George M. Church, Ph.D.

Professor

at Harvard & MIT

Dost Öngür, M.D.

Chief of the Psychotic Disorders Division, McLean Hospital

Shidong Jia, Ph.D.

Founder & CEO, Predicine Holdings Ltd.

Chris Garabedian

Chairman and CEO, Xontogeny

WilliamL. Fodor, Ph.D.

Acting CSO Biostage, Inc.

Director Translational Sciences, Cell Therapy Group

Morris J. Birnbaum, M.D., Ph.D.

SVP and CSO, Internal Medicine Research, Pfizer Inc.

Steve Yang, Ph.D.

EVP, CBO & CSO, WuXi AppTec

Yuelei Shen, Ph.D.

President and CEO, Biocytogen Co Ltd.

Shenghong Steve Yang, Ph.D.

Manager, Sales and BD at Sino Biological US Inc.

Hong Cheng, Ph.D. & MBA

Associate Vice President, Head of Research Strategy and Effectiveness for Global Research at Sanofi

Jin Li, Ph.D.

Chairman and CEO, HitGen

Yulian Zhang, Ph.D., MBA

Executive Director, Kelun-Biotech Pharmaceuticals

Bill Liang, Ph.D.

CEO, CF PharmTech, Inc.

史文钊, Ph.D.

神州医疗科技股份有限公司总裁

Libing Yu, Ph.D.

Sr. Vice President, Business Development, Viva Biotech

Wenseng Wendy Pan, J.D. & Ph.D.

Partner, Sidley Austin LLP.

Ken Li, Ph.D.

Managing Partner, Yuanming Capital

Scott Zheng, MBA

Partner & CEO, SunForest Captital

Brad Loncar

CEO, Loncar Investments

Partners

You are warmly welcome to join our "20th SAPA-NE Annual Conference and 20th Anniversary Celebration" at MIT/Marriott Cambridge on Sat-Sun 6/2-6/3/2018 (www.SAPA-NEweb.org)

The theme of 20th SAPA-NE Annual Conference (Sino-American Pharmaceutical Professionals Association - New England) is “Helping Patients with Unmet Needs through Innovation and Collaboration”. Please join us to learn and to discuss this important topic in our lives with Big Pharmaceutical Executives, Star-up Biotech Entrepreneurs, Well-known University Professors, Famous Physicians, and International Investors. We are confident that you would not only learn frontier science, grasp the latest Drug R&D trend, understand updated medical advancement, but also find the conference as a unique opportunity expand your professional network in particular with pharmaceutical/biotech and Health Care industry with Chinese origin. Hope everyone also enjoy the memorable SAPA-NE 20th Anniversary.

The Annual Conference comprises a full-day program on 6/2 Sat 9am-6pm at MIT Tang Center, Wong Auditorium at 2 Amherst St, Cambridge, MA, followed by a SAPA-NE 20th Anniversary Banquet 6:30-9:30pm at Boston Marriott Cambridge, 50 Broadway, Cambridge, MA. In addition, we will have a Biotech/HealthCare Investment Event and Special Activities at Boston Marriott Cambridge on 6/3/2018 Sunday 9am-3pm.

欢迎来波士顿参加20届新英格兰美中药协年会和20周年庆典, MIT and Marriott Cambridge, 6/2-6/3/2018. 制药公司总监，生物制药创业家，知名学术权威，著名医学专家, 和投资巨鳄和大家一起探讨<通过创新和合作来帮助危难中的病人><Helping Patients with Unmet Needs through Innovation and Collaboration>

Registration at http://sapa-neweb.org/AC2018.php

Annual Conf Admission for both 6/2 9am-6pm and 6/3 9am-3pm,

$25 early bird by 5/10; $30 regular by 5/25; $40 on site after 5/26

SAPA-NE 20th Anniversary Banquet, 6/2 6:30-9:30pm

$50 with limited capacity by 5/25; $60 on site after 5/26

Best regards,

20th SAPA-NE Annual Conference Organizing Committee

www.SAPA-NEweb.org

Taiwan Bio Forum: Healthcare Innovation Beyond Borders

Date:  Sunday, June 3rd
Venue: Joseph B. Martin Conference Center (Harvard Medical School)

REGISTER HERE

In the advent of the International BIO Convention in Boston, join us for a day of healthcare and biomedical innovations at Taiwan Bio Forum, jointly hosted by MJNE and DCB on June 3rd at the Joseph B. Martin Conference Center at Harvard Medical School. Meet and network with top leaders in biopharma, medtech, venture capital, and academia from Taiwan and around the world.

This event will feature more than 20 speakers from Sanofi Genzyme, Samsung Ventures, LEO Pharma, SR One, M Ventures, MPM Capital, F-Prime Capital, Artiman Ventures, MIT Alumni Angels, Militia Hill Ventures, and Johnson & Johnson Innovation. The audience will also hear from keynote speakers Michael LaRhette, President, MassChallenge and Kate Merton, Head of JLABS at NYC & Boston, Johnson & Johnson Innovation.

Click photos for Speaker’s Bio

Herbert Wu
President
DCB

Fong-Chin Su
Deputy Minister
Ministry of Science and Technology

Michael LaRhette
President
MassChallenge

Chen-Yang Shen
Chief Executive
Taiwan Biobank

David Lucchino
Chairman
MassBio

Johnsee Lee
Chairman
Taiwan Biotech Industry Organization

Shaoyu Chang
Investment Manager
VI Ventures

Kate Merton
Head of JLABS
Johnson & Johnson Innovation

Fulung Ko
Chief Administrative Officer
Taipei Exchange

Joan Lau
Managing Partner
Militia Hill Ventures

Akhil Saklecha
General Partner
Artiman Ventures

Greg Sieczkiewicz
Chief IP Counsel
MPM Capital

Kevin Chu
Analyst
F-Prime Capital

Christopher Kim
Managing Partner
Novatio Ventures

Patrick DeCourcy
Principal Program Manager
Sanofi Genzyme

Vikas Goyal
Associate
SR One

Hyuk-Jeen Suh
Head of Investment
Samsung Ventures

Michael Sierra
Vice President
LEO Sci. & Tech

Daniel Franke
Analyst
M Ventures

Jeng-Shin Lee
Chief Scientific Officer
AB Biosciences

Mary Ann Picard
Dir. of Operation
M2D2

Patrick Rivelli
President
Savran Technologies

Ying K. Tam
Managing Dir. of Health
MaRS Ventures

Joel Berniac
CEO and Co-Founder
Akrivis Technologies

Technology Showcase:

Company Name

Brief Company Introduction

Speaker

ACT Genomics

ACT Genomics is a leading CAP-accredited cancer molecular information service provider, with proprietary NGS-panels and chip-based platform, coupling with integrated medical informatics pipeline, we transform cancer treatment paradigm and support biopharma in biomarker exploration and companion diagnostic development.

Tsung-Kai Wu
Sr. Associate Director, Business Development

Mao Ying Genetech Inc.

Mao Ying Genetech Inc. is a bioinformatics data analytic company dedicated to providing algorithmic technologies for diagnosis and therapy of cancer. At Mao Ying, a multi-disciplinary team – comprising medical and computer scientists as well as a marketing expert – works together to develop diagnostic biomarkers for various types of cancer. By applying the novel Gene Expression Portrait, we have successfully identified gene markers with potential applications to diagnosis or therapy, and developed several clinically validated products in this line, including OncoDx and MetaDx for cancer diagnosis and OrganID for human organ identification.

Pei-Ing Hwang
General Manager

ASUS Life Corporation

ASUS Life focus on the development of smart medical application. With HealthCloud and AI application as the infrastructure, ASUS Life has PhenoFinder as a distributed database for medical data, OmniCare as a medical IoT platform, and AiNurse as a virtual application in telecare, to help hospitals develop the precision medicine.

Jerry Hsu
Senior Manager

Augmented Intelligence, Inc.

Our mission is to create patient’s virtual avatar for better visualization to serve clinical and educational needs. Through Virtual Reality, our applications allow doctors to see through patient’s body for better surgical planning or radiotherapy simulation. In the student or patient education, the interactive and immersive learning experience enables users to eliminate conceptual hurdle so they can better understand human body. In Augmented Intelligence, our goal is to advance medical intelligence through simulated visualization.

Sam Jang
CEO

Funique VR

Funique dedicated into realizing Stereoscopic 3D VR in film industry, and creating new generation platform for viewers.
Our Medical Stereo VR System - Observing Surgeries through Stereo VR Documenting all kinds of surgeries with Funique’s 8K per eye VR solution. Combining simulation and real-time footages, it solve the problems of lack of resources. And let medical students around the world have the chance to observe some of the greatest surgeons on earth.

Chien-Hsiang Chao
Project Manager

Bio Preventive Medicine Corp.

Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company, focusing on developing novel biomarker-based diagnostics for chronic diseases and oncology. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD), which has been applied to evaluate renal effect in a phase IIIb global clinical trial, MARLINA-T2D™, sponsored by Boehringer Ingelheim. We can help in the development of drugs not only in evaluating renal efficacy but also renal safety. BPM welcomes strategic partnerships in expanding the product pipeline and technology platform for biomarker detection, as well as international partnership for commercialization.

Dave Lee
Scientist

LumiSTAR Biotechnology, Inc.

LumiSTAR Biotechnology is an expert in iPSC technology, optogenetic tools and functional indicators. There are two main applications of our technique: (1) All-optical platform incorporated with AI and machine learning for phenotypic screening, drug discovery, and toxicity testing. (2) Organs-on-chips for precision/personalized medicine.

Yu-Fen Chang, Ph.D
President

GenomeFrontier Therapeutics, Inc.

CAR-T cell therapy is a gene therapy in which patients’ white blood cells are genetically engineered to fight their own cancer.  Achieving more than 90% remission rate in patients with advanced blood cancers, this innovative immunotherapy offers new hope to dying children and adults with advanced blood cancers.  Though powerful in treating advanced blood cancers, conventional CAR-T is futile in fighting solid tumors due to the drawbacks and limitation imposed by the viral vectors used in CAR-T cell engineering.  GenomeFrontier is poised to change the outlook for patients with otherwise incurable advanced solid cancers by confronting this very challenge with bold solutions using our core technologies including Quantum pBAc, a revolutionized non-viral genetic system capable of loading 30 times more genes than the viral method and an innovative cell culture system designed for expending engineered CAR-T cells to a therapeutic quantity while maintaining its potency.  With these revolutionary technologies, we are developing universal super CAR-T therapies for solid cancers which are virus-free, reversible, and potent enough for treating a wide-range of cancers in a much safer fashion than the conventional CAR-T therapies.

Chiung-Yuan Wu
CEO

Elixiron Immunotherapeutics Inc.

Elixiron Immunotherapeutics Inc. is a pre-clinical stage company focused on the development of transforming immunotherapy to treat chronic hepatitis B and cancer. Our lead product EI001 is a fully human monoclonal antibody ready for IND-enabling studies as a potentially first-in-class curative HBV immunotherapy.  For cancer immunotherapy, we are developing therapeutic antibodies targeting tumor microenvironment to reactivate anti-tumor immunity and block cancer metastasis. Elixiron is positioned to launch our first clinical trial and deliver one additional drug candidate for clinical development in 18 months.

Hung-Kai Chen, M.D., Ph.D.
CEO

Meeting Agenda:

Agenda

08:30-09:00

Registration & Breakfast

09:00-09:15

Welcome Remarks:
‧Herbert Wu, PhD, President, Development Center for Biotechnology
‧Crystal Sung, PhD, President, Monte Jade New England

09:15-09:30

Opening Remarks by Guest of Honor:
‧Deputy Minister Fong-Chin Su, PhD, Chief Executive Officer, Taiwan Biomedical Development Board

09:30-10:00

Keynote: Powering the Future of Healthcare by Empowering Global Entrepreneurs
‧Michael LaRhette, President, MassChallenge

10:00-10:20

Taiwan Biobank for the Health of Future Generations
‧Chen-Yang Shen, PhD, Chief Executive Officer, Taiwan Biobank

10:20-10:30

Coffee Break

10:30-11:00

Startup Ecosystem Panel Discussion – “Fostering Entrepreneurship and Innovation”
‧Moderator: Herbert Wu, Development Center for Biotechnology
‧David Lucchino, Chairman of Massachusetts Biotechnology Council
‧Johnsee Lee, Chairman, Taiwan Bio Industry Organization

11:00-12:00

Technology Showcase: Precision Medicine & Digital Health
‧ACT Genomics, Mao Ying Genetech, ASUS Life Corporation, Augmented Intelligence, Funique VR Studio, Bio Preventive Medicine, Lumistar Biotechnology, GenomeFrontier Biosciences, Elixiron Immunotherapeutics

12:00-13:00

Luncheon

13:00-13:10

Welcome Remark:
‧Shaoyu Chang, Investment Manager, VI Ventures

13:10-13:50

Keynote: JJI & JLABS – Partnering Globally in Healthcare Innovation
‧Kate Merton, PhD, Head of JLABS at NYC & Boston - Johnson & Johnson Innovation

14:00-14:20

The Advantages of Taiwan's Capital Market
‧Fulung Ko, Chief Administrative Officer, Taipei Exchange (TPEx)

14:30-15:15

VC Panel Discussion - "Building Cross-Border Partnerships"
‧Moderator: Joan Lau, Managing Partner, Militia Hill Ventures
‧Akhil Saklecha, General Partner, Artiman Ventures
‧Greg Sieczkiewicz, Managing Director, Chief IP Counsel, MPM Capital
‧Christopher Kim, Managing Partner, Novatio Ventures
‧Kevin Chu, Associate, F-Prime Capital Partners

15:15-16:00

Corporate Panel Discussion - "Cross-Sector Innovations in Healthcare"
‧Moderator: Patrick DeCourcy, Principal Program Manager, Global Medical Affairs, Immunology, Sanofi Genzyme
‧Vikas Goyal, Associate, SR One
‧Hyuk-Jeen Suh, Head of Samsung Ventures East Coast
‧Michael Sierra, Vice President, LEO Science & Tech Hub
‧Alicia Irurzun Lafitte, Principal, M Ventures

16:00-16:45

Academia-Industry Panel Discussion - "Fostering a Robust Ecosystem"
‧Moderator: Jeng-Shin Lee, Chief Scientific Officer at AB Biosciences
‧Mary Ann Picard, Director of Operations, M2D2 @ UMass
‧Patrick Rivelli, Director of Life Sciences Track, MIT Alumni Angels
‧Ying Tam, Head of Healthcare, MaRS Ventures
‧Joel Berniac, President, CEO and Co-Founder, Akrivis Technologies

16:45-16:50

Closing Remarks
‧Leon Chen, Vice President, Monte Jade New England

16:50-18:00

Networking

Title: US-Taiwan Night 2018: AI in Healthcare

Date & Time: 5:30 pm - 9 pm, June 6th

Venue: Boston Marriott Cambridge

Website: https://www.mj-ne.org/?p=505

Registration:  https://twbionight.eventbrite.com/

Dear CABA Members and Friends,

We cordially invite you to attend at the upcoming CABA/CBA 2018 Biopharma Forum – “Simcere Night”. The event will be held at Harvard Medical School’s Joseph B. Martin Conference Center (77 Avenue Louis Pasteur, Boston, MA 02115) from 5:30 PM to 8:30 PM on Tuesday, June 5, 2018.

As non-profit organizations based in Boston and Washington DC, respectively, Chinese-American BioMedical Association (CABA) and China Biopharmaceutical Association (CBA) strive to facilitate the communication of the latest advances in biomedical research and development; to assist in the exploration of new biotech/pharmaceutical market opportunities in the US and China; and to promote member career development and community service. Since inception, CABA and CBA have evolved into some of the most active and engaging Chinese American professional organizations locally in the greater Boston and DC Area, nationwide in the US and overseas in China.

For the upcoming 2018 Biopharma Forum, we expect to have 100+ prominent executives, investors, scientists, officials from biopharmaceutical companies, leading research institutions, venture capital investors, entrepreneurs and regulatory agencies from both US and China to come together to discuss the current state and future trend of the life science industry.

美中生物醫藥協會第11屆年會暨波士頓生物醫藥論壇 5/1

🏨Boston Marriott Newton

📍2345 Commonwealth Ave, Newton, MA 02466

🕙8:00 AM to 9:00 PM on Saturday, May 19, 2018.

SPEAKERS

Bill Fodor, PhD

Chief Scientific Officer

Biostage

Felix Hsu, MBA

SVP

Head of WuXi Advanced Therapies

Geoff Mckay

CEO

Avrobio

Birgit Schultes, PhD

VP of Immunology

Intellia Therapeutics Inc

Yide Alan Jiang, PhD

Chief Strategic Officer

Xtalpi Inc.

Xiaole Shirley Liu, PhD

Professor of Statistics, Biostatistics, and Computational Biology

Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health

Tong-Tong Xue, PhD

CEO of Kelun Bo-Tai Biological Company

Vice President of Kelun Pharmaceutical Research Institute

Cheryl Cui, PhD

Partner, Nest.Bio Ventures

Venture Partner, Venture Health

Sean Fu, PhD

Vice President of Luye Global R&D

President of Luye Boston R&D LLC

Debra Yu, MD

Managing Director, Head of Cross-Border Healthcare Investment Banking

China Renaissance

Johnson Zhang, MBA

Vice President & General Manager, Perkin Elmer APAC

John Xu, PhD, MBA

Sr Vice President of Strategic Alliance

Abpro

2018哈佛华人生物医学年会报道

哈佛医学院华人专家学者联合会（HMS-CSSA）经历十载春秋，已经成为哈佛医学院专家学者不可或缺的交流平台之一。一年一度的哈佛华人生物医学年会（以下简称“年会”）更是HMS-CSSA每年的重头戏。2018年5月5日，年会如期在在哈佛医学院波士顿儿童医院Folkman Auditorium举办。本次年会一共分为4个部分，内容涵盖了Development and Epigenetics（发育和表观遗传学）、Signaling Pathway（信号通路）、Cancer Biology（肿瘤生物学）和 Deciphering Protein Structure and Genome Sequence（蛋白结构解析和基因组测序），堪称是一场学术盛宴。现场的火爆程度不用赘述，单从报名满额的速度就能一瞥虚实。知识的力量是无限的，但交流的机会是有限的，为了不让赶不到会场的朋友们留下遗憾，协会还特意设立了分会场和网络直播，让知识能够更好的分享给大家。

大会现场座无虚席

主持人毛萍萍

晨光初起，协会成员和志愿者们就陆续忙碌起来，准备迎接广大学者的到来。与会者一个个入场，时钟也一步步走向开幕。在HMS-CSSA会长杨淞博士简单的致辞之后，哈佛医学院院长 George Daley 教授代表哈佛医学院向广大学者致以问候。他强调了科学对于人类健康的重大贡献，也重点强调了科学工作者们间交流和紧密合作的重要性，以及科学工作者的社会责任。

HMS-CSSA会长杨淞

开场致辞之后，哈佛医学院院长George Daley在第一个主题报告中，介绍了他带领的课题组攻克了20年来造血干细胞体外再生的难题，成功通过过表达7个转录因子将人工诱导干细胞重编程为造血干细胞的过程。该造血干细胞可以在体内自我更新并分化为红细胞和白细胞等各种血液细胞，为需要骨髓移植的患者带来了希望。

哈佛医学院院长George Daley精彩演讲

会议第二位报告人是来自加州大学圣迭戈分校的付向东教授，他为大家介绍了他实验室开发的用于从全基因组水平研究RNA和染色质相互作用的Grid-seq技术。通过该技术他们构建了不同细胞类型的染色质结构和基因组的三维构型，并发现了一系列在启动子-增强子网络中的关键调控节点。

加州大学圣迭戈分校付向东教授和哈佛医学院张毅教授

来自Whitehead研究所的美国科学院院士Rudolf Jaenisch教授首先介绍了他们实验室开发的甲基化报告系统，通过该系统可以在单细胞的水平下通过荧光衡量某一个基因启动子区的甲基化水平。接下来，他向我们介绍了使用改造后的CRISPR系统修改FMR1基因甲基化水平的工作，该工作为治疗脆性X染色体综合症提供了新的方向。

美国科学院院士Rudolf Jaenisch教授

哈佛医学院附属波士顿儿童医院的贺熹教授向大家讲述了他实验室最近一系列研究Wnt信号通路对于动物胚胎发育调控的分子机制，特别是他们最近发现的Tiki和Notum两个新的Wnt调控蛋白，这两个蛋白通过直接对Wnt蛋白的化学修饰来调控Wnt通路的活性。

波士顿儿童医院贺熹教授和王大之教授

William Pu教授来自哈佛医学院附属波士顿儿童医院，他生动地为大家介绍了“heart-on-a-chip”，这个技术是利用工程学手段将心肌细胞固定在芯片，并且可以模拟心脏功能特点。他们组利用该工具研究了包括Barth综合症和心律失常等心脏相关疾病的致病机制并筛选了可能的治疗药物。

波士顿儿童医院 William Pu教授

赵瑾（Jean Zhao）教授阐述了她对于结合靶向药物和目前迅速崛起的免疫疗法在癌症治疗中的最新发现及独到见解。她的研究显示对细胞周期蛋白依赖性激酶CDK4/6的抑制可增强肿瘤细胞的抗原呈递，并增加肿瘤内T细胞浸润，同时减少调节性T细胞（T-regs）。她同时向我们展示了联合使用p110beta 和 PD-1抑制剂在前列腺癌中的显著抗癌效果及相关最新发现。

丹娜法伯癌症研究院赵瑾（Jean Zhao）教授和祁军教授

来自哈佛医学院附属Beth Israel Deaconess医学中心的魏文毅教授为我们介绍了S6K1的最长可变剪切体p85在癌症中的重要作用。他实验室最近发现p85作为一种癌细胞分泌蛋白，可以在细胞系和小鼠模型中促进癌细胞的生长和转移。

Beth Israel Deaconess医学中心魏文毅教授

Nathanael Gray博士分享了一种新的靶向治疗癌症的策略，通过双功能小分子借用细胞自身的泛素化降解系统，以及以此技术为基础的dTAG技术，精准的定点降解靶标蛋白，来达到癌症治疗的目的。同时他们发现使用降解技术可以有效提高药物选择性，在CDK9的降解工作中他们完美解决了CDK9和CDK家族其他蛋白的选择性问题，为靶向治疗提供了新的机会。

丹娜法伯癌症研究院Nathanael Gray教授

王家槐教授从结构生物学的视角为我们阐释了神经生长因子Netrin-1与Draxin与神经受体的相互作用机制。这两个神经生长因子分别与同一神经受体DCC相互作用会引发吸引与排斥两种不同的反应。通过对三组复合物的X射线晶体结构研究及相关的神经生物学研究，揭示了通过 DCC－Draxin－Netrin-1－DCC 搭建起的桥梁形成神经细胞接触与生长的分子机制。

哈佛医学院王家槐老师和刘小乐教授

大会最后由美国国家科学院，国家医学院和文理科学院院士谢晓亮教授以生动幽默的演讲回顾了自己在哈佛大学二十年的科研经历。从早期的单分子酶学，到近期的单细胞全基因组学，谢晓亮教授向大家介绍了他在基础科研和临床应用两方面的重要工作成果。报告最后，他还详细阐述了他的研究组在单细胞三维基因组结构和单细胞转录调控模块领域的最新研究成果。谢晓亮教授的这些研究不但对于理解生物中心法则的运作方式有重要贡献，而且还极大地促进了包括产前筛查等人类健康领域的发展。谢晓亮教授将于近期赴北京大学全职工作，他此次和大家分享的科研和人生经历无疑为在座的年轻学者们提供了最为宝贵的经验。

三院院士谢晓亮教授

最后是2018年哈佛华人生命医学优秀学术奖颁奖典礼。涌金集团特别赞助了本年度学术奖的奖金，以激励哈佛的年轻学者们。经过激烈的竞争，十二位在哈佛工作的优秀学者获得今年的学术奖。哈佛医学院刘小乐教授和谢晓亮教授为获奖者颁发了证书与奖金，以嘉奖他们在多个生物医学领域的出色成果。

2018年涌金哈佛华人生命医学优秀学术奖颁奖典礼

在热烈的掌声中，年会也落下帷幕。学术的宴席虽然会散场，但相信知识的延伸就像直线一样没有终点。这也是HMS-CSSA举办年会的意义，希望在这条直线上留下印记，能够让学者们驻足交流。从2010年第一届年会以来，HMS-CSSA就秉承着自由开放的原则，让每个人都能感受到学术的魅力。这也是为什么每次都有众多学术带头人前来分享，让年会成为中美生命科学和医学领域的重要学术会议之一的原因。学术无国界，思想无界限，希望哈佛华人生物医学年会能够越办越好，更好的为广大学者们服务！

2018哈佛华人生物医学年会组织者合影

撰稿：黄岳，岳宏，蔡文青，曹婵，周慡，段松伟

摄影：黄岳，杜广延
Harvard Chinese Life Science Annual Symposium 2018

May 5th, 2018

Folkman Auditorium, Enders Building, Boston Children’s Hospital320 Longwood Ave, Boston, MA 02115

Organizing Committee

Harvard Medical School - Chinese Scientists & Scholars Association(HMS-CSSA)

Song Yang, Qiong Ye, Linchang Huang, Wenqing Cai, Wei Li, Bin Li, Xiaoqing Wang, Shuxi Qiao, Hong Yue, Jingyu Peng, Yue Zhang, Xianrui Yang, Miao Liu, Chan Cao, Yiming Zhou, An Xiao, Yang Zhang, Yue Huang, Lijie Xing, Mohui Wei, Shengqing Gu, Tao Wang, Xiaofeng Li, Zhengnian Li, Hui Liu, Jiye Liu, Junlin Guo, Pingping Mao, Su Wang, Shuang Zhou, Jinmiao Chen, Songwei Duan, Yanan Qi

Organizing Committee Advisors

Jianzhu Chen, Professor, Massachusetts Institute of Technology

Chuan He, Professor, University of Chicago

Xi He, Professor, Boston Children’s Hospital, Harvard Medical School

Zhigang He, Professor, Boston Children’s Hospital, Harvard Medical School

Frank Hu, Professor, Harvard T.H.Chan School of Public Health

Xiaole Shirley Liu, Professor, Dana-Farber Cancer Institute / Harvard T.H.Chan School of Public Health

Hongbo Luo, Associate Professor, Harvard Medical School

William Pu, Professor, Boston Children’s Hospital, Harvard Medical School

Yang Shi, Professor, Boston Children’s Hospital, Harvard Medical School

Jiping Wang, Assistant Professor, Brigham and Women’s Hospital, Harvard Medical School

Hao Wu, Professor, Boston Children’s Hospital, Harvard Medical School

Yingzi Yang, Professor, Harvard School of Dental Medicine

Junying Yuan, Professor, Harvard Medical School

Yi Zhang, Professor, Boston Children’s Hospital, Harvard Medical School

Jean Zhao, Professor, Dana-Farber Cancer Institute, Harvard Medical School

Invited Speakers

George Daley, MD, PhDHarvard Medical School, Boston Children’s Hospital

Dr. George Q. Daley seeks to translate insights in stem cell biology into improved therapies for genetic and malignant diseases. Important research contributions from his laboratory include the creation of customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008). As a graduate student working with Nobel Laureate Dr. David Baltimore, Dr. Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.

Dr. Daley received his bachelor's degree magna cum laude from Harvard University (1982), a Ph.D. in biology from MIT (1989), and the M.D. from Harvard Medical School, where he was one of twelve individuals in the school’s history to be awarded the degree summa cum laude (1991). He served as Chief Resident in Internal Medicine at the Massachusetts General Hospital (94-95) and is currently a staff physician in Hematology/Oncology at the Children's Hospital and the Dana Farber Cancer Institute, and a member of the Hematology Division of the Brigham and Women’s Hospital in Boston. He has been elected the National Academy of Medicine(NAM), the American Society for Clinical Investigation, the American Association of Physicians, and the American Pediatric Societies, and is a fellow of the American Academy of Arts and Sciences (AAAS) and the American Association for the Advancement of Science.

Xiang-Dong Fu, PhDDepartment of Cellular and Molecular Medicine, University of California, San Diego

Dr. Fu’s laboratory is interested in molecular and cell biology of RNA metabolism and regulation in higher eukaryotic cells. Current research interests in the Fu lab include the regulation of alternative splicing, functional RNA elements in mammalian genomes, transcription/splicing coupling, nuclear architecture, and cellular reprogramming. Dr. Fu was a major contributor for co-discovery of SR proteins, a family of RNA binding proteins involved in constitutive and alternative pre-mRNA processing. His laboratory was the first to identify a family of kinases specific for SR proteins and demonstrated that these kinases are critical for transducing external and intracellular signals to regulate alternative splicing in the nucleus. Dr. Fu's group elucidated a series of regulatory mechanisms for splice site selection in mammalian cells and developed multiple key technologies for high throughput analysis of gene expression, mRNA isoforms, and genomic interactions. Dr. Fu's current research is focused on integrated regulation of gene expression at transcriptional and post-transcriptional levels. Dr. Fu's contribution to biomedical science has been recognized by selection for the Searle Scholar award (1994) and the Leukemia and Lymphoma Society Scholar award (1997) and election to Fellow of American Association for the Advancement of Science (2010).

Dr. Fu is a Professor of Cellular and Molecular Medicine at University of California, San Diego. Dr. Fu received his MS degree in Virology from Wuhan University, China in 1982, PhD degree in Biochemistry from Case Western Reserve University in 1988 (via the CUSBEA program), and postdoctoral training at Harvard from 1988 to 1992. Dr. Fu joined the faculty of University of California, San Diego in 1992 (Assistant Professor, 1992-1998; Associate Professor, 1998 to 2002; and Full Professor, 2002-present).

Rudolf Jaenisch, PhD

Founding Member of Whitehead InstituteDepartment of Biology, MIT

Dr. Jaenisch lab’s expertise is in epigenetics, reprogramming and stem cells. Dr. Jaenisch began his research career as a pioneer making transgenic mice, some of which have produced important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities. These methods have been used to explore basic questions such as the role of DNA modification, genomic imprinting, X chromosome inactivation, nuclear cloning, and, most recently, the nature of stem cells. In addition, using mice as a model and a technique called “altered nuclear transfer,” Dr. Jaenisch has demonstrated that it is possible to procure embryonic stem cells without harming a viable embryo. More recently he has demonstrated that somatic cells can be reprogrammed in vitro to pluripotent ES-like cells and that these cells are suitable to correct both genetic and induced defects in mice by transplantation therapy. Using this technique for turning skin cells into stem cells, the lab has been able to cure mice of sickle cell anemia -- the first direct proof that these easily obtained cells can reverse an inherited disease.

Dr. Jaenisch is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He has been granted numerous awards from organizations across the world. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases. Dr. Jaenisch received his doctorate in medicine from the University of Munich in 1967. He became a postdoc at the Max Planck Institute in Munich, studying bacteriophages. He left Germany in 1970 for research positions at Princeton University, Fox Chase Institute for Cancer Research and the Salk Institute. He returned to Germany in 1977 to become the head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He arrived at MIT in 1984. He participated in the 2005 science conference on human cloning at the United Nations and serves on the science advisory boards of the Genetics Policy Institute and Stemgent.

Xi He, PhDBoston Children’s Hospital, Harvard Medical School

Dr. He’s laboratory seeks to understand the molecular basis of cell-to-cell communication, and how this communication regulates embryonic and neural development in vertebrates. Dr. He is also interested in learning how defective regulation of cell communication causes human cancers and diseases. In particular, Dr. He is investigating signaling mechanisms employed by secreted growth factors of the Wnt family, which play critical roles in establishing the anterior-posterior axis of the embryo and underlie the formation of head versus trunk regions during early embryogenesis. Wnt signaling pathways are also pivotal in the development of human cancers--as several key Wnt signaling components are encoded by human oncogenes or tumor suppressor genes--and in the pathogenesis of many human diseases, such as osteoporosis and degenerative disorders. Dr. He aims to identify molecular components of Wnt signaling pathways and the mechanisms by which Wnt pathways are activated and governed during embryonic development and human tumorigenesis.

Dr. He received his bachelor’s degree in engineering at Huazhong University of Science and Technology (HUST), Wuhan, China, and Ph.D. in Dr. Michael G. Rosenfeld’s lab at University of California, San Diego (UCSD). After his postdoctoral training with Dr. Harold Varmus at National Cancer Institute (NCI), Dr. He became an Assistant Professor at Boston Children’s Hospital in 1997. He was promoted to professor in 2007. Dr. He was a Pew Scholar, a Klingenstein Fellow, a W. M. Keck Distinguished Young Scholar and a Leukemia and Lymphoma Society Scholar. Dr. He received the Young Investigator Award from the Society of Chinese Bioscientists in America (SCBA) in 2004, and holds a Chang Jiang Guest Professorship and 1000 Talent Plan (B) Professorship at HUST. Dr. He is an elected Fellow of American Association for the Advancement of Science and an American Cancer Society Research Professor. He has served on numerous review and advisory boards in academia and the biopharmaceutical industry in the USA, Canada, EU, UK and China.

William Pu, MDBoston Children's Hospital, Harvard Medical School

The Pu lab is interested in the regulation of gene expression and cell lineage specification in heart development, disease, and regeneration using various technologies including genetically engineered mice, conditional gene inactivation, genome-wide chromatin occupancy analysis, and RNA expression profiling. The major goals of Dr. Pu's research include: 1. To understand the transcriptional network regulating heart development and disease; 2. To understand cell lineage specification in heart development and regeneration; 3. To understand genetic contributions to congenital heart disease.

Dr. Pu received an MD from Harvard Medical School. He completed his internship, residence, and pediatric cardiology training at Boston Children’s Hospital. Dr. Pu has been an independent PI since 2004 and has an established track record of innovation in cardiovascular biology. Dr. Pu has 19 successful postdoctoral fellow “alumni”. Among those, 12 remain in academic medicine, 11 have faculty appointments, and 8 are PIs of independent research labs in Europe, North America, and China. Dr. Pu is also the contact PI of the Boston Children’s Hospital Department of Cardiology T32 training grant and the Director of Basic and Translational Cardiovascular Research for the Department of Cardiology at Boston Children’s Hospital.

Jean Zhao, PhDDana-Farber Cancer Institute, Harvard Medical School

Dr. Zhao’s research centers on understanding kinase signaling pathways in cancer. Her laboratory has pioneered a new front for understanding signal transduction by integrating mouse genetics, chemical biology and immunology in the field of translational cancer research. Her productive and insightful work on deciphering the role of PI3-kinase isoforms and the cyclin D1-CDK4/6 pathway in cancer not only addresses important basic science questions, but also has had a significant clinical impact. By providing a mechanistic understanding of the synergies gained for targeting PI3K isoforms and CDK4/6 in combination with immune checkpoint blockade in cancer, her lab has guided the design of current clinical trials of integrating immunotherapy and targeted therapy both here at DFCI and internationally.

Dr. Jean Zhao is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI). Dr. Zhao has been widely recognized for her innovation and excellence in the field. After obtaining her Ph.D. degree with honors from Tufts University School of Medicine in Boston, Dr. Zhao completed her postdoctoral training in the laboratory of Dr. Thomas M. Roberts at DFCI. Dr. Zhao began her independent research at HMS and DFCI in 2006. Her honors and awards include the Career Development Awards from NIH/NCI, the V Scholar Award, the Starr Foundation Award and, recently, the Outstanding Investigator Award from NIH/NCI. Dr. Zhao serves as a member on multiple scientific boards and committees, including the Executive Committee for Research and the Committee for Women Faculty at DFCI, the Steering Committee of Breast Cancer at DF/Harvard Cancer Center and the Advisory Council of the National Brain Tumor Society.

Wenyi Wei, PhDBeth Israel Deaconess Medical Center, Harvard Medical School

The major focus of research in Dr. Wei’s laboratory is aimed at understanding how APC and SCF activities contribute towards cell cycle regulation and subsequent tumor formation. More specifically, Dr. Wei is interested in elucidating the underlying mechanisms that define the oscillation of APC and SCF activity in different cell cycle phases. Currently, he is pursuing the underlying mechanisms that timely regulate APC/Cdh1 activity in different cell cycle phases. Additionally, Dr. Wei is also interested in understanding whether other layers of crosstalk between the APC and SCF complex exist. Furthermore, Dr. Wei would like to identify novel downstream targets for both APC and SCF complexes, which will help pinpoint their functions in both cell cycle control and tumor formation. To this end, Dr. Wei has developed biochemical purification approaches that would allow him to identify novel downstream targets for APC/Cdh1 and SCF/Fbw7 complexes. In addition, he is also interested in defining the tumor suppressor function of Cdh1 utilizing conditional Cdh1 knockout mice. To achieve these goals, Dr. Wei’s lab will use multidisciplinary approaches including biochemical and genetic analysis.

Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards Dr. Wei received his Ph.D. training in the Department of Molecular Biology, Cell Biology & Biochemistry (MCB) at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI and Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center and Department of Pathology at Harvard Medical School.

Nathanael Gray, PhD

Dana-Farber Cancer Institute, Harvard Medical School

Dr. Nathanael Gray’s research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance. Dr. Gray has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Amongst the additional notable achievements of Dr. Gray’s research laboratory are: development of the first T790M selective EGFR inhibitors, ATP-competitive mTor inhibitor, Torin1, and its use to discover that rapamycin is an incomplete inhibitor of mTOR; development of the first inhibitors of ERK5 (BMK1), CDK7 and CDK12.

Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. In 2006, Dr. Gray returned to academia and accepted a faculty appointment at the Dana Farber Cancer Institute and Harvard Medical School in Boston. Dr. Gray’s scientific contributions have been recognized through numerous awards including the Career Award of the National Science Foundation in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011.

Jiahuai Wang, PhDDana-Farber Cancer Institute, Harvard Medical School

Dr. Wang’s lab has been focusing on structures of cell surface receptors that play critical roles in the immune system and nervous system. In collaboration with colleagues within Dana-Farber and Harvard Medical School, the Wang lab has worked out structures of a number of key immune molecules, including T cell receptors, MHC molecules, co-receptors and their interacting complexes. His group has also determined structures of many cell adhesion molecules, such as CD2, CD58, Cadherin, ICAM family members and the complexes with their interacting partners. More recently he begins to turn his interests into neuronal receptors. Most recently in collaboration with a group at EMBL, Hamburg, Dr. Wang has determined the structure of netrin-1 in complex with DCC, uncovering the molecular mechanism of netrin-1 bi-functionality, a long-standing puzzle in the neuroscience field.

Dr. Jiahuai Wang obtained his B.A from the University of Science and Technology of China in 1963 and an equivalent Ph.D. from the Beijing Biophysics Institute, Chinese Academy of Sciences in 1979. He had worked in Biophysics Institute in the period of 1963-1979. During 1979-1982, he was a visiting scholar at University of Wisconsin at Madison and at Harvard University, the Department of Biochemistry and Molecular Biology. In 1982-1988 he was back in Beijing Biophysics Institute, promoted to Associate Professor and later Professor. He served as director of Protein Crystallography Department there in 1987-1988. He was appointed as a member of National 863 Committee of Biotechnology of China in 1986-1990. He came to the United States again late in 1988 working at Harvard Medical School, the same department till 1996 before moving to Dana-Farber Cancer Institute as a Principal Investigator. In 2001, he was promoted as an Associate Professor of Pediatrics and Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Xiaoliang Sunney Xie, PhDDepartment of Chemistry and Chemical Biology, Harvard University

Dr. Xiaoliang Sunney Xie received a B.S. from Peking University in 1984, and his Ph.D. from the University of California at San Diego in 1990, followed by a short postdoctoral experience at the University of Chicago. In 1992, Xie joined Pacific Northwest National Laboratory, where he later became a Chief Scientist. In 1999, he was appointed Professor of Chemistry at Harvard University. He was the first full professor at Harvard University from the People's Republic of China since China's reform in 1978. He is currently the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard, and the Director of Beijing Advanced Innovation Center for Genomics at Peking University.

Xie is among the first to conduct fluorescence studies of single molecules at room temperature in the early 1990s. He has made major contributions to the emergence of the field of single-molecule biophysical chemistry and its application to biology. His team also pioneered the development of coherent Raman scattering microscopy and single cell whole genome sequencing.

His honors include the Albany Prize in Medicine and Biomedical Research, the U. S. Department of Energy E. O. Lawrence Award, the Biophysical Society’s Founders Award, the National Institute of Health Director’s Pioneer Award, the Sackler Prize for Physical Sciences and the American Chemical Society’s Peter Debye Award. Xie is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He is also an honorary fellow of the Chinese Chemical Society and has received scholarly awards from China, Germany and Israel.

2017年对全球医疗卫生事业是意义非凡的一年。中国于今年启动了“健康中国2030长期规划”，政府与民间正如火如荼地投入到医疗大健康的领域；美国的政府与民间也在医疗健康领域积极寻求变革策略。本届峰会以“大健康，大趋势”为主题，将重点探讨：

1）全球卫生健康面临的复杂挑战

2）健康和医学科学技术的大趋势

3）健康和医疗服务创新大趋势

我们诚挚邀请您参与这场中美医疗界的年度盛会，共同探讨未来的健康医疗大趋势！峰会现开放注册，注册请扫描文末二维码。

部分演讲嘉宾：

Ezra Vogel

哈佛大学社会科学荣誉教授

主旨演讲

William Haseltine
ACCESS健康国际有限公司董事长兼总裁

Arthur Kleinman
哈佛医学院社会医学人类学教授

刘远立

北京协和医学院公共卫生学院院长

Mark Elliott

哈佛大学国际事务副教务长

Kyu Rhee
IBM Watson Health副总裁兼首席卫生官

Randall Moore
Mercy Virtual Health主席

David Blumenthal
英联邦基金会主席

Robert Huckman

哈佛商学院工商管理教授

Donald Ingber
哈佛威士研究所创始主任

Alan Trager
公私伙伴关系倡议创始人兼主任; 清华大学PPP研究中心国际比较研究中心首席专家

孙喜琢

深圳市罗湖医院集团总院长

Time:

Sep 9th (Saturday) 2017, 10am - 2pm

Location:

Dana Building 1620, Dana-Farbar Cancer Institute

450 Brookline Ave, Boston, MA 02215

Lunch will be provided

沒有留言:

發佈留言

訂閱：文章 (Atom)

4/30 昆市公校「華埠崛起」放映會

🎥Chinatown Rising 📆Wednesday, Apr 30, 2025, 02:45 PM 📍North Quincy High School, Hancock Street, North Quincy, MA, USA Quincy Public Schools presents filmmaker Josh Chuck, Wednesday, April 30th at 2:45pm, North Quincy High School Auditorium, to share his award-winning documentary film Chinatown Rising directed by a father-son team, featuring members of San Francisco's Chinese American community fighting for social justice. Meet the director, Josh Chuck, to discuss the important contributions Asian Americans have made and be inspired to take action within our own community! FREE! Light refreshments available! Please share throughout all social media networks and with your friends, neighbors, and families alike! RSVP https://bit.ly/3FRV4ef! Seats are limited! Hope to see you soon!

5/1 BTBA 薪資談判講座

總是不知道怎麼談薪水？想爭取更高薪資卻卡關？這場從人資角度出發的線上講座就是為你設計！活動詳情： 🗓️ 日期：5月1日（星期四） ⏰ 時間：美東時間（EDT）晚上8:00 - 9:00 💻 形式：Zoom 線上會議（報名成功後寄送連結） 🗣️ 語言：中文進行在美近十年資深人資專家 Susie 助你自信開口，贏得理想薪酬！報名只到4/25！🔥 👇 點此報名 👇 🔗https://docs.google.com/.../1FAIpQLSdKhuht4FH.../viewform...

5/1-22 李湘畫展

Dear friends, we are excited to announce Xiang Li's next solo exhibit at the Cambridge Public Library main branch located at 449 Broadway in Cambridge MA starting May 1-22. It’ll be located at the lower level. We have an opening reception scheduled for Thursday May 8! Registration is not required but recommended: https://bit.ly/3G5cG6m Please come by to say hi, enjoy the beautiful empress prints, some original pieces, artist talk and more. Light refreshment will be served. Bring a friend or two, can’t wait to see you there!

5/1 紐英崙華人歷史協會

Thirty-second Annual Meeting & Dinner The Chinese Historical Society of New England is pleased to invite you to its Annual Meeting and Dinner on Thursday, May 1, 2025, at Empire Garden Restaurant in Boston’s Chinatown. Together we will celebrate our Sojourner Award recipients Boston Asian Youth Essential Service (YES) and community historian David Chang, as well as highlight our activities of the Year. Proceeds from this event support our work as the first educational organization dedicated solely to documenting, preserving, and promoting the history and legacy of Chinese immigration in New England. Your support ensures that current and future generations can continue to experience and share the rich history of Chinese Immigrants in New England.

5/3 牛頓台灣日

噹噹噹~一年一度、麻州最大的台灣園遊會來囉！ 📅 日期： 2025年5月3日（星期六） ⏰ 時間：上午11:30 - 下午3:00 📍 地點： Hyde Community Center / 僑教中心旁的草地 🏡 地址： 90 Lincoln St., Newton Highlands, MA 02461 🚇 距離 Newton Highlands T 站僅5分鐘步行還有免費路邊停車！ ~~~~~ 🍜 美味台灣小吃與飲料~ ✅ 台灣特色商品與展覽~ 🎶 兩個多小時的文化與音樂表演~ 🎯 趣味遊戲與互動活動~ 😎 遇到老朋友與認識新朋友的好機會! ~~~~~ 🌟 活動免費，歡迎大家帶非台灣朋友參加，讓更多人認識我們的國家！ 📅 立刻記下行事曆，今年 5 月 3 日 ——我們不見不散！

5/3 林以信音樂會向貝多芬致敬

中華表演藝術基金會（Chinese Performing Arts Foundation）將於5月3日（週六）晚8點，以「貝多芬慶典：小提琴家林以信與好友們」為主題，在新英格蘭音樂學院 (NEC) 喬丹廳 (Jordan Hall) 舉辦音樂會，向貝多芬致敬。音樂會票價分為 $20 (7-13 歲)、$40、$60。主辦單位還提供14歲以上學生免費票及非學生贈送券，敬請事先預訂。線上售票將於5月3日下午3時關閉，現場恕不提供免費票贈送，僅販售現金票，票價為10美元。6歲以下兒童謝絕入場。欲了解更多詳情，請瀏覽中華表演藝術基金會官網：http://www.chineseperformingarts.net/contents/season/20250503/index.html。

5/7 Strangers In The Land 書談

Here is the book tour schedule as it currently stands! Launch event will be at the Museum of Chinese in America with the novelist Min Jin Lee and then I’m off on a cross-country sprint. Nine cities in nine days. After I return, I’ll be doing additional events in New York and a virtual event. Extremely grateful to all of my conversation partners. All of the events are collected in one place here. Please come out and pre-order a book! https://www.penguinrandomhouse.com/authors/2264613/michael-luo/ https://www.facebook.com/share/p/1A8AvrLALf/?mibextid=wwXIfr

5/10 慈濟三節合一日

佛誕節、母親節、全球慈濟日『三節合一』，讓人人回歸真正佛教，盛大而普遍的浴佛典禮，讓世人知曉佛教徒慶祝教主的生日。以浴佛的方式進行，浴佛，是禮佛足、淨自心。佛在世時，世人對佛陀的恭敬禮是五體投地，以手觸摸佛陀的腳，以額頭觸及佛陀的腳，這稱為「敬足禮」，表示最為虔誠的禮敬。雙手放置「福慧足」上、躬身禮敬佛像之足，代表「禮佛足」的至誠禮敬，以最尊敬的心禮佛足，其實是淨化自己的心。慈濟基金會波士頓聯絡處誠摯邀請您闔家大小蒞臨，以清淨心為緬甸震災及全球苦難眾生祈福，讓我們齊心祈願平安，化善念為力量，安定自心，守護世界，共同傳遞希望與溫暖。地點： 15 Summer St, Newton MA 02464 時間： 5/10 9:40 ~ 12pm 9:40 朝山 10:00 浴佛大典典禮後有素食及茶點和大家分享。慈濟紐約分會波士頓聯絡處合十

5/11 流光歲月音樂會

[2025 劍橋合唱團春季音樂會] 大家好！學生會與劍橋合唱團(CCCS)共同舉辦的春季音樂會將在5/11 下午兩點在MIT Main Kresge舉辦。有興趣的人歡迎用以下表單登記。非ROCSA會員也歡迎用購票連結購票！早鳥優惠只到5/1！ ROCSA會員：免費，但需要用此連結登記（https://forms.gle/gLpyvkynqdpN7CvA9）非會員及一般大眾：請用此連結購票（https://tiny.universitytickets.com/7zswc9ts） Concert Details 音樂會資訊: 日期: 2025年5月11號時間: 下午2:00至下午3:00 購票: $10 早鳥優惠, $15 普通票免費: 12歲以下的孩子免費入場對象: 歡迎任何年齡報名參加地點: MIT Main Kresge (48 Mass Ave, Cambridge, MA 02139) 電子郵件聯絡: contact@mitcccs.org

5/11 勒星頓中文學校母親節開放日

你知道嗎？LCS 勒星頓中文學校是一個充滿熱情與溫度的學習大家庭，致力於推廣中文教育，培養孩子們對語言與文化的熱愛。不只是學中文，還是認識朋友、探索文化、成長茁壯的地方！我們每周日下午在 Belmont 的 Chenery Upper Elementary School 開設語言課程與文化課外活動。本學期重頭戲之一——2025 母親節開放參觀日 Mother's Day Open House 將於 5月11日 (週日) 下午2:00至5:00 盛大登場！當天活動內容豐富，包括課堂參觀、幼兒園表演、課外活動展示以及文化藝術展覽，誠摯邀請家長與新朋友共襄盛舉！雖然這學年還有兩個月才畫下句點，我們已經迫不及待開始為 2025-2026 學年度暖身啦！現正同步展開招生與尋師活動～無論你是剛起步的新手老師、經驗豐富的退休教師，還是想重拾教育熱情的空巢期家長，只要你對孩子、對中文教學有愛，我們都熱烈歡迎你加入！請大家幫我們「找人、找緣分」～邀請更多人走進 LCS，成為這段中文教學旅程中的重要夥伴！ https://www.lcs-chinese.org/

5/16-6/1 創舞台新作

At CHUANG Stage, we believe in the power of theatre to uplift marginalized voices and illuminate untold stories. We are proud to co-produce Learning How to Read By Moonlight by Gaven D. Trinidad with Company One Theatre, a world premiere that travels across Boston’s cultural hubs. This tour—from the Boston Center for the Arts to Pao Arts Center and beyond—reflects our commitment to bringing theatre directly to the communities whose stories we tell. Each night, a special guest narrator—local artists, community organizers, and elected officials—joins the performance, creating a one-of-a-kind communal experience that highlights the ongoing struggles and triumphs of immigrant families. As part of CHUANG Stage’s 2024-25 season theme, Letters to Our Younger Selves, Trinidad's new play guides us to find light through community, memory, and dreams, in a time when AAPI immigrant advocacy in Boston is more urgent than ever. GET TICKETS A CHUANG Stage & Company One Theatre co-production Learning How to Read by Moonlight a new play by Gaven D. Trinidad directed by Natsu Onoda Power dramaturgy & tour direction by Michelle M. Aguillon featuring Elijah Punzal, Jude Torres*, Christine Armenion, Alfredo Reyes, Nicholas Papayoanou, and Jenine Florence Jacinto Boston Center for the Arts, Plaza Theatre (May 16 – 24) Pao Arts Center (May 29 – June 1) Third venue to be announced! All tickets are Pay-What-You-Want! GET TICKETS

5/16 Communities Coming & Rising Together

We are back: Communities Coming Together 👍 This year, "Communities Coming & Rising Together", hosted by Chinese American Heritage Foundation, Our Dynasty, Harris Zhao and VIVA Karaoke X Studio; plus cosponsoring by CALex MA , KACL, BAAFF, BPAC, BACC, JCL, Ea.st Movement, and CAAC. Come join us for a night of networking and connection as we bring communities together to rise up and support each other! Please register at: https://www.eventbrite.com/e/1319362140679?aff=oddtdtcreator — with Linda Champion and 2 others .

5/17 波士頓臺灣同鄉會春季健行

🌿🌿春天的呼喚，五月的健行🌿🌿 波士頓台灣同鄉會歡迎大家作伙來hiking! 🌷地點: Blue Hills Reservation Houghton's Pond 環湖步道 1.2 miles | easy trail ☀️ 日期： 5/17/2025 Saturday 🌷 集合時間： 10:00 AM – 10:15 AM (遲到的朋友歡迎自行進入步道會合) ☀️ 集合地點： 840 Hillside St Parking, Milton, MA 02186 🌿 步道介紹： https://www.mass.gov/locat.../houghtons-pond-recreation-area ♥️ 溫馨提醒： * 請自備餐點，飲料 * 野餐墊等歡迎攜帶 * 建議穿著長袖長褲及帽子 * 自備防蚊藥物及野外相關用具 * Restroom available at Visitor Center * Enjoy nature responsibly! Leave no trace ⏭️ 活動相關問題: * 請洽TAA.BOSTON1@gmail.com * 或私訊TAA-Boston FB粉絲專頁 * Rain Reserved Date: 5/18 Sunday * 更新消息將於同鄉會FB專頁統一發佈

5/31 香港節

Date: Saturday, May 31, 2025 (Rain Date: June 1) 📣 Time: 11am-5pm 📣 Location: Seven Hills Park, Somerville MA (Right outside Davis Square T Station, 78 Meacham Rd, Somerville, MA 02144) Join us at the second New England Hong Kong Festival at Seven Hills Park, right outside Davis Square T Station, on May 31st from 11am to 5pm (Rain date: June 1st)! Immerse yourself in Hong Kong culture with local Asian and Hong Kong goods, delicious bites, live cultural and music performances, and free games and interactive activities, all brought to you by local vendors, small businesses, and artists! This event is co-hosted with SomerViva: Office of Immigrant Affairs. Learn more on our website (https://newenglandhkfest.com/) and follow our Instagram and Facebook for the latest updates! 誠邀大家參加5月31日上午11時至下午5時 (雨備日期: 6/1)在薩默維爾Davis Square地鐵站旁的Seven Hills公園舉辦的第二屆新英格蘭香港節！齊來感受香港文化，享受由本地小型企業和藝術家為您帶來的亞洲和香港商品、美食佳餚、現場音樂及文化表演，屆時更會有免費遊戲和活動！此活動是與薩默維爾移民事務辦事處共同協辦。請瀏覽活動網站(https://newenglandhkfest.com/)，並關注我們的Instagram 和 Facebook 以獲取最近活動資訊

5/31 全美加青少年國畫書法比賽

The 34th Annual (2025) All-American and Canada Chinese Brush Painting and Calligraphy Competition welcomes all students in US and Canada, age up to 22 as of May 31, 2025 to participate. Four age groups: 9 and under, 10 to 13, 14 to 17, 18 to 22. Age refers to the Application Deadline May 31, 2025. Each student could submit 2 pieces of either brush painting or calligraphy, or both, up to 4 pieces total. Application Forms and Art Works Specification: http://www.chineseperformingarts.net/.../2025/index.html Application Fee: USD $10 per person for up to 4 pieces of artworks submission. Application Deadline: May 31, 2025 Results Announced: June 25, 2025 Cash Award up to USD $250 Jury 2025 (alphabetically): Dr. Edward Chiang 蔣宗壬, Dr. Doris Chu 朱蓉, Dr. Wei Du 杜瑋, Mr. Ho-Chung Lam 林浩宗, Mr. Qingxiong Ma 馬清雄

7/12-13 BTBA 年會

BTBA-Boston Taiwanese Biotechnology Association dooprtsneS8 : 1 t1 0 llh tt5 i m 0 r if 7 ft M a l3fl P p 5f 5 i5tau67   m a 0 A t l 9 · 🎉 BTBA Symposium 2025 – Early Bird Tickets Are Now Live! 🧬 📅Date: July 12–13, 2025 📍Location: Northwest Building, Harvard University Get ready to connect, learn, and be inspired at the Boston Taiwanese Biotechnology Association (BTBA) Symposium 2025 — a two-day gathering of scientists, industry leaders, entrepreneurs, and students at the forefront of biotech innovation. 🚨 Early Bird Registration is Now Open! Secure your spot at a discounted rate before May 31, 2025. 🎟️ Merch of the year -Cross-body phone strap -Two types of badge/ card holder with a retractable clip *You are the lobster in my DNA *You are BIRDiful Discounted price for the bundle!!! Whether you’re advancing cutting-edge research, launching a biotech venture, or exploring career paths in life sciences, this is the community-driven event you won’t want to miss. 🔗 https://www.tickettailor.com/events/btba/1638644 🚨🚨🚨BESIDES! We warmly invite you to be part of something exciting! Submit your poster abstract for the 2025 BTBA Annual Symposium for a chance to win a $30 gift card and have your registration fee waived. With ready-to-use poster abstract templates, getting started is easy. Don’t miss this excellent opportunity to share your amazing work—we can’t wait to meet you! 🙌 📩 Poster Submission Link: https://forms.gle/vbo2mWdXSAeYAVMg7 📁 Poster Abstract Template: https://shorturl.at/7AbLT #BTBASymposium2025 #BiotechCommunity #BTBA #Networking #EarlyBird 🎉 BTBA 2025年會｜早鳥票開賣啦！ 📅時間｜2025 年 7 月 12 - 13 日 📍 地點｜哈佛大學 Northwest Building 一年一度、眾所期待的波士頓台灣人生技協會年會強勢回歸！從學界到業界，從創業者到生科新鮮人，兩天滿滿精彩內容、前沿議題與深度交流，等你加入！ 🚨 早鳥報名現正開放中！即日起至 5 月 31 日止，搶先以優惠價格卡位生技界盛會！ 🎟️ 今年的年會限定周邊也太可以了吧？！ • 🧬 超實用「斜背手機掛繩」 • 兩款證件夾，配有伸縮扣設計 • 💬 限定款式: A. 🦞你是我DNA裡的小龍蝦 / B. 🐦You are BIRDiful • ✨ 周邊組合享加購優惠價！無論你是衝刺論文的研究生、剛起步的新創創辦人，還是想在生技領域一探究竟的職涯探險家，這場活動就是為你而辦的。 🔗 立即報名：https://www.tickettailor.com/events/btba/1638644 🚨🚨🚨除此之外，來參加年會有得聽有得吃，還有得賺錢！提交海報摘要，就有機會贏得 $30 禮品卡，並免除報名費。海報摘要範本都準備好了，還不快動動手指報名～別錯過這個好機會，來和我們分享你的研究成果吧——我們已經等不及要和各位一起交流學術研究的精彩與奧妙了！ 🙌 📩 海報投稿連結：https://forms.gle/vbo2mWdXSAeYAVMg7 📁 海報大綱模板：https://shorturl.at/7AbLT 📍 5月25日晚間11:59（美東時間）投稿截止 📍 6月8日公告演講錄取名單 Photo credit: muillust.com

3/1-5/31 美食攝影大賽

你是否曾被一道精致的亚洲美食所惊艳？是否想用镜头记录下餐厅里温馨的用餐氛围？又或者，你心中早已构思出一道独一无二的亚洲美食菜谱，只待将它呈现给世界？现在，机会来了！由麻州亚裔餐饮协会(MARA)和波士顿华人摄影协会(BCPA)联合主办的 2025年“舌尖上的亚洲”摄影大赛正式启动！我们诚挚邀请亚裔餐馆和摄影爱好者踊跃参与，用镜头捕捉亚洲美食的魅力，分享你对美食的热爱！本次大赛主题：美食: 用镜头展现亚洲美食的色香味形，记录令人垂涎欲滴的瞬间。美食环境: 捕捉餐厅独特的氛围，展现美食与文化、环境的完美融合。美食菜谱设计: 用创意和摄影技巧，将你的独家菜谱呈现得更加诱人。参赛资格: 所有麻州亚裔餐馆和麻州摄影爱好者均可报名参加。参赛时间: 2025年3月1日 - 5月31日更多细节即将推出，敬请关注！不要犹豫，拿起你的相机，加入我们，一起用镜头记录亚洲美食的精彩瞬间，赢取丰厚大奖! 更多详情请关注：麻州亚裔餐饮协会官网：[ma-ara.org] 波士顿华人摄影协会官网：[thebcpa.org/about-us/] 联系方式: * 邮箱：[info@ma-ara.org] * 电话：[774-315-0133]

Boston Orange 波士頓菊子

網頁

生物醫藥 - BTBA Mentor/Mentee 招募開跑

BTBA-Boston Taiwanese Biotechnology Association

New England Healthcare
Executive Network

12th Annual Summer Social with Lightning Pitches

August 1st, 2022

8:00am - 10:00am

About this event

2020 CABA Boston BioForum Online

7月11日 OCEAN-BIO SEMINAR：中美投资并购中的国家安全审查和出口管制问题

SAPA 健康投资论坛暨路演六月线上举行项目资本双向征集

2019-2020 BTBA Seminar series

Sunday, December 8, 2019 at 2 PM – 3:30 PM EST

Tomorrow

MIT Building E25: Room 119/121

[11/17/2019]
Ming-Ru Wu 吳明儒: Synthetic Genetic Circuits for Cancer Immunotherapy: Turning Cancer Cells Against Themselves
Yu-Ru Lee 李育儒: Targeting PTEN Dimerization and Selective Ubiquitination for Cancer Therapy

The 11th CABA MDDI SYMPOSIUM

2019美中生物医药协会投资创业论坛

2019 SAPA-NE 21st Annual Conference

Deliver Optimal Medicines to All Patients

(Boston Cambridge Marriott, June 8th, 2019)

2019年哈佛华人生物医学年会

【YSA x Z-Park】构建精准医疗未来版图（Frontiers in Precision Medicine）

2019 Boston BioForum

2019 SAPA-NE职业发展研讨会: Jump-Start Your Career!

WUXI BIOLOGICS TO INVEST $60 MILLION TO ESTABLISH A BIOLOGICS PRODUCTION FACILITY IN THE UNITED STATES

20th SAPA-NE Annual Conference, Cambridge, MA,

Jun 2-3

美中生物醫藥協會第11屆年會暨波士頓生物醫藥論壇 5/1

沒有留言:

S	M	T	W	T	F	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

姓名	单位、职务	研究方向
施扬	哈佛医学院，波士顿儿童医院	可控的表观遗传机制和转录调节因子
Harvey Lodish	麻省理工学院生物工程系、Whitehead研究所创始成员；美国科学院院士，《分子细胞》作者	红血细胞，脂肪细胞功能及生物疗法应用；长链非编码RNA功能
何志刚	哈佛医学院、波士顿儿童医院	中枢神经系统损伤和其他神经系统功能的恢复
Ed Boyden	麻省理工学院、神经技术学	复杂生物(大脑)系统和功能的修复
任兵	加州大学圣地亚哥分校基因组医学研究所	人类胚胎干细胞分化和哺乳动物发育的基因组、表观基因组的分析
袁国丞	哈佛陈曾熙公共卫生学院、丹娜-法伯癌症研究所	计算生物学与生物信息学基因组分析以理解基因调控机制
蔡理慧	麻省理工学院Picower学习与记忆研究所所长	神经修复与阿尔兹海默症
冯国平	麻省理工学院大脑与认知科学系	神经突触和环路功能及精神疾病发生机理
刘勇军	赛诺飞研发高级副总裁兼全球研究负责人	肿瘤免疫转化医学
陈建柱	麻省理工学院生物学系	免疫记忆，抗肿瘤T细胞反应；人源小鼠模型的建立和应用

	Herbert Wu President DCB		Fong-Chin Su Deputy Minister Ministry of Science and Technology
	Michael LaRhette President MassChallenge		Chen-Yang Shen Chief Executive Taiwan Biobank
	David Lucchino Chairman MassBio		Johnsee Lee Chairman Taiwan Biotech Industry Organization
	Shaoyu Chang Investment Manager VI Ventures		Kate Merton Head of JLABS Johnson & Johnson Innovation
	Fulung Ko Chief Administrative Officer Taipei Exchange		Joan Lau Managing Partner Militia Hill Ventures
	Akhil Saklecha General Partner Artiman Ventures		Greg Sieczkiewicz Chief IP Counsel MPM Capital
	Kevin Chu Analyst F-Prime Capital		Christopher Kim Managing Partner Novatio Ventures
	Patrick DeCourcy Principal Program Manager Sanofi Genzyme		Vikas Goyal Associate SR One
	Hyuk-Jeen Suh Head of Investment Samsung Ventures		Michael Sierra Vice President LEO Sci. & Tech
	Daniel Franke Analyst M Ventures		Jeng-Shin Lee Chief Scientific Officer AB Biosciences
	Mary Ann Picard Dir. of Operation M2D2		Patrick Rivelli President Savran Technologies
	Ying K. Tam Managing Dir. of Health MaRS Ventures		Joel Berniac CEO and Co-Founder Akrivis Technologies

Company Name	Brief Company Introduction	Speaker
ACT Genomics	ACT Genomics is a leading CAP-accredited cancer molecular information service provider, with proprietary NGS-panels and chip-based platform, coupling with integrated medical informatics pipeline, we transform cancer treatment paradigm and support biopharma in biomarker exploration and companion diagnostic development.	Tsung-Kai Wu Sr. Associate Director, Business Development
Mao Ying Genetech Inc.	Mao Ying Genetech Inc. is a bioinformatics data analytic company dedicated to providing algorithmic technologies for diagnosis and therapy of cancer. At Mao Ying, a multi-disciplinary team – comprising medical and computer scientists as well as a marketing expert – works together to develop diagnostic biomarkers for various types of cancer. By applying the novel Gene Expression Portrait, we have successfully identified gene markers with potential applications to diagnosis or therapy, and developed several clinically validated products in this line, including OncoDx and MetaDx for cancer diagnosis and OrganID for human organ identification.	Pei-Ing Hwang General Manager
ASUS Life Corporation	ASUS Life focus on the development of smart medical application. With HealthCloud and AI application as the infrastructure, ASUS Life has PhenoFinder as a distributed database for medical data, OmniCare as a medical IoT platform, and AiNurse as a virtual application in telecare, to help hospitals develop the precision medicine.	Jerry Hsu Senior Manager
Augmented Intelligence, Inc.	Our mission is to create patient’s virtual avatar for better visualization to serve clinical and educational needs. Through Virtual Reality, our applications allow doctors to see through patient’s body for better surgical planning or radiotherapy simulation. In the student or patient education, the interactive and immersive learning experience enables users to eliminate conceptual hurdle so they can better understand human body. In Augmented Intelligence, our goal is to advance medical intelligence through simulated visualization.	Sam Jang CEO
Funique VR	Funique dedicated into realizing Stereoscopic 3D VR in film industry, and creating new generation platform for viewers. Our Medical Stereo VR System - Observing Surgeries through Stereo VR Documenting all kinds of surgeries with Funique’s 8K per eye VR solution. Combining simulation and real-time footages, it solve the problems of lack of resources. And let medical students around the world have the chance to observe some of the greatest surgeons on earth.	Chien-Hsiang Chao Project Manager
Bio Preventive Medicine Corp.	Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company, focusing on developing novel biomarker-based diagnostics for chronic diseases and oncology. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD), which has been applied to evaluate renal effect in a phase IIIb global clinical trial, MARLINA-T2D™, sponsored by Boehringer Ingelheim. We can help in the development of drugs not only in evaluating renal efficacy but also renal safety. BPM welcomes strategic partnerships in expanding the product pipeline and technology platform for biomarker detection, as well as international partnership for commercialization.	Dave Lee Scientist
LumiSTAR Biotechnology, Inc.	LumiSTAR Biotechnology is an expert in iPSC technology, optogenetic tools and functional indicators. There are two main applications of our technique: (1) All-optical platform incorporated with AI and machine learning for phenotypic screening, drug discovery, and toxicity testing. (2) Organs-on-chips for precision/personalized medicine.	Yu-Fen Chang, Ph.D President
GenomeFrontier Therapeutics, Inc.	CAR-T cell therapy is a gene therapy in which patients’ white blood cells are genetically engineered to fight their own cancer. Achieving more than 90% remission rate in patients with advanced blood cancers, this innovative immunotherapy offers new hope to dying children and adults with advanced blood cancers. Though powerful in treating advanced blood cancers, conventional CAR-T is futile in fighting solid tumors due to the drawbacks and limitation imposed by the viral vectors used in CAR-T cell engineering. GenomeFrontier is poised to change the outlook for patients with otherwise incurable advanced solid cancers by confronting this very challenge with bold solutions using our core technologies including Quantum pBAc, a revolutionized non-viral genetic system capable of loading 30 times more genes than the viral method and an innovative cell culture system designed for expending engineered CAR-T cells to a therapeutic quantity while maintaining its potency. With these revolutionary technologies, we are developing universal super CAR-T therapies for solid cancers which are virus-free, reversible, and potent enough for treating a wide-range of cancers in a much safer fashion than the conventional CAR-T therapies.	Chiung-Yuan Wu CEO
Elixiron Immunotherapeutics Inc.	Elixiron Immunotherapeutics Inc. is a pre-clinical stage company focused on the development of transforming immunotherapy to treat chronic hepatitis B and cancer. Our lead product EI001 is a fully human monoclonal antibody ready for IND-enabling studies as a potentially first-in-class curative HBV immunotherapy. For cancer immunotherapy, we are developing therapeutic antibodies targeting tumor microenvironment to reactivate anti-tumor immunity and block cancer metastasis. Elixiron is positioned to launch our first clinical trial and deliver one additional drug candidate for clinical development in 18 months.	Hung-Kai Chen, M.D., Ph.D. CEO

	Agenda
08:30-09:00	Registration & Breakfast
09:00-09:15	Welcome Remarks: ‧Herbert Wu, PhD, President, Development Center for Biotechnology ‧Crystal Sung, PhD, President, Monte Jade New England
09:15-09:30	Opening Remarks by Guest of Honor: ‧Deputy Minister Fong-Chin Su, PhD, Chief Executive Officer, Taiwan Biomedical Development Board
09:30-10:00	Keynote: Powering the Future of Healthcare by Empowering Global Entrepreneurs ‧Michael LaRhette, President, MassChallenge
10:00-10:20	Taiwan Biobank for the Health of Future Generations ‧Chen-Yang Shen, PhD, Chief Executive Officer, Taiwan Biobank
10:20-10:30	Coffee Break
10:30-11:00	Startup Ecosystem Panel Discussion – “Fostering Entrepreneurship and Innovation” ‧Moderator: Herbert Wu, Development Center for Biotechnology ‧David Lucchino, Chairman of Massachusetts Biotechnology Council ‧Johnsee Lee, Chairman, Taiwan Bio Industry Organization
11:00-12:00	Technology Showcase: Precision Medicine & Digital Health ‧ACT Genomics, Mao Ying Genetech, ASUS Life Corporation, Augmented Intelligence, Funique VR Studio, Bio Preventive Medicine, Lumistar Biotechnology, GenomeFrontier Biosciences, Elixiron Immunotherapeutics
12:00-13:00	Luncheon
13:00-13:10	Welcome Remark: ‧Shaoyu Chang, Investment Manager, VI Ventures
13:10-13:50	Keynote: JJI & JLABS – Partnering Globally in Healthcare Innovation ‧Kate Merton, PhD, Head of JLABS at NYC & Boston - Johnson & Johnson Innovation
14:00-14:20	The Advantages of Taiwan's Capital Market ‧Fulung Ko, Chief Administrative Officer, Taipei Exchange (TPEx)
14:30-15:15	VC Panel Discussion - "Building Cross-Border Partnerships" ‧Moderator: Joan Lau, Managing Partner, Militia Hill Ventures ‧Akhil Saklecha, General Partner, Artiman Ventures ‧Greg Sieczkiewicz, Managing Director, Chief IP Counsel, MPM Capital ‧Christopher Kim, Managing Partner, Novatio Ventures ‧Kevin Chu, Associate, F-Prime Capital Partners
15:15-16:00	Corporate Panel Discussion - "Cross-Sector Innovations in Healthcare" ‧Moderator: Patrick DeCourcy, Principal Program Manager, Global Medical Affairs, Immunology, Sanofi Genzyme ‧Vikas Goyal, Associate, SR One ‧Hyuk-Jeen Suh, Head of Samsung Ventures East Coast ‧Michael Sierra, Vice President, LEO Science & Tech Hub ‧Alicia Irurzun Lafitte, Principal, M Ventures
16:00-16:45	Academia-Industry Panel Discussion - "Fostering a Robust Ecosystem" ‧Moderator: Jeng-Shin Lee, Chief Scientific Officer at AB Biosciences ‧Mary Ann Picard, Director of Operations, M2D2 @ UMass ‧Patrick Rivelli, Director of Life Sciences Track, MIT Alumni Angels ‧Ying Tam, Head of Healthcare, MaRS Ventures ‧Joel Berniac, President, CEO and Co-Founder, Akrivis Technologies
16:45-16:50	Closing Remarks ‧Leon Chen, Vice President, Monte Jade New England
16:50-18:00	Networking

S	M	T	W	T	F	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

網頁

生物醫藥 - BTBA Mentor/Mentee 招募 開跑

BTBA-Boston Taiwanese Biotechnology Association

New England Healthcare Executive Network

12th Annual Summer Social with Lightning Pitches

August 1st, 2022

8:00am - 10:00am

About this event

2020 CABA Boston BioForum Online

7月11日 OCEAN-BIO SEMINAR：中美投资并购中的国家安全审查和出口管制问题

SAPA 健康投资论坛暨路演六月线上举行 项目资本双向征集

2019-2020 BTBA Seminar series

clock Sunday, December 8, 2019 at 2 PM – 3:30 PM EST Tomorrow pin MIT Building E25: Room 119/121

[11/17/2019]Ming-Ru Wu 吳明儒: Synthetic Genetic Circuits for Cancer Immunotherapy: Turning Cancer Cells Against Themselves Yu-Ru Lee 李育儒: Targeting PTEN Dimerization and Selective Ubiquitination for Cancer Therapy

The 11th CABA MDDI SYMPOSIUM

2019美中生物医药协会投资创业论坛

2019 SAPA-NE 21st Annual Conference

Deliver Optimal Medicines to All Patients

(Boston Cambridge Marriott, June 8th, 2019)

2019年哈佛华人生物医学年会

【YSA x Z-Park】构建精准医疗未来版图（Frontiers in Precision Medicine）

2019 Boston BioForum

2019 SAPA-NE职业发展研讨会: Jump-Start Your Career!

WUXI BIOLOGICS TO INVEST $60 MILLION TO ESTABLISH A BIOLOGICS PRODUCTION FACILITY IN THE UNITED STATES

20th SAPA-NE Annual Conference, Cambridge, MA,

Jun 2-3

美中生物醫藥協會第11屆年會暨波士頓生物醫藥論壇 5/1

沒有留言:

生物醫藥 - BTBA Mentor/Mentee 招募開跑

New England Healthcare
Executive Network

SAPA 健康投资论坛暨路演六月线上举行项目资本双向征集

Sunday, December 8, 2019 at 2 PM – 3:30 PM EST

Tomorrow

MIT Building E25: Room 119/121

[11/17/2019]
Ming-Ru Wu 吳明儒: Synthetic Genetic Circuits for Cancer Immunotherapy: Turning Cancer Cells Against Themselves
Yu-Ru Lee 李育儒: Targeting PTEN Dimerization and Selective Ubiquitination for Cancer Therapy

S	M	T	W	T	F	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31